Modified peptides as therapeutic agents

ABSTRACT

The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising:  
     a) selecting at least one peptide that modulates the activity of a protein of interest; and  
     b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide.  
     Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display,  E. coli  display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.

BACKGROUND OF THE INVENTION

[0001] Recombinant proteins are an emerging class of therapeutic agents. Such recombinant therapeutics have engendered advances in protein formulation and chemical modification. Such modifications can protect therapeutic proteins, primarily by blocking their exposure to proteolytic enzymes. Protein modifications may also increase the therapeutic protein's stability, circulation time, and biological activity. A review article describing protein modification and fusion proteins is Francis (1992), Focus on Growth Factors 3:4-10 (Mediscript, London), which is hereby incorporated by reference.

[0002] One useful modification is combination with the “Fc” domain of an antibody. Antibodies comprise two functionally independent parts, a variable domain known as “Fab”, which binds antigen, and a constant domain known as “Fc”, which links to such effector functions as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas an Fab is short-lived. Capon et al. (1989), Nature 337: 525-31. When constructed together with a therapeutic protein, an Fc domain can provide longer half-life or incorporate such functions as Fc receptor binding, protein A binding, complement fixation and perhaps even placental transfer. Id. Table 1 summarizes use of Fc fusions known in the art. TABLE 1 Fc fusion with therapeutic proteins Fusion Therapeutic Form of Fc partner implications Reference IgG1 N-terminus of Hodgkin's disease; U.S. Pat. No. CD30-L anaplastic lymphoma; T- 5,480,981 cell leukemia Murine Fcγ2a IL-10 anti-inflammatory; Zheng et al. (1995), J. transplant rejection Immunol. 154: 5590-600 IgG1 TNF receptor septic shock Fisher et al. (1996), N. Engl. J. Med. 334: 1697-1702; Van Zee K. et al. (1996), J. Immunol. 156: 2221-30 IgG, IgA, TNF receptor inflammation, autoimmune U.S. Pat. No. 5,808,029, IgM, or IgE disorders issued Sep. 15, (excluding 1998 the first domain) IgG1 CD4 receptor AIDS Capon et al. (1989), Nature 337: 525-31 IgG1, N-terminus anti-cancer, antiviral Harvill et al. (1995), lgG3 of IL-2 Immunotech. 1: 95-105 IgG1 C-terminus of osteoarthritis; WO 97/23614, published OPG bone density Jul. 3, 1997 IgG1 N-terminus of anti-obesity PCT/US 97/23183, filed leptin Dec. 11, 1997 Human Ig CTLA-4 autoimmune disorders Linsley (1991), J. Exp. Cγ1 Med. 174: 561-9

[0003] A much different approach to development of therapeutic agents is peptide library screening. The interaction of a protein ligand with its receptor often takes place at a relatively large interface. However, as demonstrated for human growth hormone and its receptor, only a few key residues at the interface contribute to most of the binding energy. Clackson et al. (1995), Science 267: 383-6. The bulk of the protein ligand merely displays the binding epitopes in the right topology or serves functions unrelated to binding. Thus, molecules of only “peptide” length (2 to 40 amino acids) can bind to the receptor protein of a given large protein ligand. Such peptides may mimic the bioactivity of the large protein ligand (“peptide agonists”) or, through competitive binding, inhibit the bioactivity of the large protein ligand (“peptide antagonists”).

[0004] Phage display peptide libraries have emerged as a powerful method in identifying such peptide agonists and antagonists. See, for example, Scott et al. (1990), Science 249: 386; Devlin et al. (1990), Science 249: 404; U.S. Pat. No. 5,223,409, issued Jun. 29, 1993; U.S. Pat. No. 5,733,731, issued Mar. 31, 1998; U.S. Pat. No. 5,498,530, issued Mar. 12, 1996; U.S. Pat. No. 5,432,018, issued Jul. 11, 1995; U.S. Pat. No. 5,338,665, issued Aug. 16, 1994; U.S. Pat. No. 5,922,545, issued Jul. 13, 1999; WO 96/40987, published Dec. 19, 1996; and WO 98/15833, published Apr. 16, 1998 (each of which is incorporated by reference). In such libraries, random peptide sequences are displayed by fusion with coat proteins of filamentous phage. Typically, the displayed peptides are affinity-eluted against an antibody-immobilized extracellular domain of a receptor. The retained phages may be enriched by successive rounds of affinity purification and repropagation. The best binding peptides may be sequenced to identify key residues within one or more structurally related families of peptides. See, e.g., Cwirla et al. (1997), Science 276: 1696-9, in which two distinct families were identified. The peptide sequences may also suggest which residues may be safely replaced by alanine scanning or by mutagenesis at the DNA level. Mutagenesis libraries may be created and screened to further optimize the sequence of the best binders. Lowman (1997), Ann. Rev. Biophys. Biomol. Struct. 26: 401-24.

[0005] Other methods compete with phage display in peptide research. A peptide library can be fused to the carboxyl terminus of the lac repressor and expressed in E. coli. Another E. coli-based method allows display on the cell's outer membrane by fusion with a peptidoglycan-associated lipoprotein (PAL). Hereinafter, these and related methods are collectively referred to as “E. coli display.” Another biological approach to screening soluble peptide mixtures uses yeast for expression and secretion. See Smith et al. (1993), Mol. Pharmacol. 43: 741-8. Hereinafter, the method of Smith et al. and related methods are referred to as “yeast-based screening.” In another method, translation of random RNA is halted prior to ribosome release, resulting in a library of polypeptides with their associated RNA still attached. Hereinafter, this and related methods are collectively referred to as “ribosome display.” Other methods employ chemical linkage of peptides to RNA; see, for example, Roberts & Szostak (1997), Proc. Natl. Acad. Sci. USA, 94: 12297-303. Hereinafter, this and related methods are collectively referred to as “RNA-peptide screening.” Chemically derived peptide libraries have been developed in which peptides are immobilized on stable, non-biological materials, such as polyethylene rods or solvent-permeable resins. Another chemically derived peptide library uses photolithography to scan peptides immobilized on glass slides. Hereinafter, these and related methods are collectively referred to as “chemical-peptide screening.” Chemical-peptide screening may be advantageous in that it allows use of D-amino acids and other unnatural analogues, as well as non-peptide elements. Both biological and chemical methods are reviewed in Wells & Lowman (1992), Curr. Opin. Biotechnol. 3: 355-62.

[0006] In the case of known bioactive peptides, rational design of peptide ligands with favorable therapeutic properties can be completed. In such an approach, one makes stepwise changes to a peptide sequence and determines the effect of the substitution upon bioactivity or a predictive biophysical property of the peptide (e.g., solution structure). Hereinafter, these techniques are collectively referred to as “rational design.” In one such technique, one makes a series of peptides in which one replaces a single residue at a time with alanine. This technique is commonly referred to as an “alanine walk” or an “alanine scan.” When two residues (contiguous or spaced apart) are replaced, it is referred to as a “double alanine walk.” The resultant amino acid substitutions can be used alone or in combination to result in a new peptide entity with favorable therapeutic properties.

[0007] Structural analysis of protein-protein interaction may also be used to suggest peptides that mimic the binding activity of large protein ligands. In such an analysis, the crystal structure may suggest the identity and relative orientation of critical residues of the large protein ligand, from which a peptide may be designed. See, e.g., Takasaki et al. (1997), Nature Biotech. 15: 1266-70. Hereinafter, these and related methods are referred to as “protein structural analysis.” These analytical methods may also be used to investigate the interaction between a receptor protein and peptides selected by phage display, which may suggest further modification of the peptides to increase binding affinity.

[0008] Conceptually, one may discover peptide mimetics of any protein using phage display and the other methods mentioned above. These methods have been used for epitope mapping, for identification of critical amino acids in protein-protein interactions, and as leads for the discovery of new therapeutic agents. E.g., Cortese et al. (1996), Curr. Opin. Biotech. 7: 616-21. Peptide libraries are now being used most often in immunological studies, such as epitope mapping. Kreeger (1996), The Scientist 10(13): 19-20.

[0009] Of particular interest here is use of peptide libraries and other techniques in the discovery of pharmacologically active peptides. A number of such peptides identified in the art are summarized in Table 2. The peptides are described in the listed publications, each of which is hereby incorporated by reference. The pharmacologic activity of the peptides is described, and in many instances is followed by a shorthand term therefor in parentheses. Some of these peptides have been modified (e.g., to form C-terminally cross-linked dimers). Typically, peptide libraries were screened for binding to a receptor for a pharmacologically active protein (e.g., EPO receptor). In at least one instance (CTLA4), the peptide library was screened for binding to a monclonal antibody. TABLE 2 Pharmacologically active peptides Binding partner/ Form of protein of Pharmacologic peptide interest^(a) activity Reference intrapeptide EPO receptor EPO-mimetic Wrighton et al. (1996), disulfide- Science 273: 458-63; bonded U.S. Pat. No. 5,773,569, issued Jun. 30, 1998 to Wrighton et al. C-terminally EPO receptor EPO-mimetic Livnah et al. (1996), cross-linked Science 273: 464-71; dimer Wrighton et al. (1997), Nature Biotechnology 15: 1261-5; International patent application WO 96/40772, published Dec. 19, 1996 linear EPO receptor EPO-mimetic Naranda et al. (1999), Proc. Natl. Acad. Sci. USA, 96: 7569-74; WO 99/47151, published Sep. 23, 1999 linear c-Mpl TPO-mimetic Cwirla et al. (1997) Science 276: 1696-9; U.S. Pat. No. 5,869,451, issued Feb. 9, 1999; U.S. Pat. No. 5,932,946, issued Aug. 3, 1999 C-terminally c-Mpl TPO-mimetic Cwirla et al. (1997), cross-linked Science 276: 1696-9 dimer disulfide- stimulation of Paukovits et al. (1984), linked dimer hematopoiesis Hoppe-Seylers Z. (“G-CSF-mimetic”) Physiol. Chem. 365: 303-11; Laerum et al. (1988), Exp. Hemat. 16: 274-80 alkylene- G-CSF-mimetic Bhatnagar et al. (1996), linked dimer J. Med. Chem. 39: 3814-9; Cuthbertson et al. (1997), J. Med. Chem. 40: 2876-82; King et al. (1991), Exp. Hematol. 19: 481; King et al. (1995), Blood 86 (Suppl. 1): 309a linear IL-1 receptor inflammatory and U.S. Pat. No. 5,608,035; autoimmune diseases U.S. Pat. No. 5,786,331; (“IL-1 antagonist” or U.S. Pat. No. 5,880,096; “IL-1ra-mimetic”) Yanofsky et al. (1996), Proc. Natl. Acad. Sci. 93: 7381-6; Akeson et al. (1996), J. Biol. Chem. 271: 30517-23; Wiekzorek et al. (1997), Pol. J. Pharmacol. 49: 107-17; Yanofsky (1996), PNAs, 93: 7381-7386. linear Facteur stimulation of lymphocytes Inagaki-Ohara et al. thymique (“FTS-mimetic”) (1996), Cellular Immunol. serique (FTS) 171: 30-40; Yoshida (1984), Int. J. Immunopharmacol, 6: 141-6. intrapeptide CTLA4 MAb CTLA4-mimetic Fukumoto et al. (1998), disulfide Nature Biotech. 16: 267-70 bonded exocyclic TNF-α receptor TNF-α antagonist Takasaki et al. (1997), Nature Biotech. 15: 1266-70; WO 98/53842, published Dec. 3, 1998 linear TNF-α receptor TNF-α antagonist Chirinos-Rojas ( ), J. Imm., 5621-5626. intrapeptide C3b inhibition of complement Sahu et al. (1996), J. disulfide activation; autoimmune Immunol. 157: 884-91; bonded diseases Morikis et al. (1998), (“C3b-antagonist”) Protein Sci. 7: 619-27 linear vinculin cell adhesion processes- Adey et al. (1997), cell growth, differentiation, Biochem. J. 324: 523-8 wound healing, tumor metastasis (“vinculin binding”) linear C4 binding anti-thrombotic Linse et al. (1997), J. protein (C4BP) Biol. Chem. 272: 14658-65 linear urokinase processes associated with Goodson et al. (1994), receptor urokinase interaction with Proc. Natl. Acad. Sci. 91: its receptor (e.g., 7129-33; International angiogenesis, tumor cell application WO invasion and metastasis); 97/35969, published (“UKR antagonist”) Oct. 2, 1997 linear Mdm2, Hdm2 Inhibition of inactivation of Picksley et al. (1994), p53 mediated by Mdm2 or Oncogene 9: 2523-9; hdm2; anti-tumor Bottger et al. (1997) J. (“Mdm/hdm antagonist”) Mol. Biol. 269: 744-56; Bottger et al. (1996), Oncogene 13: 2141-7 linear p21^(WAF1) anti-tumor by mimicking Ball et al. (1997), Curr. the activity of p21^(WAF1) Biol. 7: 71-80 linear farnesyl anti-cancer by preventing Gibbs et al. (1994), Cell transferase activation of ras oncogene 77: 175-178 linear Ras effector anti-cancer by inhibiting Moodie et al. (1994), domain biological function of the Trends Genet 10: 44-48 ras oncogene Rodriguez et al. (1994), Nature 370: 527-532 linear SH2/SH3 anti-cancer by inhibiting Pawson et al (1993), domains tumor growth with Curr. Biol. 3: 434-432 activated tyrosine kinases; Yu et al. (1994), Cell treatment of SH3- 76: 933-945; Rickles et al. mediated disease states (1994), EMBO J. 13: (“SH3 antagonist”) 5598-5604; Sparks et al. (1994), J. Biol. Chem. 269: 23853-6; Sparks et al. (1996), Proc. Natl. Acad. Sci. 93: 1540-4; U.S. Pat. No. 5,886,150, issued Mar. 23, 1999; U.S. Pat. No. 5,888,763, issued Mar. 30, 1999 linear p16^(INK4) anti-cancer by mimicking Fahraeus et al. (1996), activity of p16; e.g., Curr. Biol. 6: 84-91 inhibiting cyclin D-Cdk complex (“p16-mimetic”) linear Src, Lyn inhibition of Mast cell Stauffer et al. (1997), activation, IgE-related Biochem. 36: 9388-94 conditions, type I hypersensitivity (“Mast cell antagonist”) linear Mast cell treatment of inflammatory International application protease disorders mediated by WO 98/33812, published release of tryptase-6 Aug. 6, 1998 (“Mast cell protease inhibitors”) linear HBV core treatment of HBV viral Dyson & Muray (1995), antigen (HBcAg) infections (“anti-HBV”) Proc. Natl. Acad. Sci. 92: 2194-8 linear selectins neutrophil adhesion; Martens et al. (1995), J. inflammatory diseases Biol. Chem. 270: 21129-36; (“selectin antagonist”) European patent application EP 0 714 912, published Jun. 5, 1996 linear, calmodulin calmodulin antagonist Pierce et al. (1995), cyclized Molec. Diversity 1: 259-65; Dedman et al. (1993), J. Biol. Chem. 268: 23025-30; Adey & Kay (1996), Gene 169: 133-4 linear, integrins tumor-homing; treatment International applications cyclized- for conditions related to WO 95/14714, published integrin-mediated cellular Jun. 1, 1995; WO events, including platelet 97/08203, published aggregation, thrombosis, Mar. 6, 1997; WO wound healing, 98/10795, published osteoporosis, tissue Mar. 19, 1998; WO repair, angiogenesis (e.g., 99/24462, published May for treatment of cancer), 20, 1999; Kraft et al. and tumor invasion (1999), J. Biol. Chem. (“integrin-binding”) 274: 1979-1985 cyclic, linear fibronectin and treatment of inflammatory WO 98/09985, published extracellular and autoimmune Mar. 12, 1998 matrix conditions components of T cells and macrophages linear somatostatin treatment or prevention of European patent and cortistatin hormone-producing application 0 911 393, tumors, acromegaly, published Apr. 28, 1999 giantism, dementia, gastric ulcer, tumor growth, inhibition of hormone secretion, modulation of sleep or neural activity linear bacterial antibiotic; septic shock; U.S. Pat. No. 5,877,151, lipopolysaccharide disorders modulatable by issued Mar. 2, 1999 CAP37 linear or pardaxin, mellitin antipathogenic WO 97/31019, published cyclic, 28 Aug. 1997 including D- amino acids linear, cyclic VIP impotence, WO 97/40070, published neurodegenerative Oct. 30, 1997 disorders linear CTLs cancer EP 0 770 624, published May 2, 1997 linear THF-gamma2 Burnstein (1988), Biochem., 27: 4066-71. linear Amylin Cooper (1987), Proc. Natl. Acad. Sci., 84: 8628-32. linear Adrenomedullin Kitamura (1993), BBRC, 192: 553-60. cyclic, linear VEGF anti-angiogenic; cancer, Fairbrother (1998), rheumatoid arthritis, Biochem., 37: 17754-17764. diabetic retinopathy, psoriasis (“VEGF antagonist”) cyclic MMP inflammation and Koivunen (1999), Nature autoimmune disorders; Biotech., 17: 768-774. tumor growth (“MMP inhibitor”) HGH fragment treatment of obesity U.S. Pat. No. 5,869,452 Echistatin inhibition of platelet Gan (1988), J. Biol. aggregation Chem., 263: 19827-32. linear SLE SLE WO 96/30057, published autoantibody Oct. 3, 1996 GD1alpha suppression of tumor Ishikawa et al. (1998), metastasis FEBS Lett. 441 (1): 20-4 antiphospholipid endothelial cell activation, Blank et al. (1999), Proc. beta-2- antiphospholipid Natl. Acad. Sci. USA 96: glycoprotein-l syndrome (APS), 5164-8 (β2GPl) thromboembolic antibodies phenomena, thrombocytopenia, and recurrent fetal loss linear T Cell Receptor diabetes WO 96/11214, published beta chain Apr. 18, 1996. Antiproliferative, antiviral WO 00/01402, published Jan. 13, 2000. anti-ischemic, growth WO 99/62539, published hormone-liberating Dec. 9, 1999. anti-angiogenic WO 99/61476, published Dec. 2, 1999. linear Apoptosis agonist; WO 99/38526, published treatment of T cell- Aug. 5, 1999. associated disorders (e.g., autoimmune diseases, viral infection, T cell leukemia, T cell lymphoma) linear MHC class II treatment of autoimmune U.S. Pat. No. 5,880,103, diseases issued Mar. 9, 1999. linear androgen R, proapoptotic, useful in WO 99/45944, published p75, MJD, DCC, treating cancer Sep. 16, 1999. huntingtin linear von Willebrand inhibition of Factor VIII WO 97/41220, published Factor; Factor interaction; anticoagulants Apr. 29, 1997. VIII linear lentivirus LLP1 antimicrobial U.S. Pat. No. 5,945,507, issued Aug. 31, 1999. linear Delta-Sleep sleep disorders Graf (1986), Peptides Inducing Peptide 7: 1165. linear C-Reactive inflammation and cancer Barna (1994), Cancer Protein (CRP) Immunol. Immunother. 38: 38 (1994). linear Sperm- infertility Suzuki (1992), Comp. Activating Biochem. Physiol. Peptides 102B: 679. linear angiotensins hematopoietic factors for Lundergan (1999), J. hematocytopenic Periodontal Res. conditions from cancer, 34(4): 223-228. AIDS, etc. linear HIV-1 gp41 anti-AIDS Chan (1998), Cell 93: 681-684. linear PKC inhibition of bone Moonga (1998), Exp. resorption Physiol. 83: 717-725. linear defensins (HNP- antimicrobial Harvig (1994), Methods 1, −2, −3, −4) Enz. 236: 160-172. linear p185^(HER2/neu), C- AHNP-mimetic: anti-tumor Park (2000), Nat. erbB-2 Biotechnol. 18: 194-198. linear gp130 IL-6 antagonist WO 99/60013, published Nov. 25, 1999. linear collagen, other autoimmune diseases WO 99/50282, published joint, cartilage, Oct. 7, 1999. arthritis-related proteins linear HIV-1 envelope treatment of neurological WO 99/51254, published protein degenerative diseases Oct. 14, 1999. linear IL-2 autoimmune disorders WO 00/04048, published (e.g., graft rejection, Jan. 27, 2000; WO rheumatoid arthritis) 00/11028, published Mar. 2, 2000.

[0010] Peptides identified by peptide library screening have been regarded as “leads” in development of therapeutic agents rather than as therapeutic agents themselves. Like other proteins and peptides, they would be rapidly removed in vivo either by renal filtration, cellular clearance mechanisms in the reticuloendothelial system, or proteolytic degradation. Francis (1992), Focus on Growth Factors 3: 4-11. As a result, the art presently uses the identified peptides to validate drug targets or as scaffolds for design of organic compounds that might not have been as easily or as quickly identified through chemical library screening. Lowman (1997), Ann. Rev. Biophys. Biomol. Struct. 26: 401-24; Kay et al. (1998), Drug Disc. Today 3: 370-8. The art would benefit from a process by which such peptides could more readily yield therapeutic agents.

SUMMARY OF THE INVENTION

[0011] The present invention concerns a process by which the in vivo half-life of one or more biologically active peptides is increased by fusion with a vehicle. In this invention, pharmacologically active compounds are prepared by a process comprising:

[0012] a) selecting at least one peptide that modulates the activity of a protein of interest; and

[0013] b) preparing a pharmacologic agent comprising at least one vehicle covalently linked to at least one amino acid sequence of the selected peptide.

[0014] The preferred vehicle is an Fc domain. The peptides screened in step (a) are preferably expressed in a phage display library. The vehicle and the peptide may be linked through the N- or C-terminus of the peptide or the vehicle, as described further below. Derivatives of the above compounds (described below) are also encompassed by this invention.

[0015] The compounds of this invention may be prepared by standard synthetic methods, recombinant DNA techniques, or any other methods of preparing peptides and fusion proteins. Compounds of this invention that encompass non-peptide portions may be synthesized by standard organic chemistry reactions, in addition to standard peptide chemistry reactions when applicable.

[0016] The primary use contemplated is as therapeutic or prophylactic agents. The vehicle-linked peptide may have activity comparable to—or even greater than—the natural ligand mimicked by the peptide. In addition, certain natural ligand-based therapeutic agents might induce antibodies against the patient's own endogenous ligand; the vehicle-linked peptide avoids this pitfall by having little or typically no sequence identity with the natural ligand.

[0017] Although mostly contemplated as therapeutic agents, compounds of this invention may also be useful in screening for such agents. For example, one could use an Fc-peptide (e.g., Fc-SH2 domain peptide) in an assay employing anti-Fc coated plates. The vehicle, especially Fc, may make insoluble peptides soluble and thus useful in a number of assays.

[0018] The compounds of this invention may be used for therapeutic or prophylactic purposes by formulating them with appropriate pharmaceutical carrier materials and administering an effective amount to a patient, such as a human (or other mammal) in need thereof. Other related aspects are also included in the instant invention.

[0019] Numerous additional aspects and advantages of the present invention will become apparent upon consideration of the figures and detailed description of the invention.

BRIEF DESCRIPTION OF THE FIGURES

[0020]FIG. 1 shows a schematic representation of an exemplary process of the invention. In this preferred process, the vehicle is an Fc domain, which is linked to the peptide covalently by expression from a DNA construct encoding both the Fc domain and the peptide. As noted in FIG. 1, the Fc domains spontaneously form a dimer in this process.

[0021]FIG. 2 shows exemplary Fc dimers that may be derived from an IgG1 antibody. “Fc” in the figure represents any of the Fc variants within the meaning of “Fc domain” herein. “X¹” and “X²” represent peptides or linker-peptide combinations as defined hereinafter. The specific dimers are as follows:

[0022] A, D: Single disulfide-bonded dimers. IgG1 antibodies typically have two disulfide bonds at the hinge region between the constant and variable domains. The Fc domain in FIGS. 2A and 2D may be formed by truncation between the two disulfide bond sites or by substitution of a cysteinyl residue with an unreactive residue (e.g., alanyl). In FIG. 2A, the Fc domain is linked at the amino terminus of the peptides; in 2D, at the carboxyl terminus.

[0023] B, E: Doubly disulfide-bonded dimers. This Fc domain may be formed by truncation of the parent antibody to retain both cysteinyl residues in the Fc domain chains or by expression from a construct including a sequence encoding such an Fc domain. In FIG. 2B, the Fc domain is linked at the amino terminus of the peptides; in 2E, at the carboxyl terminus.

[0024] C, F: Noncovalent dimers. This Fc domain may be formed by elimination of the cysteinyl residues by either truncation or substitution. One may desire to eliminate the cysteinyl residues to avoid impurities formed by reaction of the cysteinyl residue with cysteinyl residues of other proteins present in the host cell. The noncovalent bonding of the Fc domains is sufficient to hold together the dimer.

[0025] Other dimers may be formed by using Fc domains derived from different types of antibodies (e.g., IgG2, IgM).

[0026]FIG. 3 shows the structure of preferred compounds of the invention that feature tandem repeats of the pharmacologically active peptide. FIG. 3A shows a single chain molecule and may also represent the DNA construct for the molecule. FIG. 3B shows a dimer in which the linker-peptide portion is present on only one chain of the dimer. FIG. 3C shows a dimer having the peptide portion on both chains. The dimer of FIG. 3C will form spontaneously in certain host cells upon expression of a DNA construct encoding the single chain shown in FIG. 3A. In other host cells, the cells could be placed in conditions favoring formation of dimers or the dimers can be formed in vitro.

[0027]FIG. 4 shows exemplary nucleic acid and amino acid sequences (SEQ ID NOS: 1 and 2, respectively) of human IgG1 Fc that may be used in this invention.

[0028]FIG. 5 shows a synthetic scheme for the preparation of PEGylated peptide 19 (SEQ ID NO: 3).

[0029]FIG. 6 shows a synthetic scheme for the preparation of PEGylated peptide 20 (SEQ ID NO: 4).

[0030]FIG. 7 shows the nucleotide and amino acid sequences (SEQ ID NOS: 5 and 6, respectively) of the molecule identified as “Fc-TMP” in Example 2 hereinafter.

[0031]FIG. 8 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 7 and 8, respectively) of the molecule identified as “Fc-TMP-TMP” in Example 2 hereinafter.

[0032]FIG. 9 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 9 and 10, respectively) of the molecule identified as “TMP-TMP-Fc” in Example 2 hereinafter.

[0033]FIG. 10 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 11 and 12, respectively) of the molecule identified as “TMP-Fc” in Example 2 hereinafter.

[0034]FIG. 11 shows the number of platelets generated in vivo in normal female BDF1 mice treated with one 100 μg/kg bolus injection of various compounds, with the terms defined as follows.

[0035] PEG-MGDF: 20 kD average molecular weight PEG attached by reductive amination to the N-terminal amino group of amino acids 1-163 of native human TPO, which is expressed in E. coli (so that it is not glycosylated);

[0036] TMP: the TPO-mimetic peptide having the amino acid sequence IEGPTLRQWLAARA (SEQ ID NO: 13);

[0037] TMP-TMP: the TPO-mimetic peptide having the amino acid sequence IEGPTLRQWLAARA-GGGGGGGG-IEGPTLRQWLAARA (SEQ ID NO: 14);

[0038] PEG-TMP-TMP: the peptide of SEQ ID NO: 14, wherein the PEG group is a 5 kD average molecular weight PEG attached as shown in FIG. 6;

[0039] Fc-TMP-TMP: the compound of SEQ ID NO: 8 (FIG. 8) dimerized with an identical second monomer (i.e., Cys residues 7 and 10 are bound to the corresponding Cys residues in the second monomer to form a dimer, as shown in FIG. 2); and

[0040] TMP-TMP-Fc is the compound of SEQ ID NO: 10 (FIG. 9) dimerized in the same way as TMP-TMP-Fc except that the Fc domain is attached at the C-terminal end rather than the N-terminal end of the TMP-TMP peptide.

[0041]FIG. 12 shows the number of platelets generated in vivo in normal BDF1 mice treated with various compounds delivered via implanted osmotic pumps over a 7-day period. The compounds are as defined for FIG. 7.

[0042]FIG. 13 shows the nucleotide and amino acid sequences (SEQ. ID. NOS: 15 and 16, respectively) of the molecule identified as “Fc-EMP” in Example 3 hereinafter.

[0043]FIG. 14 shows the nucleotide and amino acid sequences (SEQ ID NOS: 17 and 18, respectively) of the molecule identified as “EMP-Fc” in Example 3 hereinafter.

[0044]FIG. 15 shows the nucleotide and amino acid sequences (SEQ ID NOS:19 and 20, respectively) of the molecule identified as “EMP-EMP-Fc” in Example 3 hereinafter.

[0045]FIG. 16 shows the nucleotide and amino acid sequences (SEQ ID NOS: 21 and 22, respectively) of the molecule identified as “Fc-EMP-EMP” in Example 3 hereinafter.

[0046]FIGS. 17A and 17B show the DNA sequence (SEQ ID NO: 23) inserted into pCFM1656 between the unique AatII (position #4364 in pCFM1656) and SacII (position #4585 in pCFM1656) restriction sites to form expression plasmid pAMG21 (ATCC accession no. 98113).

[0047]FIG. 18A shows the hemoglobin, red blood cells, and hematocrit generated in vivo in normal female BDF1 mice treated with one 100 μg/kg bolus injection of various compounds. FIG. 18B shows the same results with mice treated with 100 μg/kg per day delivered by 7-day micro-osmotic pump with the EMPs delivered at 100 μg/kg, rhEPO at 30U/mouse. (In both experiments, neutrophils, lymphocytes, and platelets were unaffected.) In these figures, the terms are defined as follows.

[0048] Fc-EMP: the compound of SEQ ID NO: 16 (FIG. 13) dimerized with an identical second monomer (i.e., Cys residues 7 and 10 are bound to the corresponding Cys residues in the second monomer to form a dimer, as shown in FIG. 2);

[0049] EMP-Fc: the compound of SEQ ID NO: 18 (FIG. 14) dimerized in the same way as Fc-EMP except that the Fc domain is attached at the C-terminal end rather than the N-terminal end of the EMP peptide.

[0050] “EMP-EMP-Fc” refers to a tandem repeat of the same peptide (SEQ ID NO: 20) attached to the same Fc domain by the carboxyl terminus of the peptides. “Fc-EMP-EMP” refers to the same tandem repeat of the peptide but with the same Fc domain attached at the amino terminus of the tandem repeat. All molecules are expressed in E. coli and so are not glycosylated.

[0051]FIGS. 19A and 19B show the nucleotide and amino acid sequences (SEQ ID NOS: 1055 and 1056) of the Fc-TNF-α inhibitor fusion molecule described in Example 4 hereinafter.

[0052]FIGS. 20A and 20B show the nucleotide and amino acid sequences (SEQ ID NOS: 1057 and 1058) of the TNF-α inhibitor-Fc fusion molecule described in Example 4 hereinafter.

[0053]FIGS. 21A and 21B show the nucleotide and amino acid sequences (SEQ ID NOS: 1059 and 1060) of the Fc-IL-1 antagonist fusion molecule described in Example 5 hereinafter.

[0054]FIGS. 22A and 22B show the nucleotide and amino acid sequences (SEQ ID NOS: 1061 and 1062) of the IL-1 antagonist-Fc fusion molecule described in Example 5 hereinafter.

[0055]FIGS. 23A, 23B, and 23C show the nucleotide and amino acid sequences (SEQ ID NOS: 1063 and 1064) of the Fc-VEGF antagonist fusion molecule described in Example 6 hereinafter.

[0056]FIGS. 24A and 24B show the nucleotide and amino acid sequences (SEQ ID NOS: 1065 and 1066) of the VEGF antagonist-Fc fusion molecule described in Example 6 hereinafter.

[0057]FIGS. 25A and 25B show the nucleotide and amino acid sequences (SEQ ID NOS: 1067 and 1068) of the Fc-MMP inhibitor fusion molecule described in Example 7 hereinafter.

[0058]FIGS. 26A and 26B show the nucleotide and amino acid sequences (SEQ ID NOS: 1069 and 1070) of the MMP inhibitor-Fc fusion molecule described in Example 7 hereinafter.

DETAILED DESCRIPTION OF THE INVENTION Definition of Terms

[0059] The terms used throughout this specification are defined as follows, unless otherwise limited in specific instances.

[0060] The term “comprising” means that a compound may include additional amino acids on either or both of the N- or C-termini of the given sequence. Of course, these additional amino acids should not significantly interfere with the activity of the compound.

[0061] The term “vehicle” refers to a molecule that prevents degradation and/or increases half-life, reduces toxicity, reduces immunogenicity, or increases biological activity of a therapeutic protein. Exemplary vehicles include an Fc domain (which is preferred) as well as a linear polymer (e.g., polyethylene glycol (PEG), polylysine, dextran, etc.); a branched-chain polymer (see, for example, U.S. Pat. No. 4,289,872 to Denkenwalter et al., issued Sep. 15, 1981; 5,229,490 to Tam, issued Jul. 20, 1993; WO 93/21259 by Frechet et al., published 28 Oct. 1993); a lipid; a cholesterol group (such as a steroid); a carbohydrate or oligosaccharide; or any natural or synthetic protein, polypeptide or peptide that binds to a salvage receptor. Vehicles are further described hereinafter.

[0062] The term “native Fc” refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody, whether in monomeric or multimeric form. The original immunoglobulin source of the native Fc is preferably of human origin and may be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Native Fc's are made up of monomeric polypeptides that may be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG (see Ellison et al. (1982), Nucleic Acids Res. 10: 4071-9). The term “native Fc” as used herein is generic to the monomeric, dimeric, and multimeric forms.

[0063] The term “Fc variant” refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn. International applications WO 97/34631 (published 25 Sep. 1997) and WO 96/32478 describe exemplary Fc variants, as well as interaction with the salvage receptor, and are hereby incorporated by reference. Thus, the term “Fc variant” comprises a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises sites that may be removed because they provide structural features or biological activity that are not required for the fusion molecules of the present invention. Thus, the term “Fc variant” comprises a molecule or sequence that lacks one or more native Fc sites or residues that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further detail hereinafter.

[0064] The term “Fc domain” encompasses native Fc and Fc variant molecules and sequences as defined above. As with Fc variants and native Fc's, the term “Fc domain” includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by other means.

[0065] The term “multimer” as applied to Fc domains or molecules comprising Fc domains refers to molecules having two or more polypeptide chains associated covalently, noncovalently, or by both covalent and non-covalent interactions. IgG molecules typically form dimers; IgM, pentamers; IgD, dimers; and IgA, monomers, dimers, trimers, or tetramers. Multimers may be formed by exploiting the sequence and resulting activity of the native Ig source of the Fc or by derivatizing (as defined below) such a native Fc.

[0066] The term “dimer” as applied to Fc domains or molecules comprising Fc domains refers to molecules having two polypeptide chains associated covalently or non-covalently. Thus, exemplary dimers within the scope of this invention are as shown in FIG. 2.

[0067] The terms “derivatizing” and “derivative” or “derivatized” comprise processes and resulting compounds respectively in which (1) the compound has a cyclic portion; for example, cross-linking between cysteinyl residues within the compound; (2) the compound is cross-linked or has a cross-linking site; for example, the compound has a cysteinyl residue and thus forms cross-linked dimers in culture or in vivo; (3) one or more peptidyl linkage is replaced by a non-peptidyl linkage; (4) the N-terminus is replaced by —NRR¹, NRC(O)R¹, —NRC(O)OR¹, —NRS(O)₂R¹, —NHC(O)NHR, a succinimide group, or substituted or unsubstituted benzyloxycarbonyl-NH—, wherein R and R¹ and the ring substituents are as defined hereinafter; (5) the C-terminus is replaced by —C(O)R² or —NR³R⁴ wherein R², R³ and R⁴ are as defined hereinafter; and (6) compounds in which individual amino acid moieties are modified through treatment with agents capable of reacting with selected side chains or terminal residues. Derivatives are further described hereinafter.

[0068] The term “peptide” refers to molecules of 2 to 40 amino acids, with molecules of 3 to 20 amino acids preferred and those of 6 to 15 amino acids most preferred. Exemplary peptides may be randomly generated by any of the methods cited above, carried in a peptide library (e.g., a phage display library), or derived by digestion of proteins.

[0069] The term “randomized” as used to refer to peptide sequences refers to fully random sequences (e.g., selected by phage display methods) and sequences in which one or more residues of a naturally occurring molecule is replaced by an amino acid residue not appearing in that position in the naturally occurring molecule. Exemplary methods for identifying peptide sequences include phage display, E. coli display, ribosome display, yeast-based screening, RNA-peptide screening, chemical screening, rational design, protein structural analysis, and the like.

[0070] The term “pharmacologically active” means that a substance so described is determined to have activity that affects a medical parameter (e.g., blood pressure, blood cell count, cholesterol level) or disease state (e.g., cancer, autoimmune disorders). Thus, pharmacologically active peptides comprise agonistic or mimetic and antagonistic peptides as defined below.

[0071] The terms “-mimetic peptide” and “-agonist peptide” refer to a peptide having biological activity comparable to a protein (e.g., EPO, TPO, G-CSF) that interacts with a protein of interest. These terms further include peptides that indirectly mimic the activity of a protein of interest, such as by potentiating the effects of the natural ligand of the protein of interest; see, for example, the G-CSF-mimetic peptides listed in Tables 2 and 7. Thus, the term “EPO-mimetic peptide” comprises any peptides that can be identified or derived as described in Wrighton et al. (1996), Science 273: 458-63, Naranda et al. (1999), Proc. Natl. Acad. Sci. USA 96: 7569-74, or any other reference in Table 2 identified as having EPO-mimetic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0072] The term “TPO-mimetic peptide” comprises peptides that can be identified or derived as described in Cwirla et al. (1997), Science 276: 1696-9, U.S. Pat. Nos. 5,869,451 and 5,932,946 and any other reference in Table 2 identifed as having TPO-mimetic subject matter, as well as the U.S. patent application, “Thrombopoietic Compounds,” filed on even date herewith and hereby incorporated by reference. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0073] The term “G-CSF-mimetic peptide” comprises any peptides that can be identified or described in Paukovits et al. (1984), Hoppe-Seylers Z. Physiol. Chem. 365: 303-11 or any of the references in Table 2 identified as having G-CSF-mimetic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0074] The term “CTLA4-mimetic peptide” comprises any peptides that can be identified or derived as described in Fukumoto et al. (1998), Nature Biotech. 16: 267-70. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0075] The term “-antagonist peptide” or “inhibitor peptide” refers to a peptide that blocks or in some way interferes with the biological activity of the associated protein of interest, or has biological activity comparable to a known antagonist or inhibitor of the associated protein of interest. Thus, the term “TNF-antagonist peptide” comprises peptides that can be identified or derived as described in Takasaki et al. (1997), Nature Biotech. 15: 1266-70 or any of the references in Table 2 identified as having TNF-antagonistic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0076] The terms “IL-1 antagonist” and “IL-1ra-mimetic peptide” comprises peptides that inhibit or down-regulate activation of the IL-1 receptor by IL-1. IL-1 receptor activation results from formation of a complex among IL-1, IL-1 receptor, and IL-1 receptor accessory protein. IL-1 antagonist or IL-1ra-mimetic peptides bind to IL-1, IL-1 receptor, or IL-1 receptor accessory protein and obstruct complex formation among any two or three components of the complex. Exemplary IL-1 antagonist or IL-1ra-mimetic peptides can be identified or derived as described in U.S. Pat. Nos. 5,608,035, 5,786,331, 5,880,096, or any of the references in Table 2 identified as having IL-1ra-mimetic or IL-1 antagonistic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0077] The term “VEGF-antagonist peptide” comprises peptides that can be identified or derived as described in Fairbrother (1998), Biochem. 37: 17754-64, and in any of the references in Table 2 identified as having VEGF-antagonistic subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0078] The term “MMP inhibitor peptide” comprises peptides that can be identified or derived as described in Koivunen (1999), Nature Biotech. 17: 768-74 and in any of the references in Table 2 identified as having MMP inhibitory subject matter. Those of ordinary skill in the art appreciate that each of these references enables one to select different peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.

[0079] Additionally, physiologically acceptable salts of the compounds of this invention are also encompassed herein. By “physiologically acceptable salts” is meant any salts that are known or later discovered to be pharmaceutically acceptable. Some specific examples are: acetate; trifluoroacetate; hydrohalides, such as hydrochloride and hydrobromide; sulfate; citrate; tartrate; glycolate; and oxalate.

Structure of Compounds

[0080] In General. In the compositions of matter prepared in accordance with this invention, the peptide may be attached to the vehicle through the peptide's N-terminus or C-terminus. Thus, the vehicle-peptide molecules of this invention may be described by the following formula I:

(X¹)_(a)—F¹—(X²)_(b)   I

[0081] wherein:

[0082] F¹ is a vehicle (preferably an Fc domain);

[0083] X¹ and X² are each independently selected from -(L¹)_(c)-P¹, -(L¹)_(c)-P¹-(L²)_(d)-P², -(L¹)_(c)-P¹-(L²)_(d)-P²-(L³)_(e)-P³, and -(L¹)_(c)-P¹-(L²)_(d)-P²-(L³)_(e)-P³-(L⁴)_(f)-P⁴

[0084] P¹, P², P³, and P⁴ are each independently sequences of pharmacologically active peptides;

[0085] L¹, L², L³, and L⁴ are each independently linkers; and

[0086] a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

[0087] Thus, compound I comprises preferred compounds of the formulae

X¹—F¹   II

[0088] and multimers thereof wherein F¹ is an Fc domain and is attached at the C-terminus of X¹;

F¹—X²   III

[0089] and multimers thereof wherein F¹ is an Fc domain and is attached at the N-terminus of X²;

F¹-(L¹)_(c)-P¹   IV

[0090] and multimers thereof wherein F¹ is an Fc domain and is attached at the N-terminus of -(L¹)_(c)-P¹; and

F¹-(L¹)_(c)-P¹-(L²)_(d)-P^(2 V)

[0091] and multimers thereof wherein F¹ is an Fc domain and is attached at the N-terminus of -L¹-P¹-L²-P².

[0092] Peptides. Any number of peptides may be used in conjunction with the present invention. Of particular interest are peptides that mimic the activity of EPO, TPO, growth hormone, G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF-α, and TGF-β. Peptide antagonists are also of interest, particularly those antagonistic to the activity of TNF, leptin, any of the interleukins (IL-1, 2, 3, . . . ), and proteins involved in complement activation (e.g., C3b). Targeting peptides are also of interest, including tumor-homing peptides, membrane-transporting peptides, and the like. All of these classes of peptides may be discovered by methods described in the references cited in this specification and other references.

[0093] Phage display, in particular, is useful in generating peptides for use in the present invention. It has been stated that affinity selection from libraries of random peptides can be used to identify peptide ligands for any site of any gene product. Dedman et al. (1993), J. Biol. Chem. 268: 23025-30. Phage display is particularly well suited for identifying peptides that bind to such proteins of interest as cell surface receptors or any proteins having linear epitopes. Wilson et al. (1998), Can. T. Microbiol. 44: 313-29; Kay et al. (1998), Drug Disc. Today 3: 370-8. Such proteins are extensively reviewed in Herz et al. (1997), J. Receptor & Signal Transduction Res. 17(5): 671-776, which is hereby incorporated by reference. Such proteins of interest are preferred for use in this invention.

[0094] A particularly preferred group of peptides are those that bind to cytokine receptors. Cytokines have recently been classified according to their receptor code. See Inglot (1997), Archivum Immunologiae et Therapiae Experimentalis 45: 353-7, which is hereby incorporated by reference. Among these receptors, most preferred are the CKRs (family I in Table 3). The receptor classification appears in Table 3. TABLE 3 Cytokine Receptors Classified by Receptor Code Cytokines (ligands) Receptor Type family subfamily family subfamily I. Hematopoietic 1. IL-2, IL-4, IL-7, I. Cytokine R 1. shared γCr, IL- cytokines IL-9, IL-13, IL- (CKR) 9R, IL-4R 15 2. IL-3, IL-5, GM- 2. shared GP 140 CSF βR 3. 1L-6, IL-11, IL- 3. 3.shared RP 12, LIF, OSM, 130, IL-6 R, CNTF, Leptin Leptin R (OB) 4. G-CSF, EPO, 4. “single chain” TPO, PRL, GH R, GCSF-R, TPO-R, GH-R 5. 1L-17, HVS-IL- 5. other R^(c) 17 II. IL-10 ligands IL-10, BCRF-1, II. IL-10 R HSV-IL-10 III. Interferons 1. IFN-α1, α2, α4, III. Interferon R 1. IFNAR m, t, IFN-β^(d) 2. IFN-γ 2. IFNGR IV. IL-1 and IL-1 1. IL-1α, IL-1β, IL- IV. IL-1R 1. IL-1R, IL- like ligands 1Ra 1RAcP 2. IL-18, IL-18BP 2. IL-18R, IL- 18RAcP V. TNF family 1. TNF-α, TNF-β 3. NGF/TNF R^(e) TNF-RI, AGP-3R, (LT), FASL, DR4, DR5, OX40, CD40 L, OPG, TACI, CD40, CD30L, CD27 FAS, ODR L, OX40L, OPGL, TRAIL, APRIL, AGP-3, BLys, TL5, Ntn-2, KAY, Neutrokine-α VI. Chemokines 1. α chemokines: 4. Chemokine R 1. CXCR IL-8, GRO α, β, γ, IF-10, PF-4, SDF-1 2. β chemokines: 2. CCR MIP1α, MIPβ, MIP1α, MIP1β, MCP-1, 2, 3, 4, RANTES, eotaxin 3. CR 3. γ chemokines: lymphotactin 4. DARC^(f) VII. Growth factors 1.1 SCF, M-CSF, VII. RKF 1. TK sub-family PDGF-AA, AB, 1.1 IgTK III R, BB, KDR, FLT- VEGF-RI, 1, FLT-3L, VEGF-RII VEGF, SSV- PDGF, HGF, SF 1.2 FGFα, FGFβ 1.2 IgTK IV R 1.3 EGF, TGF-α, 1.3 Cysteine-rich VV-F19 (EGF- TK-I like) 1.4 IGF-I, IGF-II, 1.4 Cysteine rich Insulin TK-II, IGF-RI 1.5 NGF, BDNF, 1.5 Cysteine knot NT-3, NT-4^(g) TK V 2. TGF-β1, β2, β3 2. Serine- threonine kinase subfamily (STKS)^(h)

[0095]

[0096] Particular proteins of interest as targets for peptide generation in the present invention include the following:

[0097] αvβ3

[0098] αVβ1

[0099] Ang-2

[0100] B7

[0101] B7RP1

[0102] CRP1

[0103] Calcitonin

[0104] CD28

[0105] CETP

[0106] cMet

[0107] Complement factor B

[0108] C4b

[0109] CTLA4

[0110] Glucagon

[0111] Glucagon Receptor

[0112] LIPG

[0113] MPL

[0114] splice variants of molecules preferentially expressed on tumor cells; e.g., CD44, CD30

[0115] unglycosylated variants of mucin and Lewis Y surface glycoproteins

[0116] CD19, CD20, CD33, CD45

[0117] prostate specific membrane antigen and prostate specific cell antigen

[0118] matrix metalloproteinases (MMPs), both secreted and membrane-bound (e.g., MMP-9)

[0119] Cathepsins

[0120] angiopoietin-2

[0121] TIE-2 receptor

[0122] heparanase

[0123] urokinase plasminogen activator (UPA), UPA receptor parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), PTH-RI, PTH-RII

[0124] Her2

[0125] Her3

[0126] Insulin—

[0127] Exemplary peptides for this invention appear in Tables 4 through 20 below. These peptides may be prepared by methods disclosed in the art. Single letter amino acid abbreviations are used. The X in these sequences (and throughout this specification, unless specified otherwise in a particular instance) means that any of the 20 naturally occurring amino acid residues may be present. Any of these peptides may be linked in tandem (i.e., sequentially), with or without linkers, and a few tandem-linked examples are provided in the table. Linkers are listed as “A” and may be any of the linkers described herein. Tandem repeats and linkers are shown separated by dashes for clarity. Any peptide containing a cysteinyl residue may be cross-linked with another Cys-containing peptide, either or both of which may be linked to a vehicle. A few cross-linked examples are provided in the table. Any peptide having more than one Cys residue may form an intrapeptide disulfide bond, as well; see, for example, EPO-mimetic peptides in Table 5. A few examples of intrapeptide disulfide-bonded peptides are specified in the table. Any of these peptides may be derivatized as described herein, and a few derivatized examples are provided in the table. Derivatized peptides in the tables are exemplary rather than limiting, as the associated underivatized peptides may be employed in this invention, as well. For derivatives in which the carboxyl terminus may be capped with an amino group, the capping amino group is shown as —NH₂. For derivatives in which amino acid residues are substituted by moieties other than amino acid residues, the substitutions are denoted by a, which signifies any of the moieties described in Bhatnagar et al. (1996), J. Med. Chem. 39: 3814-9 and Cuthbertson et al. (1997), J. Med. Chem. 40: 2876-82, which are incorporated by reference. The J substituent and the Z substituents (Z₅, Z₆, . . . Z₄₀) are as defined in U.S. Pat. Nos. 5,608,035 ,5,786,331, and 5,880,096, which are incorporated by reference. For the EPO-mimetic sequences (Table 5), the substituents X₂ through X₁₁, and the integer “n” are as defined in WO 96/40772, which is incorporated by reference. Also for the EPO-mimetic sequences, the substituents X_(na), X_(1a), X_(2a), X_(3a), X_(4a), X_(5a) and X_(ca) follow the definitions of X_(n), X₁, X₂, X₃, X₄, X₅, and X_(c), respectively, of WO 99/47151, which is also incorporated by reference. The substituents “Ψ,” “Θ,” and “+” are as defined in Sparks et al. (1996), Proc. Natl. Acad. Sci. 93: 1540-4, which is hereby incorporated by reference. X₄, X₅, X₆, and X₇ are as defined in U.S. Pat. No. 5,773,569, which is hereby incorporated by reference, except that: for integrin-binding peptides, X₁, X₂, X₃, X₄, X₅, X₆, X₇, and X₈ are as defined in International applications WO 95/14714, published Jun. 1, 1995 and WO 97/08203, published Mar. 6, 1997, which are also incorporated by reference; and for VIP-mimetic peptides, X₁, X₁′, X₁″, X₂, X₃, X₄, X₅, X₆ and Z and the integers m and n are as defined in WO 97/40070, published Oct. 30, 1997, which is also incorporated by reference. Xaa and Yaa below are as defined in WO 98/09985, published Mar. 12, 1998, which is incorporated by reference. AA₁, AA₂, AB₁, AB₂, and AC are as defined in International application WO 98/53842, published Dec. 3, 1998, which is incorporated by reference. X¹, X², X³, and X⁴ in Table 17 only are as defined in European application EP 0 911 393, published Apr. 28, 1999. Residues appearing in boldface are D-amino acids. All peptides are linked through peptide bonds unless otherwise noted. Abbreviations are listed at the end of this specification. In the “SEQ ID NO.” column, “NR” means that no sequence listing is required for the given sequence. TABLE 4 IL-1 antagonist peptide sequences SEQ Sequence/structure ID NO: Z₁₁Z₇Z₈QZ₅YZ₆Z₉Z₁₀ 212 XXQZ₅YZ₆XX 907 Z₇XQZ₅YZ₆XX 908 Z₇Z₈QZ₅YZ₆Z₉Z₁₀ 909 Z₁₁Z₇Z₈QZ₅YZ₆Z₉Z₁₀ 910 Z₁₂Z₁₃Z₁₄Z₁₅Z₁₆Z₁₇Z₁₈Z₁₉Z₂₀Z₂₁Z₂₂Z₁₁Z₇Z₈QZ₅YZ₆Z₉Z₁₀L 917 Z₂₃NZ₂₄Z₃₉Z₂₅Z₂₆Z₂₇Z₂₈Z₂₉Z₃₀Z₄₀ 979 TANVSSFEWTPYYWQPYALPL 213 SWTDYGYWQPYALPISGL 214 ETPFTWEESNAYYWQPYALPL 215 ENTYSPNWADSMYWQPYALPL 216 SVGEDHNFWTSEYWQPYALPL 217 DGYDRWRQSGERYWQPYALPL 218 FEWTPGYWQPY 219 FEWTPGYWQHY 220 FEWTPGWYQJY 221 AcFEWTPGWYQJY 222 FEWTPGWpYQJY 223 FAWTPGYWQJY 224 FEWAPGYWQJY 225 FEWVPGYWQJY 226 FEWTPGYWQJY 227 AcFEWTPGYWQJY 228 FEWTPaWYQJY 229 FEWTPSarWYQJY 230 FEWTPGYYQPY 231 FEWTPGWWQPY 232 FEWTPNYWQPY 233 FEWTPvYWQJY 234 FEWTPecGYWQJY 235 FEWTPAibYWQJY 236 FEWTSarGYWQJY 237 FEWTPGYWQPY 238 FEWTPGYWQHY 239 FEWTPGWYQJY 240 AcFEWTPGWYQJY 241 FEWTPGW-pY-QJY 242 FAWTPGYWQJY 243 FEWAPGYWQJY 244 FEWVPGYWQJY 245 FEWTPGYWQJY 246 AcFEWTPGYWQJY 247 FEWTPAWYQJY 248 FEWTPSarWYQJY 249 FEWTPGYYQPY 250 FEWTPGWWQPY 251 FEWTPNYWQPY 252 FEWTPVYWQJY 253 FEWTPecGYWQJY 254 FEWTPAibYWQJY 255 FEWTSarGYWQJY 256 FEWTPGYWQPYALPL 257 1NapEWTPGYYQJY 258 YEWTPGYYQJY 259 FEWVPGYYQJY 260 FEWTPSYYQJY 261 FEWTPNYYQJY 262 TKPR 263 RKSSK 264 RKQDK 265 NRKQDK 266 RKQDKR 267 ENRKQDKRF 268 VTKFYF 269 VTKFY 270 VTDFY 271 SHLYWQPYSVQ 671 TLVYWQPYSLQT 672 RGDYWQPYSVQS 673 VHVYWQPYSVQT 674 RLVYWQPYSVQT 675 SRVWFQPYSLQS 676 NMVYWQPYSIQT 677 SVVFWQPYSVQT 678 TFVYWQPYALPL 679 TLVYWQPYSIQR 680 RLVYWQPYSVQR 681 SPVFWQPYSIQI 682 WIEWWQPYSVQS 683 SLIYWQPYSLQM 684 TRLYWQPYSVQR 685 RCDYWQPYSVQT 686 MRVFWQPYSVQN 687 KIVYWQPYSVQT 688 RHLYWQPYSVQR 689 ALVWWQPYSEQI 690 SRVWFQPYSLQS 691 WEQPYALPLE 692 QLVWWQPYSVQR 693 DLRYWQPYSVQV 694 ELVWWQPYSLQL 695 DLVWWQPYSVQW 696 NGNYWQPYSFQV 697 ELVYWQPYSIQR 698 ELMYWQPYSVQE 699 NLLYWQPYSMQD 700 GYEWYQPYSVQR 701 SRVWYQPYSVQR 702 LSEQYQPYSVQR 703 GGGWWQPYSVQR 704 VGRWYQPYSVQR 705 VHVYWQPYSVQR 706 QARWYQPYSVQR 707 VHVYWQPYSVQT 708 RSVYWQPYSVQR 709 TRVWFQPYSVQR 710 GRIWFQPYSVQR 711 GRVWFQPYSVQR 712 ARTWYQPYSVQR 713 ARVWWQPYSVQM 714 RLMFYQPYSVQR 715 ESMWYQPYSVQR 716 HFGWWQPYSVHM 717 ARFWWQPYSVQR 718 RLVYWQ PYAPIY 719 RLVYWQ PYSYQT 720 RLVYWQ PYSLPI 721 RLVYWQ PYSVQA 722 SRVWYQ PYAKGL 723 SRVWYQ PYAQGL 724 SRVWYQ PYAMPL 725 SRVWYQ PYSVQA 726 SRVWYQ PYSLGL 727 SRVWYQ PYAREL 728 SRVWYQ PYSRQP 729 SRVWYQ PYFVQP 730 EYEWYQ PYALPL 731 IPEYWQ PYALPL 732 SRIWWQ PYALPL 733 DPLFWQ PYALPL 734 SRQWVQ PYALPL 735 IRSWWQ PYALPL 736 RGYWQ PYALPL 737 RLLWVQ PYALPL 738 EYRWFQ PYALPL 739 DAYWVQ PYALPL 740 WSGYFQ PYALPL 741 NIEFWQ PYALPL 742 TRDWVQ PYALPL 743 DSSWYQ PYALPL 744 IGNWYQ PYALPL 745 NLRWDQ PYALPL 746 LPEFWQ PYALPL 747 DSYWWQ PYALPL 748 RSQYYQ PYALPL 749 ARFWLQ PYALPL 750 NSYFWQ PYALPL 751 RFMYWQPYSVQR 752 AHLFWQPYSVQR 753 WWQPYALPL 754 YYQPYALPL 755 YFQPYALGL 756 YWYQPYALPL 757 RWWQPYATPL 758 GWYQPYALGF 759 YWYQPYALGL 760 IWYQPYAMPL 761 SNMQPYQRLS 762 TFVYWQPY AVGLPAAETACN 763 TFVYWQPY SVQMTITGKVTM 764 TFVYWQPY SSHXXVPXGFPL 765 TFVYWQPY YGNPQWAIHVRH 766 TFVYWQPY VLLELPEGAVRA 767 TFVYWQPY VDYVWPIPIAQV 768 GWYQPYVDGWR 769 RWEQPYVKDGWS 770 EWYQPYALGWAR 771 GWWQPYARGL 772 LFEQPYAKALGL 773 GWEQPYARGLAG 774 AWVQPYATPLDE 775 MWYQPYSSQPAE 776 GWTQPYSQQGEV 777 DWFQPYSIQSDE 778 PWIQPYARGFG 779 RPLYWQPYSVQV 780 TLIYWQPYSVQI 781 RFDYWQPYSDQT 782 WHQFVQPYALPL 783 EWDS VYWQPYSVQ TLLR 784 WEQN VYWQPYSVQ SFAD 785 SDV VYWQPYSVQ SLEM 786 YYDG VYWQPYSVQ VMPA 787 SDIWYQ PYALPL 788 QRIWWQ PYALPL 789 SRIWWQ PYALPL 790 RSLYWQ PYALPL 791 TIIWEQ PYALPL 792 WETWYQ PYALPL 793 SYDWEQ PYALPL 794 SRIWCQ PYALPL 795 EIMFWQ PYALPL 796 DYVWQQ PYALPL 797 MDLLVQ WYQPYALPL 798 GSKVIL WYQPYALPL 799 RQGANI WYQPYALPL 800 GGGDEP WYQPYALPL 801 SQLERT WYQPYALPL 802 ETWVRE WYQPYALPL 803 KKGSTQ WYQPYALPL 804 LQARMN WYQPYALPL 805 EPRSQK WYQPYALPL 806 VKQKWR WYQPYALPL 807 LRRHDV WYQPYALPL 808 RSTASI WYQPYALPL 809 ESKEDQ WYQPYALPL 810 EGLTMK WYQPYALPL 811 EGSREG WYQPYALPL 812 VIEWWQ PYALPL 813 VWYWEQ PYALPL 814 ASEWWQ PYALPL 815 FYEWWQ PYALPL 816 EGWWVQ PYALPL 817 WGEWLQ PYALPL 818 DYVWEQ PYALPL 819 AHTWWQ PYALPL 820 FIEWFQ PYALPL 821 WLAWEQ PYALPL 822 VMEWWQ PYALPL 823 ERMWQ PYALPL 824 NXXWXX PYALPL 825 WGNWYQ PYALPL 826 TLYWEQ PYALPL 827 VWRWEQ PYALPL 828 LLWTQ PYALPL 829 SRIWXX PYALPL 830 SDIWYQ PYALPL 831 WGYYXX PYALPL 832 TSGWYQ PYALPL 833 VHPYXX PYALPL 834 EHSYFQ PYALPL 835 XXIWYQ PYALPL 836 AQLHSQ PYALPL 837 WANWFQ PYALPL 838 SRLYSQ PYALPL 839 GVTFSQ PYALPL 840 SIVWSQ PYALPL 841 SRDLVQ PYALPL 842 HWGH VYWQPYSVQ DDLG 843 SWHS VYWQPYSVQ SVPE 844 WRDS VYWQPYSVQ PESA 845 TWDA VYWQPYSVQ KWLD 846 TPPW VYWQPYSVQ SLDP 847 YWSS VYWQPYSVQ SVHS 848 YWY QPY ALGL 849 YWY QPY ALPL 850 EWI QPY ATGL 851 NWE QPY AKPL 852 AFY QPY ALPL 853 FLY QPY ALPL 854 VCK QPY LEWC 855 ETPFTWEESNAYYWQPYALPL 856 QGWLTWQDSVDMYWQPYALPL 857 FSEAGYTWPENTYWQPYALPL 858 TESPGGLDWAKIYWQPYALPL 859 DGYDRWRQSGERYWQPYALPL 860 TANVSSFEWTPGYWQPYALPL 861 SVGEDHNFWTSE YWQPYALPL 862 MNDQTSEVSTFP YWQPYALPL 863 SWSEAFEQPRNL YWQPYALPL 864 QYAEPSALNDWG YWQPYALPL 865 NGDWATADWSNY YWQPYALPL 866 THDEHI YWQPYALPL 867 MLEKTYTTWTPG YWQPYALPL 868 WSDPLTRDADL YWQPYALPL 869 SDAFTTQDSQAM YWQPYALPL 870 GDDAAWRTDSLT YWQPYALPL 871 AIIRQLYRWSEM YWQPYALPL 872 ENTYSPNWADSM YWQPYALPL 873 MNDQTSEVSTFP YWQPYALPL 874 SVGEDHNFWTSE YWQPYALPL 875 QTPFTWEESNAY YWQPYALPL 876 ENPFTWQESNAY YWQPYALPL 877 VTPFTWEDSNVF YWQPYALPL 878 QIPFTWEQSNAY YWQPYALPL 879 QAPLTWQESAAY YWQPYALPL 880 EPTFTWEESKAT YWQPYALPL 881 TTTLTWEESNAY YWQPYALPL 882 ESPLTWEESSAL YWQPYALPL 883 ETPLTWEESNAY YWQPYALPL 884 EATFTWAESNAY YWQPYALPL 885 EALFTWKESTAY YWQPYALPL 886 STP-TWEESNAY YWQPYALPL 887 ETPFTWEESNAY YWQPYALPL 888 KAPFTWEESQAY YWQPYALPL 889 STSFTWEESNAY YWQPYALPL 890 DSTFTWEESNAY YWQPYALPL 891 YIPFTWEESNAY YWQPYALPL 892 QTAFTWEESNAY YWQPYALPL 893 ETLFTWEESNAT YWQPYALPL 894 VSSFTWEESNAY YWQPYALPL 895 QPYALPL 896 Py-1-NapPYQJYALPL 897 TANVSSFEWTPG YWQPYALPL 898 FEWTPGYWQPYALPL 899 FEWTPGYWQJYALPL 900 FEWTPGYYQJYALPL 901 ETPFTWEESNAYYWQPYALPL 902 FTWEESNAYYWQJYALPL 903 ADVL YWQPYA PVTLWV 904 GDVAE YWQPYA LPLTSL 905 SWTDYG YWQPYA LPISGL 906 FEWTPGYWQPYALPL 911 FEWTPGYWQJYALPL 912 FEWTPGWYQPYALPL 913 FEWTPGWYQJYALPL 914 FEWTPGYYQPYALPL 915 FEWTPGYYQJYALPL 916 TANVSSFEWTPGYWQPYALPL 918 SWTDYGYWQPYALPISGL 919 ETPFTWEESNAYYWQPYALPL 920 ENTYSPNWADSMYWQPYALPL 921 SVGEDHNFWTSEYWQPYALPL 922 DGYDRWRQSGERYWQPYALPL 923 FEWTPGYWQPYALPL 924 FEWTPGYWQPY 925 FEWTPGYWQJY 926 EWTPGYWQPY 927 FEWTPGWYQJY 928 AEWTPGYWQJY 929 FAWTPGYWQJY 930 FEATPGYWQJY 931 FEWAPGYWQJY 932 FEWTAGYWQJY 933 FEWTPAYWQJY 934 FEWTPGAWQJY 935 FEWTPGYAQJY 936 FEWTPGYWQJA 937 FEWTGGYWQJY 938 FEWTPGYWQJY 939 FEWTJGYWQJY 940 FEWTPecGYWQJY 941 FEWTPAibYWQJY 942 FEWTPSarWYQJY 943 FEWTSarGYWQJY 944 FEWTPNYWQJY 945 FEWTPVYWQJY 946 FEWTVPYWQJY 947 AcFEWTPGWYQJY 948 AcFEWTPGYWQJY 949 INap-EWTPGYYQJY 950 YEWTPGYYQJY 951 FEWVPGYYQJY 952 FEWTPGYYQJY 953 FEWTPsYYQJY 954 FEWTPnYYQJY 955 SHLY-Nap-QPYSVQM 956 TLVY-Nap-QPYSLQT 957 RGDY-Nap-QPYSVQS 958 NMVY-Nap-QPYSIQT 959 VYWQPYSVQ 960 VY-Nap-QPYSVQ 961 TFVYWQJYALPL 962 FEWTPGYYQJ-Bpa 963 XaaFEWTPGYYQJ-Bpa 964 FEWTPGY-Bpa-QJY 965 AcFEWTPGY-Bpa-QJY 966 FEWTPG-Bpa-YQJY 967 AcFEWTPG-Bpa-YQJY 968 AcFE-Bpa-TPGYYQJY 969 AcFE-Bpa-TPGYYQJY 970 Bpa-EWTPGYYQJY 971 AcBpa-EWTPGYYQJY 972 VYWQPYSVQ 973 RLVYWQPYSVQR 974 RLVY-Nap-QPYSVQR 975 RLDYWQPYSVQR 976 RLVWFQPYSVQR 977 RLVYWQPYSIQR 978 DNSSWYDSFLL 980 DNTAWYESFLA 981 DNTAWYENFLL 982 PARE DNTAWYDSFLI WC 983 TSEY DNTTWYEKFLA SQ 984 SQIP DNTAWYQSFLL HG 985 SPFI DNTAWYENFLL TY 986 EQIY DNTAWYDHFLL SY 987 TPFI DNTAWYENFLL TY 988 TYTY DNTAWYERFLM SY 989 TMTQ DNTAWYENFLL SY 990 TI DNTAWYANLVQ TYPQ 991 TI DNTAWYERFLA QYPD 992 HI DNTAWYENFLL TYTP 993 SQ DNTAWYENFLL SYKA 994 QI DNTAWYERFLL QYNA 995 NQ DNTAWYESFLL QYNT 996 TI DNTAWYENFLL NHNL 997 HY DNTAWYERFLQ QGWH 998 ETPFTWEESNAYYWQPYALPL 999 YIPFTWEESNAYYWQPYALPL 1000 DGYDRWRQSGERYWQPYALPL 1001 pY-INap-pY-QJYALPL 1002 TANVSSFEWTPGYWQPYALPL 1003 FEWTPGYWQJYALPL 1004 FEWTPGYWQPYALPLSD 1005 FEWTPGYYQJYALPL 1006 FEWTPGYWQJY 1007 AcFEWTPGYWQJY 1008 AcFEWTPGWYQJY 1009 AcFEWTPGYYQJY 1010 AcFEWTPaYWQJY 1011 AcFEWTPaWYQJY 1012 AcFEWTPaYYQJY 1013 FEWTPGYYQJYALPL 1014 FEWTPGYWQJYALPL 1015 FEWTPGWYQJYALPL 1016 TANVSSFEWTPGYWQPYALPL 1017 AcFEWTPGYWQJY 1018 AcFEWTPGWYQJY 1019 AcFEWTPGYYQJY 1020 AcFEWTPAYWQJY 1021 AcFEWTPAWYQJY 1022 AcFEWTPAYYQJY 1023

[0128] TABLE 5 EPO-mimetic peptide sequences SEQ Sequence/structure ID NO: YXCXXGPXTWXCXP 83 YXCXXGPXTWXCP-YXCXXGPXTWXCXP 84 YXCXXGPXTWXCXP-Λ-YXCXXGPXTWXCXP 85

86 86 GGTYSCHFGPLTWVCKPQGG 87 GGDYHCRMGPLTWVCKPLGG 88 GGVYACRMGPITWVCSPLGG 89 VGNYMCHFGPITWVCRPGGG 90 GGLYLCRFGPVTWDCGYKGG 91 GGTYSCHFGPLTWVCKPQGG- 92 GGTYSCHFGPLTWVCKPQGG GGTYSCHFGPLTWVCKPQGG-Λ- 93 GGTYSCHFGPLTWVCKPQGG GGTYSCGFGPLTWVCKPQGGSSK 94 GGTYSCHFGPLTWVCKPQGGSSK- 95 GGTYSCHFGPLTWVCKPQGGSSK GGTYSCHFGPLTWVCKPQGGSSK-Λ- 96 GGTYSCGFGPLTWVCKPQGGSSK

GGTYSCHFGPTLWVCKPQGGSSK(-Λ-biotin) 98 CX₄X₅GPX₆TWX₇C 421 GGTYSCHGPLTWVCKPQGG 422 VGNYMAHMGPITWVCRPGG 423 GGPHHVYACRMGPLTWIC 424 GGTYSCHFGPLTWVCKPQ 425 GGLYACHMGPMTWVCQPLRG 426 TIAQYICYMGPETWECRPSPKA 427 YSCHFGPLTWVCK 428 YCHFGPLTWVC 429 X₃X₄X₅GPX₆TWX₇X₈ 124 YX₂X₃X₄X₅GPX₆TWX₇X₈ 461 X₁YX₂X₃X₄X₅GPX₆TWX₇X₈X₉X₁₀X₁₁ 419 X₁YX₂CX₄X₅GPX₆TWX₇X₈X₉X₁₀X₁₁ 420 GGLYLCRFGPVTWDCGYKGG 1024 GGTYSCHFGPLTWVCKPQGG 1025 GGDYHCRMGPLTWVCKPLGG 1026 VGNYMCHFGPITWVCRPGGG 1029 GGVYACRMGPITWVCSPLGG 1030 VGNYMAHMGPITWVCRPGG 1035 GGTYSCHFGPLTWVCKPQ 1036 GGLYACHMGPMTWVCQPLRG 1037 TIAQYICYMGPETWECRPSPKA 1038 YSCHFGPLTWVCK 1039 YCHFGPLTWVC 1040 SCHFGPTLWVCK 1041 (AX₂)_(n)X₃X₄X₅GPX₆TWX₇X₈ 1042 X_(n)CX₁X₂GWVGX₃X₄X₅WX₆ 1110

[0129] TABLE 6 TPO-mimetic peptide sequences SEQ Sequence/structure ID NO: IEGPTLRQWLAARA 13 IEGPTLRQWLAAKA 24 IEGPTLREWLAARA 25 IEGPTLRQWLAARA-Λ-IEGPTLRQWLAARA 26 IEGPTLRQWLAAKA-Λ-IEGPTLRQWLAAKA 27

28 IEGPTLRQWLAARA-Λ-K(BrAc)-Λ-IEGPTLRQWLAARA 29 IEGPTLRQWLAARA-Λ-K(PEG)-Λ-IEGPTLRQWLAARA 30

31 31

32 32 VRDQIXXXL 33 TLREWL 34 GRVRDQVAGW 35 GRVKDQIAQL 36 GVRDQVSWAL 37 ESVREQVMKY 38 SVRSQISASL 39 GVRETVYRHM 40 GVREVIVMHML 41 GRVRDQIWAAL 42 AGVRDQILIWL 43 GRVRDQIMLSL 44 GRVRDQI(X)₃L 45 CTLRQWLQGC 46 CTLQEFLEGC 47 CTRTEWLHGC 48 CTLREWLHGGFC 49 CTLREWVFAGLC 50 CTLRQWLILLGMC 51 CTLAEFLASGVEQC 52 CSLQEFLSHGGYVC 53 CTLREFLDPTTAVC 54 CTLKEWLVSHEVWC 55 CTLREWL(X)₂₋₈C 56-60 REGPTLRQWM 61 EGPTLRQWLA 62 ERGPFWAKAC 63 REGPRCVMWM 64 CGTEGPTLSTWLDC 65 CEQDGPTLLEWLKC 66 CELVGPSLMSWLTC 67 CLTGPFVTQWLYEC 68 CRAGPTLLEWLTLC 69 CADGPTLREWISFC 70 C(X)₁₋₂EGPTLREW(X)₁₋₂C 71-74 GGCTLREWLHGGFCGG 75 GGCADGPTLREWISFCGG 76 GNADGPTLRQWLEGRRPKN 77 LAIEGPTLRQWLHGNGRDT 78 HGRVGPTLREWKTQVATKK 79 TIKGPTLRQWLKSREHTS 80 ISDGPTLRQWLKSREHTS 80 ISDGPTLKEWLSVTRGAS 81 SIEGPTLREWLTSRTPHS 82

[0130] TABLE 7 G-CSF-mimetic peptide sequences Sequence/structure SEQ ID NO: EEDCK 99 EEDCK 99 ```| EEDCK 99 EEDσK 100 EEDσK 100 ```| EEDσK 100 pGluEDσK 101 pGluEDσK 101 ``````| pGluEDσK 101 PicSDσK 102 PicSDσK 102 `````| PicSDσK 102 EEDCK-Λ-EEDCK 103 EEDXK-Λ-EEDXK 104

[0131] TABLE 8 TNF-antagonist peptide sequences SEQ Sequcne/structure ID NO: YCFTASENHCY 106 YCFTNSENHCY 107 YCFTRSENHCY 108 FCASENHCY 109 YCASENHCY 110 FCNSENHCY 111 FCNSENRCY 112 FCNSVENRCY 113 YCSQSVSNDCF 114 FCVSNDRCY 115 YCRKELGQVCY 116 TCKEPGQCY 117 YCRKEMGCY 118 FCRKEMGCY 119 YCWSQNLCY 120 YCELSQYLCY 121 YCWSQNYCY 122 YCWSQYLCY 123 DFLPHYKNTSLGHRP 1085

NR

[0132] TABLE 9 Integrin-binding peptide sequences SEQ Sequence/structure ID NO: RX₁ETX₂WX₃ 441 RX₁ETX₂WX₃ 442 RGDGX 443 CRGDGXC 444 CX₁X₂RLDX₃X₄C 445 CARRLDAPC 446 CPSRLDSPC 447 X₁X₂X₃RGDX₄X₅X₆ 448 CX₂CRGDCX₅C 449 CDCRGDCFC 450 CDCRGDCLC 451 CLCRGDCIC 452 X₁X₂DDX₄X₅X₇X₈ 453 X₁X₂X₃DDX₄X₅X₆X₇X₈ 454 CWDDGWLC 455 CWDDLWWLC 456 CWDDGLMC 457 CWDDGWMC 458 CSWDDGWLC 459 CPDDLWWLC 460 NGR NR GSL NR RGD NR CGRECPRLCQSSC 1071 CNGRCVSGCAGRC 1072 CLSGSLSC 1073 RGD NR NGR NR GSL NR NGRAHA 1074 CNGRC 1075 CDCRGDCFC 1076 CGSLVRC 1077 DLXXL 1043 RTDLDSLRTYTL 1044 RTDLDSLRTY 1053 RTDLDSLRT 1054 RTDLDSLR 1078 GDLDLLKLRLTL 1079 GDLHSLRQLLSR 1080 RDDLHMLRLQLW 1081 SSDLHALKKRYG 1082 RGDLKQLSELTW 1083 RGDLAALSAPPV 1084

[0133] TABLE 10 Selectin antagonist peptide sequences SEQ Sequence/structure ID NO: DITWDQLWDLMK 147 DITWDELWKIMN 148 DYTWFELWDMMQ 149 QITWAQLWNMMK 150 DMTWHDLWTLMS 151 DYSWHDLWEMMS 152 EITWDQLWEVMN 153 HVSWEQLWDIMN 154 HITWDQLWRIMT 155 RNMSWLELWEHMK 156 AEWTWDQLWHVMNPAESQ 157 HRAEWLALWEQMSP 158 KKEDWLALWRIMSV 159 ITWDQLWDLMK 160 DITWDQLWDLMK 161 DITWDQLWDLMK 162 DITWDQLWDLMK 163 CQNRYTDLVAIQNKNE 462 AENWADNEPNNKRNNED 463 RKNNKTWTWVGTKKALTNE 464 KKALTNEAENWAD 465 CQXRYTDLVAIQNKXE 466 RKXNXXWTWVGTXKXLTEE 467 AENWADGEPNNKXNXED 468 CXXXYTXLVAIQNKXE 469 RKXXXXWXWVGTXKXLTXE 470 AXNWXXXEPNNXXXED 471 XKXKTXEAXNWXX 472

[0134] TABLE 11 Antipathogenic peptide sequences SEQ Sequence/structure ID NO: GFFALIPKIISSPLFKTLLSAVGSALSSSGGQQ 503 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE 504 GFFALIPKIISSPLFKTLLSAV 505 GFFALIPKIISSPLFKTLLSAV 506 KGFFALIPKIISSPLFKTLLSAV 507 KKGFFALIPKIISSPLFKTLLSAV 508 KKGFFALIPKIISSPLFKTLLSAV 509 GFFALIPKIIS 510 GIGAVLKVLTTGLPALISWIKRKRQQ 511 GIGAVLKVLTTGLPALISWIKRKRQQ 512 GIGAVLKVLTTGLPALISWIKRKRQQ 513 GIGAVLKVLTTGLPALISWIKR 514 AVLKVLTTGLPALISWIKR 515 KLLLLLKLLLLK 516 KLLLKLLLKLLK 517 KLLLKLKLKLLK 518 KKLLKLKLKLKK 519 KLLLKLLLKLLK 520 KLLLKLKLKLLK 521 KLLLLK 522 KLLLKLLK 523 KLLLKLKLKLLK 524 KLLLKLKLKLLK 525 KLLLKLKLKLLK 526 KAAAKAAAKAAK 527 KVVVKVVVKVVK 528 KVVVKVKVKVVK 529 KVVVKVKVKVK 530 KVVVKVKVKVVK 531 KLILKL 532 KVLHLL 533 LKLRLL 534 KPLHLL 535 KLILKLVR 536 KVFHLLHL 537 HKFRILKL 538 KPFHILHL 539 KIIIKIKIKIIK 540 KIIIKIKIKIIK 541 KIIIKIKIKIIK 542 KIPIKIKIKIPK 543 KIPIKIKIKIVK 544 RIIIRIRIRIIR 545 RIIIRIRIRIIR 546 RIIIRIRIRIIR 547 RIVIRIRIRLIR 548 RIIVRIRLRIIR 549 RIGIRLRVRIIR 550 KIVIRIRIRLIR 551 RIAVKWRLRFIK 552 KIGWKLRVRIIR 553 KKIGWLIIRVRR 554 RIVIRIRIRLIRIR 555 RIIVRIRLRIIRVR 556 RIGIRLRVRIIRRV 557 KIVIRIRARLIRIRIR 558 RIIVKIRLRIIKKIRL 559 KIGIKARVRIIRVKII 560 RIIVHIRLRIIHHIRL 561 HIGIKAHVRIIRVHII 562 RIYVKIHLRYIKKIRL 563 KIGHKARVHIIRYKII 564 RIYVKPHPRYIKKIRL 565 KPGHKARPHIIRYKII 566 KIVIRIRIRLIRIRIRKIV 567 RIIVKIRLRIIKKIRLIKK 568 KIGWKLRVRIIRVKIGRLR 569 KIVIRIRIRLIRIRIRKIVKVKRIR 570 RFAVKIRLRIIKKIRLIKKIRKRVIK 571 KAGWKLRVRIIRVKIGRLRKIGWKKRVRIK 572 RIYVKPHPRYIKKIRL 573 KPGHKARPHIIRYKII 574 KIVIRIRIRLIRIRIRKIV 575 RIIVKIRLRIIKKIRLIKK 576 RIYVSKISIYIKKIRL 577 KIVIFTRIRLTSIRIRSIV 578 KPIHKARPTIIRYKMI 579 cyclicCKGFFALIPKIISSPLFKTLLSAVC 580 CKKGFFALIPKIISSPLFKTLLSAVC 581 CKKKGFFALIPKIISSPLFKTLLSAVC 582 CyclicCRIVIRIRIRLIRIRC 583 CyclicCKPGHKARPHIIRYKIIC 584 CyclicCRFAVKIRLRIIKKIRLIKKIRKRVIKC 585 KLLLKLLL KLLKC 586 KLLLKLLLKLLK 587 KLLLKLKLKLLKC 588 KLLLKLLLKLLK 589

[0135] TABLE 12 VIP-mimetic peptide sequences SEQ Sequence/structure ID NO: HSDAVFYDNYTR LRKQMAVKKYLN SILN 590 Mle HSDAVFYDNYTR LRKQMAVKKYLN SILN 591 X₁X₁′X₁″X₂ 592 X₃ S X₄ LN 593

594 KKYL 595 NSILN 596 KKYL 597 KKYA 598 AVKKYL 599 NSILN 600 KKYV 601 SILauN 602 KKYLNle 603 NSYLN 604 NSIYN 605 KKYLPPNSILN 606 LauKKYL 607 CapKKYL 608 KYL NR KKYNle 609 VKKYL 610 LNSILN 611 YLNSILN 612 KKYLN 613 KKYNS 614 KKYLNSI 615 KKYLNSIL 616 KKYL 617 KKYDA 618 AVKKYL 619 NSILN 620 KKYV 621 SILauN 622 NSYLN 623 NSIYN 624 KKYLNle 625 KKYLPPNSILN 626 KKYL 627 KKYDA 628 AVKKYL 629 NSILN 630 KKYV 631 SILauN 632 LauKKYL 633 CapKKYL 634 HYL NR KYL NR KKYNle 635 VKKYL 636 LNSILN 637 YLNSILN 638 KKYNle 639 KKYLN 640 KKYLNS 641 KKYLNSI 642 KKYLNSIL 643 KKKYLD 644 cyclicCKKYLC 645

646 KKYA 647 WWTDTGLW 648 WWTDDGLW 649 WWDTRGLWVWTI 650 FWGNDGIWLESG 651 DWDQFGLWRGAA 652 RWDDNGLWVVVL 653 SGMWSHYGIWMG 654 GGRWDQAGLWVA 655 KLWSEQGQIWMGE 656 CWSMHGLWLC 657 GCWDNTGIWVPC 658 DWDTRGLWVY 659 SLWDENGAWI 660 KWDDRGLWMH 661 QAWNERGLWT 662 QWDTRGLWVA 663 WNVHGIWQE 664 SWDTRGLWVE 665 DWDTRGLWVA 666 SWGRDGLWIE 667 EWTDNGLWAL 668 SWDEKGLWSA 669 SWDSSGLWMD 670

[0136] TABLE 13 Mdm/hdm antagonist peptide sequences SEQ Sequence/structure ID NO: TFSDLW 130 QETFSDLWKLLP 131 QPTFSDLWKLLP 132 QETFSDYWKLLP 133 QPTFSDYWKLLP 134 MPRFMDYWEGLN 135 VQNFIDYWTQQF 136 TGPAFTHYWATF 137 IDRAPTFRDHWFALV 138 PRPALVFADYWETLY 139 PAFSRFWSDLSAGAH 140 PAFSRFWSKLSAGAH 141 PXFXDYWXXL 142 QETFSDLWKLLP 143 QPTFSDLWKLLP 144 QETFSDYWKLLP 145 QPTFSDYWKLLP 146

[0137] TABLE 14 Calmodulin antagonist peptide sequences SEQ Sequence/structure ID NO: SCVKWGKKEFCGS 164 SCWKYWGKECGS 165 SCYEWGKLRWCGS 166 SCLRWGKWSNCGS 167 SCWRWGKYQICGS 168 SCVSWGALKLCGS 169 SCIRWGQNTFCGS 170 SCWQWGNLKICGS 171 SCVRWGQLSICGS 172 LKKFNARRKLKGAILTTMLAK 173 RRWKKNFIAVSAANRFKK 174 RKWQKTGHAVRAIGRLSS 175 INLKALAALAKKIL 176 KIWSILAPLGTTLVKLVA 177 LKKLLKLLKKLLKL 178 LKWKKLLKLLKKLLKKLL 179 AEWPSLTEIKTLSHFSV 180 AEWPSPTRVISTTYFGS 181 AELAHWPPVKTVLRSFT 182 AEGSWLQLLNLMKQMNN 183 AEWPSLTEIK 184

[0138] TABLE 15 Mast cell antagonists/Mast cell protease inhibitor peptide sequences SEQ Sequence/structure ID NO: SGSGVLKRPLPILPVTR 272 RWLSSRPLPPLPLPPRT 273 GSGSYDTLALPSLPLHPMSS 274 GSGSYDTRALPSLPLHPMSS 275 GSGSSGVTMYPKLPPHWSMA 276 GSGSSGVRMYPKLPPHWSMA 277 GSGSSSMRMVPTIPGSAKHG 278 RNR NR QT NR RQK NR NRQ NR RQK NR RNRQKT 436 RNRQ 437 RNRQK 438 NRQKT 439 RQKT 440

[0139] TABLE 16 SH3 antagonist peptide sequences SEQ Sequence/structure ID NO: RPLPPLP 282 RELPPLP 283 SPLPPLP 284 GPLPPLP 285 RPLPIPP 286 RPLPIPP 287 RRLPPTP 288 RQLPPTP 289 RPLPSRP 290 RPLPTRP 291 SRLPPLP 292 RALPSPP 293 RRLPRTP 294 RPVPPIT 295 ILAPPVP 296 RPLPMLP 297 RPLPILP 298 RPLPSLP 299 RPLPSLP 300 RPLPMIP 301 RPLPLIP 302 RPLPPTP 303 RSLPPLP 304 RPQPPPP 305 RQLPIPP 306 XXXRPLPPLPXP 307 XXXRPLPPIPXX 308 XXXRPLPPLPXX 309 RXXRPLPPLPXP 310 RXXRPLPPLPPP 311 PPPYPPPPIPXX 312 PPPYPPPPVPXX 313 LXXRPLPXΨP 314 ΨXXRPLPXLP 315 PPXΘXPPPΨP 316 +PPΨPXKPXWL 317 RPXΨPΨR+SXP 318 PPVPPRPXXTL 319 ΨPΨLPΨK 320 +ΘDXPLPXLP 321

[0140] TABLE 17 Somatostatin or cortistatin mimetic peptide sequences SEQ Sequence/structure ID NO: X¹-X²-Asn-Phe-Phe-Trp-Lys-Thr-Phe-X³-Ser-X⁴ 473 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr 474 Phe Ser Ser Cys Lys Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 475 Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 476 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys 477 Thr Phe Ser Ser Cys Met Pro Cys Arg Asn Phe Phe Trp Lys Thr 478 Phe Ser Ser Cys Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 479 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys 480 Thr Phe Ser Ser Cys Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 481 Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 482 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr 483 Phe Ser Ser Cys Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 484 Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 485 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr 486 Phe Thr Ser Cys Lys Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 487 Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 488 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys 489 Thr Phe Thr Ser Cys Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 490 Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 491 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys 492 Thr Phe Thr Ser Cys Lys Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 493 Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 494 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys 495 Thr Phe Thr Ser Cys Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 496 Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 497

[0141] TABLE 18 UKR antagonist peptide sequences SEQ Sequence/structure ID NO: AEPMPHSLNFSQYLWYT 196 AEHTYSSLWDTYSPLAF 197 AELDLWMRHYPLSFSNR 198 AESSLWTRYAWPSMPSY 199 AEWHPGLSFGSYLWSKT 200 AEPALLNWSFFFNPGLH 201 AEWSFYNLHLPEPQTIF 202 AEPLDLWSLYSLPPLAM 203 AEPTLWQLYQFPLRLSG 204 AEISFSELMWLRSTPAF 205 AELSEADLWTTWFGMGS 206 AESSLWRIFSPSALMMS 207 AESLPTLTSILWGKESV 208 AETLFMDLWHDKHILLT 209 AEILNFPLWHEPLWSTE 210 AESQTGTLNTLFWNTLR 211 AEPVYQYELDSYLRSYY 430 AELDLSTFYDIQYLLRT 431 AEFFKLGPNGYVYLHSA 432 FKLXXXGYVYL 433 AESTYHHLSLGYMYTLN 434 YHXLXXGYMYT 435

[0142] TABLE 19 Macrophage and/or T-cell inhibiting peptide sequences SEQ Sequence/structure ID NO: Xaa-Yaa-Arg NR Arg-Yaa-Xaa NR Xaa-Arg-Yaa NR Yaa-Arg-Xaa NR Ala-Arg NR Arg-Arg NR Asn-Arg NR Asp-Arg NR Cys-Arg NR Gln-Arg NR Glu-Arg NR Gly-Arg NR His-arg NR Ile-Arg NR Leu-Arg NR Lys-Arg NR Met-Arg NR Phe-Arg NR Ser-Arg NR Thr-Arg NR Trp-Arg NR Tyr-Arg NR Val-Arg NR Ala-Glu-Arg NR Arg-Glu-Arg NR Asn-Glu-Arg NR Asp-Glu-Arg NR Cys-Glu-Arg NR Gln-Glu-Arg NR Glu-Glu-Arg NR Gly-Glu-Arg NR His-Glu-Arg NR Ile-Glu-Arg NR Leu-Glu-Arg NR Lys-Glu-Arg NR Met-Glu-Arg NR Phe-Glu-Arg NR Pro-Glu-Arg NR Ser-Glu-Arg NR Thr-Glu-Arg NR Trp-Glu-Arg NR Tyr-Glu-Arg NR Val-Glu-Arg NR Arg-Ala NR Arg-Asp NR Arg-Cys NR Arg-Gln NR Arg-Glu NR Arg-Gly NR Arg-His NR Arg-Ile NR Arg-Leu NR Arg-Lys NR Arg-Met NR Arg-Phe NR Arg-Pro NR Arg-Ser NR Arg-Thr NR Arg-Trp NR Arg-Tyr NR Arg-Val NR Arg-Glu-Ala NR Arg-Glu-Asn NR Arg-Glu-Asp NR Arg-Glu-Cys NR Arg-Glu-Gln NR Arg-Glu-Glu NR Arg-Glu-Gly NR Arg-Glu-His NR Arg-Glu-Ile NR Arg-Glu-Leu NR Arg-Glu-Lys NR Arg-Glu-Met NR Arg-Glu-Phe NR Arg-Glu-Pro NR Arg-Glu-Ser NR Arg-Glu-Thr NR Arg-Glu-Trp NR Arg-Glu-Tyr NR Arg-Glu-Val NR Ala-Arg-Glu NR Arg-Arg-Glu NR Asn-Arg-Glu NR Asp-Arg-Glu NR Cys-Arg-Glu NR Gln-Arg-Glu NR Glu-Arg-Glu NR Gly-Arg-Glu NR His-Arg-Glu NR Ile-Arg-Glu NR Leu-Arg-Glu NR Lys-Arg-Glu NR Met-Arg-Glu NR Phe-Arg-Glu NR Pro-Arg-Glu NR Ser-Arg-Glu NR Thr-Arg-Glu NR Trp-Arg-Glu NR Tyr-Arg-Glu NR Val-Arg-Glu NR Glu-Arg-Ala, NR Glu-Arg-Arg NR Glu-Arg-Asn NR Glu-Arg-Asp NR Glu-Arg-Cys NR Glu-Arg-Gln NR Glu-Arg-Gly NR Glu-Arg-His NR Glu-Arg-Ile NR Glu-Arg-Leu NR Glu-Arg-Lys NR Glu-Arg-Met NR Glu-Arg-Phe NR Glu-Arg-Pro NR Glu-Arg-Ser NR Glu-Arg-Thr NR Glu-Arg-Trp NR Glu-Arg-Tyr NR Glu-Arg-Val NR

[0143] TABLE 20 Additional Exemplary Pharmacologically Active Peptides SEQ ID Sequence/structure NO: Activity VEPNCDIHVMWEWECFERL 1027 VEGF-antagonist GERWCFDGPLTWVCGEES 1084 VEGF-antagonist RGWVEICVADDNGMCVTEAQ 1085 VEGF-antagonist GWDECDVARMWEWECFAGV 1086 VEGF-antagonist GERWCFDGPRAWVCGWEI 501 VEGF-antagonist EELWCFDGPRAWVCGYVK 502 VEGF-antagonist RGWVEICAADDYGRCLTEAQ 1031 VEGF-antagonist RGWVEICESDVWGRCL 1087 VEGF-antagonist RGWVEICESDVWGRCL 1088 VEGF-antagonist GGNECDIARMWEWECFERL 1089 VEGF-antagonist RGWVEICAADDYGRCL 1090 VEGF-antagonist CTTHWGFTLC 1028 MMP inhibitor CLRSGXGC 1091 MMP inhibitor CXXHWGFXXC 1092 MMP inhibitor CXPXC 1093 MMP inhibitor CRRHWGFEFC 1094 MMP inhibitor STTHWGFTLS 1095 MMP inhibitor CSLHWGFWWC 1096 CTLA4-mimetic GFVCSGIFAVGVGRC 125 CTLA4-mimetic APGVRLGCAVLGRYC 126 CTLA4-mimetic LLGRMK 105 Antiviral (HBV) ICVVQDWGHHRCTAGHMANLTSHASAI 127 C3b antagonist ICVVQDWGHHRCT 128 C3b antagonist CVVQDWGHHAC 129 C3b antagonist STGGFDDVYDWARGVSSALTTTLVATR 185 Vinculin-binding STGGFDDVYDWARRVSSALTTTLVATR 186 Vinculin-binding SRGVNFSEWLYDMSAAMKEASNVFPSRRSR 187 Vinculin-binding SSQNWDMEAGVEDLTAAMLGLLSTIHSSSR 188 Vinculin-binding SSPSLYTQFLVNYESAATRIQDLLIASRPSR 189 Vinculin-binding SSTGWVDLLGALQRAADATRTSIPPSLQNSR 190 Vinculin-binding DVYTKKELIECARRVSEK 191 Vinculin-binding EKGSYYPGSGIAQFHIDYNNVS 192 C4BP-binding SGIAQFHIDYNNVSSAEGWHVN 193 C4BP-binding LVTVEKGSYYPGSGIAQFHIDYNNVSSAEGWHVN 194 C4BP-binding SGIAQFHIDYNNVS 195 C4BP-binding LLGRMK 279 anti-HBV ALLGRMKG 280 anti-HBV LDPAFR 281 anti-HBV CXXRGDC 322 Inhibition of platelet aggregation RPLPPLP 323 Src antagonist PPVPPR 324 Src antagonist XFXDXWXXLXX 325 Anti-cancer (particularly for sarcomas) KACRRLFGPVDSEQLSRDCD 326 p16-mimetic RERWNFDFVTETPLEGDFAW 327 p16-mimetic KRRQTSMTDFYHSKRRLIFS 328 p16-mimetic TSMTDFYHSKRRLIFSKRKP 329 p16-mimetic RRLIF 330 p16-mimetic KRRQTSATDFYHSKRRLIFSRQIKIWFQNRRMKWKK 331 p16-mimetic KRRLIFSKRQIKIWFQNRRMKWKK 332 p16-mimetic Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala 498 CAP37 mimetic/LPS Arg Phe Val Met Thr Ala Ala Ser Cys Phe Gln binding Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val 499 CAP37 mimetic/LPS Met Thr Ala Ala Ser Cys binding Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser 500 CAP37 mimetic/LPS Gly Gly Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val binding WHWRHRIPLQLAAGR 1097 carbohydrate (GD1 alpha) mimetic LKTPRV 1098 β2GPI Ab binding NTLKTPRV 1099 β2GPI Ab binding NTLKTPRVGGC 1100 β2GPI Ab binding KDKATF 1101 β2GPI Ab binding KDKATFGCHD 1102 β2GPI Ab binding KDKATFGCHDGC 1103 β2GPI Ab binding TLRVYK 1104 β2GPI Ab binding ATLRVYKGG 1105 β2GPI Ab binding CATLRVYKGG 1106 β2GPI Ab binding INLKALAALAKKIL 1107 Membrane- transporting GWT NR Membrane- transporting GWTLNSAGYLLG 1108 Membrane- transporting GWTLNSAGYLLGKINLKALAALAKKIL 1109 Membrane- transporting CVHAYRS 1111 Antiproliferative, antiviral CVHAYRA 1114 Antiproliferative, antiviral CVHAPRS 1115 Antiproliferative, antiviral CVHAPRA 1116 Antiproliferative, antiviral CVHSYRS 1133 Antiproliferative, antiviral CVHSYRA 1134 Antiproliferative, antiviral CVHSPRS 1135 Antiproliferative, antiviral CVHSPRA 1136 Antiproliferative, antiviral CVHTYRS 1137 Antiproliferative, antiviral CVHTYRA 1138 Antiproliferative, antiviral CVHTPRS 1139 Antiproliferative, antiviral CVHTPRA 1140 Antiproliferative, antiviral HWAWFK 1142 anti-ischemic, growth hormone-liberating

[0144] The present invention is also particularly useful with peptides having activity in treatment of:

[0145] cancer, wherein the peptide is a VEGF-mimetic or a VEGF receptor antagonist, a HER2 agonist or antagonist, a CD20 antagonist and the like;

[0146] asthma, wherein the protein of interest is a CKR3 antagonist, an IL-5 receptor antagonist, and the like;

[0147] thrombosis, wherein the protein of interest is a GPIIb antagonist, a GPIIIa antagonist, and the like;

[0148] autoimmune diseases and other conditions involving immune modulation, wherein the protein of interest is an IL-2 receptor antagonist, a CD40 agonist or antagonist, a CD40L agonist or antagonist, a thymopoietin mimetic and the like.

[0149] Vehicles. This invention requires the presence of at least one vehicle (F¹, F²) attached to a peptide through the N-terminus, C-terminus or a sidechain of one of the amino acid residues. Multiple vehicles may also be used; e.g., Fc's at each terminus or an Fc at a terminus and a PEG group at the other terminus or a sidechain.

[0150] An Fc domain is the preferred vehicle. The Fc domain may be fused to the N or C termini of the peptides or at both the N and C termini. For the TPO-mimetic peptides, molecules having the Fc domain fused to the N terminus of the peptide portion of the molecule are more bioactive than other such fusions, so fusion to the N terminus is preferred.

[0151] As noted above, Fc variants are suitable vehicles within the scope of this invention. A native Fc may be extensively modified to form an Fc variant in accordance with this invention, provided binding to the salvage receptor is maintained; see, for example WO 97/34631 and WO 96/32478. In such Fc variants, one may remove one or more sites of a native Fc that provide structural features or functional activity not required by the fusion molecules of this invention. One may remove these sites by, for example, substituting or deleting residues, inserting residues into the site, or truncating portions containing the site. The inserted or substituted residues may also be altered amino acids, such as peptidomimetics or D-amino acids. Fc variants may be desirable for a number of reasons, several of which are described below. Exemplary Fc variants include molecules and sequences in which:

[0152] 1. Sites involved in disulfide bond formation are removed. Such removal may avoid reaction with other cysteine-containing proteins present in the host cell used to produce the molecules of the invention. For this purpose, the cysteine-containing segment at the N-terminus may be truncated or cysteine residues may be deleted or substituted with other amino acids (e.g., alanyl, seryl). In particular, one may truncate the N-terminal 20-amino acid segment of SEQ ID NO: 2 or delete or substitute the cysteine residues at positions 7 and 10 of SEQ ID NO: 2. Even when cysteine residues are removed, the single chain Fc domains can still form a dimeric Fc domain that is held together non-covalently.

[0153] 2. A native Fc is modified to make it more compatible with a selected host cell. For example, one may remove the PA sequence near the N-terminus of a typical native Fc, which may be recognized by a digestive enzyme in E. coli such as proline iminopeptidase. One may also add an N-terminal methionine residue, especially when the molecule is expressed recombinantly in a bacterial cell such as E. coli. The Fc domain of SEQ ID NO: 2 (FIG. 4) is one such Fc variant.

[0154] 3. A portion of the N-terminus of a native Fc is removed to prevent N-terminal heterogeneity when expressed in a selected host cell. For this purpose, one may delete any of the first 20 amino acid residues at the N-terminus, particularly those at positions 1, 2, 3, 4 and 5.

[0155] 4. One or more glycosylation sites are removed. Residues that are typically glycosylated (e.g., asparagine) may confer cytolytic response. Such residues may be deleted or substituted with unglycosylated residues (e.g., alanine).

[0156] 5. Sites involved in interaction with complement, such as the C1q binding site, are removed. For example, one may delete or substitute the EKK sequence of human IgG1. Complement recruitment may not be advantageous for the molecules of this invention and so may be avoided with such an Fc variant.

[0157] 6. Sites are removed that affect binding to Fc receptors other than a salvage receptor. A native Fc may have sites for interaction with certain white blood cells that are not required for the fusion molecules of the present invention and so may be removed.

[0158] 7. The ADCC site is removed. ADCC sites are known in the art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. These sites, as well, are not required for the fusion molecules of the present invention and so may be removed.

[0159] 8. When the native Fc is derived from a non-human antibody, the native Fc may be humanized. Typically, to humanize a native Fc, one will substitute selected residues in the non-human native Fc with residues that are normally found in human native Fc. Techniques for antibody humanization are well known in the art.

[0160] Preferred Fc variants include the following. In SEQ ID NO: 2 (FIG. 4) the leucine at position 15 may be substituted with glutamate; the glutamate at position 99, with alanine; and the lysines at positions 101 and 103, with alanines. In addition, one or more tyrosine residues can be replaced by phenyalanine residues.

[0161] An alternative vehicle would be a protein, polypeptide, peptide, antibody, antibody fragment,, or small molecule (e.g., a peptidomimetic compound) capable of binding to a salvage receptor. For example, one could use as a vehicle a polypeptide as described in U.S. Pat. No. 5,739,277, issued Apr. 14, 1998 to Presta et al. Peptides could also be selected by phage display for binding to the FcRn salvage receptor. Such salvage receptor-binding compounds are also included within the meaning of “vehicle” and are within the scope of this invention. Such vehicles should be selected for increased half-life (e.g., by avoiding sequences recognized by proteases) and decreased immunogenicity (e.g., by favoring non-immunogenic sequences, as discovered in antibody humanization).

[0162] As noted above, polymer vehicles may also be used for F¹ and F². Various means for attaching chemical moieties useful as vehicles are currently available, see, e.g., Patent Cooperation Treaty (“PCT”) International Publication No. WO 96/11953, entitled “N-Terminally Chemically Modified Protein Compositions and Methods,” herein incorporated by reference in its entirety. This PCT publication discloses, among other things, the selective attachment of water soluble polymers to the N-terminus of proteins.

[0163] A preferred polymer vehicle is polyethylene glycol (PEG). The PEG group may be of any convenient molecular weight and may be linear or branched. The average molecular weight of the PEG will preferably range from about 2 kiloDalton (“kD”) to about 100 kDa, more preferably from about 5 kDa to about 50 kDa, most preferably from about 5 kDa to about 10 kDa. The PEG groups will generally be attached to the compounds of the invention via acylation or reductive alkylation through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the inventive compound (e.g., an aldehyde, amino, or ester group).

[0164] A useful strategy for the PEGylation of synthetic peptides consists of combining, through forming a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other. The peptides can be easily prepared with conventional solid phase synthesis (see, for example, FIGS. 5 and 6 and the accompanying text herein). The peptides are “preactivated” with an appropriate functional group at a specific site. The precursors are purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC. The PEGylated peptides can be easily purified by preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser desorption mass spectrometry.

[0165] Polysaccharide polymers are another type of water soluble polymer which may be used for protein modification. Dextrans are polysaccharide polymers comprised of individual subunits of glucose predominantly linked by α1-6 linkages. The dextran itself is available in many molecular weight ranges, and is readily available in molecular weights from about 1 kD to about 70 kD. Dextran is a suitable water soluble polymer for use in the present invention as a vehicle by itself or in combination with another vehicle (e.g., Fc). See, for example, WO 96/11953 and WO 96/05309. The use of dextran conjugated to therapeutic or diagnostic immunoglobulins has been reported; see, for example, European Patent Publication No. 0 315 456, which is hereby incorporated by reference. Dextran of about 1 kD to about 20 kD is preferred when dextran is used as a vehicle in accordance with the present invention.

[0166] Linkers. Any “linker” group is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer. The linker is preferably made up of amino acids linked together by peptide bonds. Thus, in preferred embodiments, the linker is made up of from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the 20 naturally occurring amino acids. Some of these amino acids may be glycosylated, as is well understood by those in the art. In a more preferred embodiment, the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. Even more preferably, a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine. Thus, preferred linkers are polyglycines (particularly (Gly)₄, (Gly)₅), poly(Gly-Ala), and polyalanines. Other specific examples of linkers are:

[0167] (Gly)₃Lys(Gly)₄ (SEQ ID NO: 333);

[0168] (Gly)₃AsnGlySer(Gly)₂ (SEQ ID NO: 334);

[0169] (Gly)₃Cys(Gly)₄ (SEQ ID NO: 335); and

[0170] GlyProAsnGlyGly (SEQ ID NO: 336).

[0171] To explain the above nomenclature, for example, (Gly)₃Lys(Gly)₄ means Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly. Combinations of Gly and Ala are also preferred. The linkers shown here are exemplary; linkers within the scope of this invention may be much longer and may include other residues.

[0172] Non-peptide linkers are also possible. For example, alkyl linkers such as —NH—(CH₂)_(s)—C(O)—, wherein s=2-20 could be used. These alkyl linkers may further be substituted by any non-sterically hindering group such as lower alkyl (e.g., C₁-C₆) lower acyl, halogen (e.g., Cl, Br), CN, NH₂, phenyl, etc. An exemplary non-peptide linker is a PEG linker,

[0173] VI

[0174] wherein n is such that the linker has a molecular weight of 100 to 5000 kD, preferably 100 to 500 kD. The peptide linkers may be altered to form derivatives in the same manner as described above.

[0175] Derivatives. The inventors also contemplate derivatizing the peptide and/or vehicle portion of the compounds. Such derivatives may improve the solubility, absorption, biological half life, and the like of the compounds. The moieties may alternatively eliminate or attenuate any undesirable side-effect of the compounds and the like. Exemplary derivatives include compounds in which:

[0176] 1. The compound or some portion thereof is cyclic. For example, the peptide portion may be modified to contain two or more Cys residues (e.g., in the linker), which could cyclize by disulfide bond formation. For citations to references on preparation of cyclized derivatives, see Table 2.

[0177] 2. The compound is cross-linked or is rendered capable of cross-linking between molecules. For example, the peptide portion may be modified to contain one Cys residue and thereby be able to form an intermolecular disulfide bond with a like molecule. The compound may also be cross-linked through its C-terminus, as in the molecule shown below.

[0178] VII

[0179] 3.

[0180] 4. One or more peptidyl [—C(O)NR—] linkages (bonds) is replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages are —CH₂carbamate [—CH₂—OC(O)NR—], phosphonate, —CH₂-sulfonamide [—CH₂—S(O)₂NR—], urea [—NHC(O)NH—], —CH₂-secondary amine, and alkylated peptide [—C(O)NR⁶— wherein R⁶ is lower alkyl].

[0181] 5. The N-terminus is derivatized. Typically, the N-terminus may be acylated or modified to a substituted amine. Exemplary N-terminal derivative groups include —NRR¹ (other than —NH₂), —NRC(O)R¹, —NRC(O)OR¹, —NRS(O)₂R¹, —NHC(O)NHR¹, succinimide, or benzyloxycarbonyl-NH— (CBZ-NH—), wherein R and R¹ are each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, chloro, and bromo.

[0182] 6. The free C-terminus is derivatized. Typically, the C-terminus is esterified or amidated. For example, one may use methods described in the art to add (NH—CH₂—CH₂—NH₂)₂ to compounds of this invention having any of SEQ ID NOS: 504 to 508 at the C-terminus. Likewise, one may use methods described in the art to add —NH₂ to compounds of this invention having any of SEQ ID NOS: 924 to 955, 963 to 972, 1005 to 1013, or 1018 to 1023 at the C-terminus. Exemplary C-terminal derivative groups include, for example, —C(O)R² wherein R² is lower alkoxy or —NR³R⁴ wherein R³ and R⁴ are independently hydrogen or C₁-C₈ alkyl (preferably C₁-C₄ alkyl).

[0183] 7. A disulfide bond is replaced with another, preferably more stable, cross-linking moiety (e.g., an alkylene). See, e.g., Bhatnagar et al. (1996), J. Med. Chem. 39: 3814-9; Alberts et al. (1993) Thirteenth Am. Pep. Symp., 357-9.

[0184] 8. One or more individual amino acid residues is modified. Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below.

[0185] Lysinyl residues and amino terminal residues may be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

[0186] Arginyl residues may be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

[0187] Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

[0188] Carboxyl sidechain groups (aspartyl or glutamyl) may be selectively modified by reaction with carbodiimides (R′—N═C═N—R′) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

[0189] Glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

[0190] Cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. See, e.g., Bhatnagar et al. (1996), J. Med. Chem. 39: 3814-9.

[0191] Derivatization with bifunctional agents is useful for cross-linking the peptides or their functional derivatives to a water-insoluble support matrix or to other macromolecular vehicles. Commonly used cross-linking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

[0192] Carbohydrate (oligosaccharide) groups may conveniently be attached to sites that are known to be glycosylation sites in proteins. Generally, O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. X is preferably one of the 19 naturally occurring amino acids other than proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycosylated compound. Such site(s) may be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). However, such sites may further be glycosylated by synthetic or semi-synthetic procedures known in the art.

[0193] Other possible modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. Creighton, Proteins: Structure and Molecule Properties (W. H. Freeman & Co., San Francisco), pp. 79-86 (1983).

[0194] Compounds of the present invention may be changed at the DNA level, as well. The DNA sequence of any portion of the compound may be changed to codons more compatible with the chosen host cell. For E. coli, which is the preferred host cell, optimized codons are known in the art. Codons may be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected host cell. The vehicle, linker and peptide DNA sequences may be modified to include any of the foregoing sequence changes.

[0195] Isotope- and toxin-conjugated derivatives. Another set of useful derivatives are the above-described molecules conjugated to toxins, tracers, or radioisotopes. Such conjugation is especially useful for molecules comprising peptide sequences that bind to tumor cells or pathogens. Such molecules may be used as therapeutic agents or as an aid to surgery (e.g., radioimmunoguided surgery or RIGS) or as diagnostic agents (e.g., radioimmunodiagnostics or RID).

[0196] As therapeutic agents, these conjugated derivatives possess a number of advantages. They facilitate use of toxins and radioisotopes that would be toxic if administered without the specific binding provided by the peptide sequence. They also can reduce the side-effects that attend the use of radiation and chemotherapy by facilitating lower effective doses of the conjugation partner.

[0197] Useful conjugation partners include:

[0198] radioisotopes, such as ⁹⁰Yttrium, ¹³¹Iodine, ²²⁵Actinium, and ²¹³Bismuth;

[0199] ricin A toxin, microbially derived toxins such as Pseudomonas endotoxin (e.g., PE38, PE40), and the like;

[0200] partner molecules in capture systems (see below);

[0201] biotin, streptavidin (useful as either partner molecules in capture systems or as tracers, especially for diagnostic use); and

[0202] cytotoxic agents (e.g., doxorubicin).

[0203] One useful adaptation of these conjugated derivatives is use in a capture system. In such a system, the molecule of the present invention would comprise a benign capture molecule. This capture molecule would be able to specifically bind to a separate effector molecule comprising, for example, a toxin or radioisotope. Both the vehicle-conjugated molecule and the effector molecule would be administered to the patient. In such a system, the effector molecule would have a short half-life except when bound to the vehicle-conjugated capture molecule, thus minimizing any toxic side-effects. The vehicle-conjugated molecule would have a relatively long half-life but would be benign and non-toxic. The specific binding portions of both molecules can be part of a known specific binding pair (e.g., biotin, streptavidin) or can result from peptide generation methods such as those described herein.

[0204] Such conjugated derivatives may be prepared by methods known in the art. In the case of protein effector molecules (e.g., Pseudomonas endotoxin), such molecules can be expressed as fusion proteins from correlative DNA constructs. Radioisotope conjugated derivatives may be prepared, for example, as described for the BEXA antibody (Coulter). Derivatives comprising cytotoxic agents or microbial toxins may be prepared, for example, as described for the BR96 antibody (Bristol-Myers Squibb). Molecules employed in capture systems may be prepared, for example, as described by the patents, patent applications, and publications from NeoRx. Molecules employed for RIGS and RID may be prepared, for example, by the patents, patent applications, and publications from NeoProbe.

[0205] A process for preparing conjugation derivatives is also contemplated. Tumor cells, for example, exhibit epitopes not found on their normal counterparts. Such epitopes include, for example, different post-translational modifications resulting from their rapid proliferation. Thus, one aspect of this invention is a process comprising:

[0206] a) selecting at least one randomized peptide that specifically binds to a target epitope; and

[0207] b) preparing a pharmacologic agent comprising (i) at least one vehicle (Fc domain preferred), (ii) at least one amino acid sequence of the selected peptide or peptides, and (iii) an effector molecule.

[0208] The target epitope is preferably a tumor-specific epitope or an epitope specific to a pathogenic organism. The effector molecule may be any of the above-noted conjugation partners and is preferably a radioisotope.

Methods of Making

[0209] The compounds of this invention largely may be made in transformed host cells using recombinant DNA techniques. To do so, a recombinant DNA molecule coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, a combination of these techniques could be used.

[0210] The invention also includes a vector capable of expressing the peptides in an appropriate host. The vector comprises the DNA molecule that codes for the peptides operatively linked to appropriate expression control sequences. Methods of effecting this operative linking, either before or after the DNA molecule is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation.

[0211] The resulting vector having the DNA molecule thereon is used to transform an appropriate host. This transformation may be performed using methods well known in the art.

[0212] Any of a large number of available and well-known host cells may be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial hosts include bacteria (such as E. coli sp.), yeast (such as Saccharomyces sp.) and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.

[0213] Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the peptides are purified from culture by methods well known in the art.

[0214] The compounds may also be made by synthetic methods. For example, solid phase synthesis techniques may be used. Suitable techniques are well known in the art, and include those described in Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), J. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Intl. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis; U.S. Pat. No. 3,941,763; Finn et al. (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al. (1976), The Proteins (3rd ed.) 2: 257-527. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides.

[0215] Compounds that contain derivatized peptides or which contain non-peptide groups may be synthesized by well-known organic chemistry techniques.

Uses of the Compounds

[0216] In general. The compounds of this invention have pharmacologic activity resulting from their ability to bind to proteins of interest as agonists, mimetics or antagonists of the native ligands of such proteins of interest. The utility of specific compounds is shown in Table 2. The activity of these compounds can be measured by assays known in the art. For the TPO-mimetic and EPO-mimetic compounds, in vivo assays are further described in the Examples section herein.

[0217] In addition to therapeutic uses, the compounds of the present invention are useful in diagnosing diseases characterized by dysfunction of their associated protein of interest. In one embodiment, a method of detecting in a biological sample a protein of interest (e.g., a receptor) that is capable of being activated comprising the steps of: (a) contacting the sample with a compound of this invention; and (b) detecting activation of the protein of interest by the compound. The biological samples include tissue specimens, intact cells, or extracts thereof. The compounds of this invention may be used as part of a diagnostic kit to detect the presence of their associated proteins of interest in a biological sample. Such kits employ the compounds of the invention having an attached label to allow for detection. The compounds are useful for identifying normal or abnormal proteins of interest. For the EPO-mimetic compounds, for example, presence of abnormal protein of interest in a biological sample may be indicative of such disorders as Diamond Blackfan anemia, where it is believed that the EPO receptor is dysfunctional.

[0218] Therapeutic uses of EPO-mimetic compounds. The EPO-mimetic compounds of the invention are useful for treating disorders characterized by low red blood cell levels. Included in the invention are methods of modulating the endogenous activity of an EPO receptor in a mammal, preferably methods of increasing the activity of an EPO receptor. In general, any condition treatable by erythropoietin, such as anemia, may also be treated by the EPO-mimetic compounds of the invention. These compounds are administered by an amount and route of delivery that is appropriate for the nature and severity of the condition being treated and may be ascertained by one skilled in the art. Preferably, administration is by injection, either subcutaneous, intramuscular, or intravenous.

[0219] Therapeutic uses of TPO-mimetic compounds. For the TPO-mimetic compounds, one can utilize such standard assays as those described in WO95/26746 entitled “Compositions and Methods for Stimulating Megakaryocyte Growth and Differentiation”. In vivo assays also appear in the Examples hereinafter.

[0220] The conditions to be treated are generally those that involve an existing megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet deficiency (e.g., because of planned surgery or platelet donation). Such conditions will usually be the result of a deficiency (temporary or permanent) of active Mpl ligand in vivo. The generic term for platelet deficiency is thrombocytopenia, and hence the methods and compositions of the present invention are generally available for treating thrombocytopenia in patients in need thereof.

[0221] Thrombocytopenia (platelet deficiencies) may be present for various reasons, including chemotherapy and other therapy with a variety of drugs, radiation therapy, surgery, accidental blood loss, and other specific disease conditions. Exemplary specific disease conditions that involve thrombocytopenia and may be treated in accordance with this invention are: aplastic anemia, idiopathic thrombocytopenia, metastatic tumors which result in thrombocytopenia, systemic lupus erythematosus, splenomegaly, Fanconi's syndrome, vitamin B12 deficiency, folic acid deficiency, May-Hegglin anomaly, Wiskott-Aldrich syndrome, and paroxysmal nocturnal hemoglobinuria. Also, certain treatments for AIDS result in thrombocytopenia (e.g., AZT). Certain wound healing disorders might also benefit from an increase in platelet numbers.

[0222] With regard to anticipated platelet deficiencies, e.g., due to future surgery, a compound of the present invention could be administered several days to several hours prior to the need for platelets. With regard to acute situations, e.g., accidental and massive blood loss, a compound of this invention could be administered along with blood or purified platelets.

[0223] The TPO-mimetic compounds of this invention may also be useful in stimulating certain cell types other than megakaryocytes if such cells are found to express Mpl receptor. Conditions associated with such cells that express the Mpl receptor, which are responsive to stimulation by the Mpl ligand, are also within the scope of this invention.

[0224] The TPO-mimetic compounds of this invention may be used in any situation in which production of platelets or platelet precursor cells is desired, or in which stimulation of the c-Mpl receptor is desired. Thus, for example, the compounds of this invention may be used to treat any condition in a mammal wherein there is a need of platelets, megakaryocytes, and the like. Such conditions are described in detail in the following exemplary sources: WO95/26746; WO95/21919; WO95/18858; WO95/21920 and are incorporated herein.

[0225] The TPO-mimetic compounds of this invention may also be useful in maintaining the viability or storage life of platelets and/or megakaryocytes and related cells. Accordingly, it could be useful to include an effective amount of one or more such compounds in a composition containing such cells.

[0226] The therapeutic methods, compositions and compounds of the present invention may also be employed, alone or in combination with other cytokines, soluble Mpl receptor, hematopoietic factors, interleukins, growth factors or antibodies in the treatment of disease states characterized by other symptoms as well as platelet deficiencies. It is anticipated that the inventive compound will prove useful in treating some forms of thrombocytopenia in combination with general stimulators of hematopoiesis, such as IL-3 or GM-CSF. Other megakaryocytic stimulatory factors, i.e., meg-CSF, stem cell factor (SCF), leukemia inhibitory factor (LIF), oncostatin M (OSM), or other molecules with megakaryocyte stimulating activity may also be employed with Mpl ligand. Additional exemplary cytokines or hematopoietic factors for such co-administration include IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11, colony stimulating factor-1 (CSF-1), SCF, GM-CSF, granulocyte colony stimulating factor (G-CSF), EPO, interferon-alpha (IFN-alpha), consensus interferon, IFN-beta, or IFN-gamma. It may further be useful to administer, either simultaneously or sequentially, an effective amount of a soluble mammalian Mpl receptor, which appears to have an effect of causing megakaryocytes to fragment into platelets once the megakaryocytes have reached mature form. Thus, administration of an inventive compound (to enhance the number of mature megakaryocytes) followed by administration of the soluble Mpl receptor (to inactivate the ligand and allow the mature megakaryocytes to produce platelets) is expected to be a particularly effective means of stimulating platelet production. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by conventional methods.

[0227] In cases where the inventive compounds are added to compositions of platelets and/or megakaryocytes and related cells, the amount to be included will generally be ascertained experimentally by techniques and assays known in the art. An exemplary range of amounts is 0.1 μg-1 mg inventive compound per 10⁶ cells.

Pharmaceutical Compositions

[0228] In General. The present invention also provides methods of using pharmaceutical compositions of the inventive compounds. Such pharmaceutical compositions may be for administration for injection, or for oral, pulmonary, nasal, transdermal or other forms of administration. In general, the invention encompasses pharmaceutical compositions comprising effective amounts of a compound of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712 which are herein incorporated by reference. The compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized form. Implantable sustained release formulations are also contemplated, as are transdermal formulations.

[0229] Oral dosage forms. Contemplated for use herein are oral solid dosage forms, which are described generally in Chapter 89 of Remington's Pharmaceutical Sciences (1990), 18th Ed., Mack Publishing Co. Easton Pa. 18042, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given in Chapter 10 of Marshall, K., Modern Pharmaceutics (1979), edited by G. S. Banker and C. T. Rhodes, herein incorporated by reference. In general, the formulation will include the inventive compound, and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.

[0230] Also specifically contemplated are oral dosage forms of the above inventive compounds. If necessary, the compounds may be chemically modified so that oral delivery is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the compound molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the compound and increase in circulation time in the body. Moieties useful as covalently attached vehicles in this invention may also be used for this purpose. Examples of such moieties include: PEG, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. See, for example, Abuchowski and Davis, Soluble Polymer-Enzyme Adducts, Enzymes as Drugs (1981), Hocenberg and Roberts, eds., Wiley-Interscience, New York, N.Y., pp 367-83; Newmark, et al. (1982), J. Appl. Biochem. 4:185-9. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are PEG moieties.

[0231] For oral delivery dosage forms, it is also possible to use a salt of a modified aliphatic amino acid, such as sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC), as a carrier to enhance absorption of the therapeutic compounds of this invention. The clinical efficacy of a heparin formulation using SNAC has been demonstrated in a Phase II trial conducted by Emisphere Technologies. See U.S. Pat. No. 5,792,451, “Oral drug delivery composition and methods”.

[0232] The compounds of this invention can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

[0233] Colorants and flavoring agents may all be included. For example, the protein (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

[0234] One may dilute or increase the volume of the compound of the invention with an inert material. These diluents could include carbohydrates, especially mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

[0235] Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

[0236] Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

[0237] An antifrictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

[0238] Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

[0239] To aid dissolution of the compound of this invention into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

[0240] Additives may also be included in the formulation to enhance uptake of the compound. Additives potentially having this property are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

[0241] Controlled release formulation may be desirable. The compound of this invention could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms e.g., gums. Slowly degenerating matrices may also be incorporated into the formulation, e.g., alginates, polysaccharides. Another form of a controlled release of the compounds of this invention is by a method based on the Oros therapeutic system (Alza Corp.), i.e., the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.

[0242] Other coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan. The therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.

[0243] A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan coater or in a fluidized bed or by compression coating.

[0244] Pulmonary delivery forms. Also contemplated herein is pulmonary delivery of the present protein (or derivatives thereof). The protein (or derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. (Other reports of this include Adjei et al., Pharma. Res. (1990) 7: 565-9; Adjei et al. (1990), Internatl. J. Pharmaceutics 63: 135-44 (leuprolide acetate); Braquet et al. (1989), J. Cardiovasc. Pharmacol. 13 (suppl.5): s.143-146 (endothelin-1); Hubbard et al. (1989), Annals Int. Med. 3: 206-12 (α1-antitrypsin); Smith et al. (1989), J. Clin. Invest. 84: 1145-6 (α1-proteinase); Oswein et al. (March 1990), “Aerosolization of Proteins”, Proc. Symp. Resp. Drug Delivery II, Keystone, Colorado (recombinant human growth hormone); Debs et al. (1988), J. Immunol. 140: 3482-8 (interferon-γ and tumor necrosis factor α) and Platz et al., U.S. Pat. No. 5,284,656 (granulocyte colony stimulating factor).

[0245] Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, N.C.; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Mass.

[0246] All such devices require the use of formulations suitable for the dispensing of the inventive compound. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to diluents, adjuvants and/or carriers useful in therapy.

[0247] The inventive compound should most advantageously be prepared in particulate form with an average particle size of less than 10 μm (or microns), most preferably 0.5 to 5 μm, for most effective delivery to the distal lung.

[0248] Pharmaceutically acceptable carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations may include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants may be used. PEG may be used (even apart from its use in derivatizing the protein or analog). Dextrans, such as cyclodextran, may be used. Bile salts and other related enhancers may be used. Cellulose and cellulose derivatives may be used. Amino acids may be used, such as use in a buffer formulation.

[0249] Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.

[0250] Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise the inventive compound dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

[0251] Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the inventive compound suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

[0252] Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the inventive compound and may also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.

[0253] Nasal delivery forms. Nasal delivery of the inventive compound is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran. Delivery via transport across other mucous membranes is also contemplated.

[0254] Buccal delivery forms. Buccal delivery of the inventive compound is also contemplated. Buccal delivery formulations are known in the art for use with peptides.

[0255] Dosages. The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, the daily regimen should be in the range of 0.1-1000 micrograms of the inventive compound per kilogram of body weight, preferably 0.1-150 micrograms per kilogram.

Specific preferred embodiments

[0256] The inventors have determined preferred peptide sequences for molecules having many different kinds of activity. The inventors have further determined preferred structures of these preferred peptides combined with preferred linkers and vehicles. Preferred structures for these preferred peptides listed in Table 21 below. TABLE 21 Preferred embodiments SEQ ID Sequence/structure NO: Activity F¹-(G)₅-IEGPTLRQWLAARA-(G)₈- 337 TPO-mimetic IEGPTLRQWLAARA IEGPTLRQWLAARA-(G)₈- 338 TPO-mimetic IEGPTLRQWLAARA-(G)₅-F¹ F¹-(G)₅-IEGPTLRQWLAARA 1032 TPO-mimetic IEGPTLRQWLAARA-(G)₅-F¹ 1033 TPO-mimetic F¹-(G)₅-GGTYSCHFGPLTWVCKPQGG-(G)₄- 339 EPO-mimetic GGTYSCHFGPLTWVCKPQGG GGTYSCHFGPLTWVCKPQGG-(G)₄- 340 EPO-mimetic GGTYSCHFGPLTWVCKPQGG-(G)₅-F¹ GGTYSCHFGPLTWVCKPQGG-(G)₅-F¹ 1034 EPO-mimetic F¹-(G)₅-DFLPHYKNTSLGHRP 1045 TNF-α inhibitor DFLPHYKNTSLGHRP-(G)₅-F¹ 1046 TNF-α inhibitor F¹-(G)₅-FEWTPGYWQPYALPL 1047 IL-1 R antagonist FEWTPGYWQPYALPL-(G)₅-F¹ 1048 IL-1 R antagonist F¹-(G)₅-VEPNCDIHVMWEWECFERL 1049 VEGF-antagonist VEPNCDIHVMWEWECFERL-(G)₅-F¹ 1050 VEGF-antagonist F¹-(G)₅-CTTHWGFTLC 1051 MMP inhibitor CTTHWGFTLC-(G)₅-F¹ 1052 MMP inhibitor

Working examples

[0257] The compounds described above may be prepared as described below. These examples comprise preferred embodiments of the invention and are illustrative rather than limiting.

EXAMPLE 1 TPO-Mimetics

[0258] The following example uses peptides identified by the numbers appearing in Table A hereinafter.

[0259] Preparation of peptide 19. Peptide 17b (12 mg) and MeO-PEG-SH 5000 (30 mg, 2 equiv.) were dissolved in 1 ml aqueous buffer (pH 8). The mixture was incubated at RT for about 30 minutes and the reaction was checked by analytical HPLC, which showed a >80% completion of the reaction. The pegylated material was isolated by preparative HPLC.

[0260] Preparation of peptide 20. Peptide 18 (14 mg) and MeO-PEG-maleimide (25 mg) were dissolved in about 1.5 ml aqueous buffer (pH 8).

[0261] The mixture was incubated at RT for about 30 minutes, at which time about 70% transformation was complete as monitored with analytical HPLC by applying an aliquot of sample to the HPLC column. The pegylated material was purified by preparative HPLC.

[0262] Bioactivity assay. The TPO in vitro bioassay is a mitogenic assay utilizing an IL-3 dependent clone of murine 32D cells that have been transfected with human mpl receptor. This assay is described in greater detail in WO 95/26746. Cells are maintained in MEM medium containing 10% Fetal Clone II and 1 ng/ml mIL-3. Prior to sample addition, cells are prepared by rinsing twice with growth medium lacking mIL-3. An extended twelve point TPO standard curve is prepared, ranging from 33 to 39 pg/ml. Four dilutions, estimated to fall within the linear portion of the standard curve, (100 to 125 pg/mi), are prepared for each sample and run in triplicate. A volume of 100 μl of each dilution of sample or standard is added to appropriate wells of a 96 well microtiter plate containing 10,000 cells/well. After forty-four hours at 37° C. and 10% CO₂, MTS (a tetrazolium compound which is bioreduced by cells to a formazan) is added to each well. Approximately six hours later, the optical density is read on a plate reader at 490 nm. A dose response curve (log TPO concentration vs. O.D.—Background) is generated and linear regression analysis of points which fall in the linear portion of the standard curve is performed. Concentrations of unknown test samples are determined using the resulting linear equation and a correction for the dilution factor.

[0263] TMP tandem repeats with polyglycine linkers. Our design of sequentially linked TMP repeats was based on the assumption that a dimeric form of TMP was required for its effective interaction with c-Mpl (the TPO receptor) and that depending on how they were wound up against each other in the receptor context, the two TMP molecules could be tethered together in the C- to N-terminus configuration in a way that would not perturb the global dimeric conformation. Clearly, the success of the design of tandem linked repeats depends on proper selection of the length and composition of the linker that joins the C- and N-termini of the two sequentially aligned TMP monomers. Since no structural information of the TMP bound to c-Mpl was available, a series of repeated peptides with linkers composed of 0 to 10 and 14 glycine residues (Table A) were synthesized. Glycine was chosen because of its simplicity and flexibility, based on the rationale that a flexible polyglycine peptide chain might allow for the free folding of the two tethered TMP repeats into the required conformation, while other amino acid sequences may adopt undesired secondary structures whose rigidity might disrupt the correct packing of the repeated peptide in the receptor context.

[0264] The resulting peptides are readily accessible by conventional solid phase peptide synthesis methods (Merrifield (1963), J. Amer. Chem. Soc. 85: 2149) with either Fmoc or t-Boc chemistry. Unlike the synthesis of the C-terminally linked parallel dimer which required the use of an orthogonally protected lysine residue as the initial branch point to build the two peptide chains in a pseudosymmetrical way (Cwirla et al. (1997), Science 276: 1696-9), the synthesis of these tandem repeats was a straightforward, stepwise assembly of the continuous peptide chains from the C- to N-terminus. Since dimerization of TMP had a more dramatic effect on the proliferative activity than binding affinity as shown for the C-terminal dimer (Cwirla et al. (1997)), the synthetic peptides were tested directly for biological activity in a TPO-dependent cell-proliferation assay using an IL-3 dependent clone of murine 32D cells transfected with the full-length c-Mpl (Palacios et al.,. Cell 41:727 (1985)). As the test results showed, all the polyglycine linked tandem repeats demonstrated >1000 fold increases in potency as compared to the monomer, and were even more potent than the C-terminal dimer in this cell proliferation assay. The absolute activity of the C-terminal dimer in our assay was lower than that of the native TPO protein, which is different from the previously reported findings in which the C-terminal dimer was found to be as active as the natural ligand (Cwirla et al. (1997)). This might be due to differences in the conditions used in the two assays. Nevertheless, the difference in activity between tandem (C terminal of first monomer linked to N terminal of second monomer) and C-terminal (C terminal of first monomer linked to C terminal of second monomer; also referred to as parallel) dimers in the same assay clearly demonstrated the superiority of tandem repeat strategy over parallel peptide dimerization. It is interesting to note that a wide range of length is tolerated by the linker. The optimal linker between tandem peptides with the selected TMP monomers apparently is composed of 8 glycines.

[0265] Other tandem repeats. Subsequent to this first series of TMP tandem repeats, several other molecules were designed either with different linkers or containing modifications within the monomer itself. The first of these molecules, peptide 13, has a linker composed of GPNG, a sequence known to have a high propensity to form a D-turn-type secondary structure. Although still about 100-fold more potent than the monomer, this peptide was found to be >10-fold less active than the equivalent GGGG-linked analog. Thus, introduction of a relatively rigid β-turn at the linker region seemed to have caused a slight distortion of the optimal agonist conformation in this short linker form.

[0266] The Trp9 in the TMP sequence is a highly conserved residue among the active peptides isolated from random peptide libraries. There is also a highly conserved Trp in the consensus sequences of EPO mimetic peptides and this Trp residue was found to be involved in the formation of a hydrophobic core between the two EMPs and contributed to hydrophobic interactions with the EPO receptor. Livnah et al. (1996), Science 273: 464-71). By analogy, the Trp9 residue in TMP might have a similar function in dimerization of the peptide ligand, and as an attempt to modulate and estimate the effects of noncovalent hydrophobic forces exerted by the two indole rings, several analogs were made resulting from mutations at the Trp. So in peptide 14, the Trp residue was replaced in each of the two TMP monomers with a Cys, and an intramolecular disulfide bond was formed between the two cysteines by oxidation which was envisioned to mimic the hydrophobic interactions between the two Trp residues in peptide dimerization. Peptide 15 is the reduced form of peptide 14. In peptide 16, the two Trp residues were replaced by Ala. As the assay data show, all three analogs were inactive. These data further demonstrated that Trp is critical for the activity of the TPO mimetic peptide, not just for dimer formation.

[0267] The next two peptides (peptide 17a, and 18) each contain in their 8-amino acid linker a Lys or Cys residue. These two compounds are precursors to the two PEGylated peptides (peptide 19 and 20) in which the side chain of the Lys or Cys is modified by a PEG moiety. A PEG moiety was introduced at the middle of a relatively long linker, so that the large PEG component (5 kDa) is far enough away from the critical binding sites in the peptide molecule. PEG is a known biocompatible polymer which is increasingly used as a covalent modifier to improve the pharmacokinetic profiles of peptide- and protein-based therapeutics.

[0268] A modular, solution-based method was devised for convenient PEGylation of synthetic or recombinant peptides. The method is based on the now well established chemoselective ligation strategy which utilizes the specific reaction between a pair of mutually reactive functionalities. So, for pegylated peptide 19, the lysine side chain was preactivated with a bromoacetyl group to give peptide 17b to accommodate reaction with a thiol-derivatized PEG. To do that, an orthogonal protecting group, Dde, was employed for the protection of the lysine ε-amine. Once the whole peptide chain was assembled, the N-terminal amine was reprotected with t-Boc. Dde was then removed to allow for the bromoacetylation. This strategy gave a high quality crude peptide which was easily purified using conventional reverse phase HPLC. Ligation of the peptide with the thiol-modified PEG took place in aqueous buffer at pH 8 and the reaction completed within 30 minutes. MALDI-MS analysis of the purified, pegylated material revealed a characteristic, bell-shaped spectrum with an increment of 44 Da between the adjacent peaks. For PEG-peptide 20, a cysteine residue was placed in the linker region and its side chain thiol group would serve as an attachment site for a maleimide-containing PEG. Similar conditions were used for the pegylation of this peptide. As the assay data revealed, these two pegylated peptides had even higher in vitro bioactivity as compared to their unpegylated counterparts.

[0269] Peptide 21 has in its 8-amino acid linker a potential glycosylation motif, NGS. Since our exemplary tandem repeats are made up of natural amino acids linked by peptide bonds, expression of such a molecule in an appropriate eukaryotic cell system should produce a glycopeptide with the carbohydrate moiety added on the side chain carboxyamide of Asn. Glycosylation is a common post-translational modification process which can have many positive impacts on the biological activity of a given protein by increasing its aqueous solubility and in vivo stability. As the assay data show, incorporation of this glycosylation motif into the linker maintained high bioactivity. The synthetic precursor of the potential glycopeptide had in effect an activity comparable to that of the -(G)₈-linked analog. Once glycosylated, this peptide is expected to have the same order of activity as the pegylated peptides, because of the similar chemophysical properties exhibited by a PEG and a carbohydrate moiety.

[0270] The last peptide is a dimer of a tandem repeat. It was prepared by oxidizing peptide 18, which formed an intermolecular disulfide bond between the two cysteine residues located at the linker. This peptide was designed to address the possibility that TMP was active as a tetramer. The assay data showed that this peptide was not more active than an average tandem repeat on an adjusted molar basis, which indirectly supports the idea that the active form of TMP is indeed a dimer, otherwise dimerization of a tandem repeat would have a further impact on the bioactivity.

[0271] In order to confirm the in vitro data in animals, one pegylated TMP tandem repeat (compound 20 in Table A) was delivered subcutaneously to normal mice via osmotic pumps. Time and dose-dependent increases were seen in platelet numbers for the duration of treatment. Peak platelet levels over 4-fold baseline were seen on day 8. A dose of 10 μg/kg/day of the pegylated TMP repeat produced a similar response to rHuMGDF (non-pegylated) at 100 μg/kg/day delivered by the same route. TABLE A TPO-mimetic Peptides Peptide Relative No. Compound SEQ ID NO: Potency TPO ++++ TMP monomer 13 + TMP C—C dimer +++− TMP-(G)_(n)-TMP:  1  n = 0 341 ++++−  2  n = 1 342 ++++  3  n = 2 343 ++++  4  n = 3 344 ++++  5  n = 4 345 ++++  6  n = 5 346 ++++  7  n = 6 347 ++++  8  n = 7 348 ++++  9  n = 8 349 ++++− 10  n = 9 350 ++++ 11  n = 10 351 ++++ 12  n = 14 352 ++++ 13  TMP-GPNG-TMP 353 +++ 14  IEGPTLRQCLAARA-GGGGGGGG-IEGPTLRQCLAARA 354 −         |                       | (cyclic) 15  IEGPTLRQCLAARA-GGGGGGGG- 355 − IEGPTLRQCLAARA (linear) 16  IEGPTLRQALAARA-GGGGGGGG- 356 − IEGPTLRQALAARA 17a TMP-GGGKGGGG-TMP 357 ++++ 17b TMP-GGGK(BrAc)GGGG-TMP 358 ND 18  TMP-GGGCGGGG-TMP 359 ++++ 19  TMP-GGGK(PEG)GGGG-TMP 360 +++++ 20  TMP-GGGC(PEG)GGGG-TMP 361 +++++ 21  TMP-GGGN*GSGG-TMP 362 ++++ 22  TMP-GGGCGGGG-TMP 363        | ++++ TMP-GGGCGGGG-TMP 363

[0272] Discussion. It is well accepted that MGDF acts in a way similar to hGH, i.e., one molecule of the protein ligand binds two molecules of the receptor for its activation. Wells et al.(1996), Ann. Rev. Biochem. 65: 609-34. Now, this interaction is mimicked by the action of a much smaller peptide, TMP. However, the present studies suggest that this mimicry requires the concerted action of two TMP molecules, as covalent dimerization of TMP in either a C—C parallel or C—N sequential fashion increased the in vitro biological potency of the original monomer by a factor of greater than 10³. The relatively low biopotency of the monomer is probably due to inefficient formation of the noncovalent dimer. A preformed covalent repeat has the ability to eliminate the entropy barrier for the formation of a noncovalent dimer which is exclusively driven by weak, noncovalent interactions between two molecules of the small, 14-residue peptide.

[0273] It is intriguing that this tandem repeat approach had a similar effect on enhancing bioactivity as the reported C—C dimerization is intriguing. These two strategies brought about two very different molecular configurations. The C—C dimer is a quasi-symmetrical molecule, while the tandem repeats have no such symmetry in their linear structures. Despite this difference in their primary structures, these two types of molecules appeared able to fold effectively into a similar biologically active conformation and cause the dimerization and activation of c-Mpl. These experimental observations provide a number of insights into how the two TMP molecules may interact with one another in binding to c-Mpl. First, the two C-termini of the two bound TMP molecules must be in relatively close proximity with each other, as suggested by data on the C-terminal dimer. Second, the respective N- and C-termini of the two TMP molecules in the receptor complex must also be very closely aligned with each other, such that they can be directly tethered together with a single peptide bond to realize the near maximum activity-enhancing effect brought about by the tandem repeat strategy. Insertion of one or more (up to 14) glycine residues at the junction did not increase (or decrease) significantly the activity any further. This may be due to the fact that a flexible polyglycine peptide chain is able to loop out easily from the junction without causing any significant changes in the overall conformation. This flexibility seems to provide the freedom of orientation for the TMP peptide chains to fold into the required conformation in interacting with the receptor and validate it as a site of modification. Indirect evidence supporting this came from the study on peptide 13, in which a much more rigid b-turn-forming sequence as the linker apparently forced a deviation of the backbone alignment around the linker which might have resulted in a slight distortion of the optimal conformation, thus resulting in a moderate (10-fold) decrease in activity as compared with the analogous compound with a 4-Gly linker. Third, Trp9 in TMP plays a similar role as Trp13 in EMP, which is involved not only in peptide:peptide interaction for the formation of dimers but also is important for contributing hydrophobic forces in peptide:receptor interaction. Results obtained with the W to C mutant analog, peptide 14, suggest that a covalent disulfide linkage is not sufficient to approximate the hydrophobic interactions provided by the Trp pair and that, being a short linkage, it might bring the two TMP monomers too close, therefore perturbing the overall conformation of the optimal dimeric structure.

[0274] An analysis of the possible secondary structure of the TMP peptide can provide further understanding on the interaction between TMP and c-Mpl. This can be facilitated by making reference to the reported structure of the EPO mimetic peptide. Livnah et al. (1996), Science 273:464-75 The receptor-bound EMP has a b-hairpin structure with a b-turn formed by the highly consensus Gly-Pro-Leu-Thr at the center of its sequence. Instead of GPLT, TMP has a highly selected GPTL sequence which is likely to form a similar turn. However, this turn-like motif is located near the N-terminal part in TMP. Secondary structure prediction using Chau-Fasman method suggests that the C-terminal half of the peptide has a tendency to adopt a helical conformation. Together with the highly conserved Trp at position 9, this C-terminal helix may contribute to the stabilization of the dimeric structure. It is interesting to note that most of our tandem repeats are more potent than the C-terminal parallel dimer. Tandem repeats seem to give the molecule a better fit conformation than does the C—C parallel dimerization. The seemingly asymmetric feature of a tandem repeat might have brought it closer to the natural ligand which, as an asymmetric molecule, uses two different sites to bind two identical receptor molecules.

[0275] Introduction of a PEG moiety was envisaged to enhance the in vivo activity of the modified peptide by providing it a protection against proteolytic degradation and by slowing down its clearance through renal filtration. It was unexpected that pegylation could further increase the in vitro bioactivity of a tandem repeated TMP peptide in the cell-based proliferation assay.

EXAMPLE 2 Fc-TMP Fusions

[0276] TMPs (and EMPs as described in Example 3) were expressed in either monomeric or dimeric form as either N-terminal or C-terminal fusions to the Fc region of human IgG1. In all cases, the expression construct utilized the luxPR promoter promoter in the plasmid expression vector pAMG21.

[0277] Fc-TMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the TPO-mimetic peptide was constructed using standard PCR technology. Templates for PCR reactions were the pFc-A3 vector and a synthetic TMP gene. The synthetic gene was constructed from the 3 overlapping oligonucleotides (SEQ ID NOS: 364, 365, and 366, respectively) shown below: 1842-97 AAA AAA GGA TCC TCG AGA TTA AGC ACG AGC AGC CAG CCA CTG ACG CAG AGT CGG ACC 1842-98 AAA GGT GGA GGT GGT GGT ATC GAA GGT CCG ACT CTG CGT 1842-99 CAG TGG CTG GCT GCT CGT GCT TAA TCT CGA GGA TCC TTT TTT

[0278] These oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 367 and 368, respectively) shown below: AAAGGTGGAGGTGGTGGTATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCT 1 ---------+---------+---------+---------+---------+---------+ 60                         CCAGGCTGAGACGCAGTCACCGACCGACGAGCACGA a K  G  G  G  G  G  I  E  G  P  T  L  R  Q  W  L  A  A  R  A − TAATCTCGAGGATCCTTTTTT 61 ---------+---------+-  81 ATTAGAGCTCCTAGGAAAAAA a *

[0279] This duplex was amplified in a PCR reaction using 1842-98 and 1842-97 as the sense and antisense primers.

[0280] The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers shown below (SEQ ID NOS: 369 and 370): 1216-52 AAC ATA AGT ACC TGT AGG ATC G 1830-51 TTCGATACCA CCACCTCCAC CTTTACCCGG AGACAGGGAG AGGCTCTTCTGC

[0281] The oligonucleotides 1830-51 and 1842-98 contain an overlap of 24 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1216-52 and 1842-97.

[0282] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3728.

[0283] The nucleotide and amino acid sequences (SEQ ID NOS: 5 and 6) of the fusion protein are shown in FIG. 7.

[0284] Fc-TMP-TMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a dimer of the TPO-mimetic peptide was constructed using standard PCR technology. Templates for PCR reactions were the pFc-A3 vector and a synthetic TMP-TMP gene. The synthetic gene was constructed from the 4 overlapping oligonucleotides (SEQ ID NOS: 371 to 374, respectively) shown below: 1830-52 AAA GGT GGA GGT GGT GGT ATC GAA GGT CCG ACT CTG CGT CAG TGG CTG GCT GCT CGT GCT 1830-53 ACC TCC ACC ACC AGC ACG AGC AGC CAG CCA CTG ACG CAG AGT CGG ACC 1830-54 GGT GGT GGA GGT GGC GGC GGA GGT ATT GAG GGC CCA ACC CTT CGC CAA TGG CTT GCA GCA CGC GCA 1830-55 AAA AAA AGG ATC CTC GAG ATT ATG CGC GTG CTG CAA GCC ATT GGC GAA GGG TTG GGC CCT CAA TAC CTC CGC CGC C

[0285] The 4 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 375 and 376, respectively) shown below: AAAGGTGGAGGTGGTGGTATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCT 1 ---------+---------+---------+---------+---------+---------+ 60                         CCAGGCTGAGACGCAGTCACCGACCGACGAGCACGA a K  G  G  G  G  G  I  E  G  P  T  L  R  Q  W  L  A  A  R  A − GGTGGTGGAGGTGGCGGCGGAGGTATTGAGGGCCCAACCCTTCGCCAATGGCTTGCAGCA 61 ---------+---------+---------+---------+---------+---------+ 120 CCACCACCTCCACCGCCGCCTCCATAACTCCCGGGTTGGGAAGCGGTTACCGAACGTCGT a G  G  G  G  G  G  G  G  I  E  G  P  T  L  R  Q  W  L  A  A − CGCGCA 121 ---------------------------148 GCGCGTATTAGAGCTCCTAGGAAAAAAA a R  A   *-

[0286] This duplex was amplified in a PCR reaction using 1830-52 and 1830-55 as the sense and antisense primers.

[0287] The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers 1216-52 and 1830-51 as described above for Fc-TMP. The full length fusion gene was obtained from a third PCR reaction using the outside primers 1216-52 and 1830-55.

[0288] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described in example 1. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3727.

[0289] The nucleotide and amino acid sequences (SEQ ID NOS: 7 and 8) of the fusion protein are shown in FIG. 8.

[0290] TMP-TMP-Fc. A DNA sequence coding for a tandem repeat of the TPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. Templates for PCR reactions were the EMP-Fc plasmid from strain #3688 (see Example 3) and a synthetic gene encoding the TMP dimer. The synthetic gene for the tandem repeat was constructed from the 7 overlapping oligonucleotides shown below (SEQ ID NOS: 377 to 383, respectively): 1885-52 TTT TTT CAT ATG ATC GAA GGT CCG ACT CTG CGT CAG TGG 1885-53 AGC ACG AGC AGC CAG CCA CTG ACG CAG AGT CGG ACC TTC GAT CAT ATG 1885-54 CTG GCT GCT CGT GCT GGT GGA GGC GGT GGG GAC AAA ACT CAC ACA 1885-55 CTG GCT GCT CGT GCT GGC GGT GGT GGC GGA GGG GGT GGC ATT GAG GGC CCA 1885-56 AAG CCA TTG GCG AAG GGT TGG GCC CTC AAT GCC ACC CCC TCC GCC ACC ACC GCC 1885-57 ACC CTT CGC CAA TGG CTT GCA GCA CGC GCA GGG GGA GGC GGT GGG GAC AAA ACT 1885-58 CCC ACC GCC TCC CCC TGC GCG TGC TGC

[0291] These oligonucleotides were annealed to form the duplex shown encoding an amino acid sequence shown below (SEQ ID NOS 384 and 385): TTTTTTCATATGATCGAAGGTCCGACTCTGCGTCAGTGGCTGGCTGCTCGTGCTGGCGGT 1 ---------+---------+---------+---------+---------+---------+ 60       GTATACTAGCTTCCAGGCTGAGACGCAGTCACCGACCGACGAGCACGACCGCCA a         M  I  E  G  P  T  L  R  Q  W  L  A  A  R  A  G  G − GGTGGCGGAGGGGGTGGCATTGAGGGCCCAACCCTTCGCCAATGGCTGGCTGCTCGTGCT 61 ---------+---------+---------+---------+---------+---------+ 120 CCACCGCCTCCCCCACCGTAACTCCCGGGTTGGGAAGCGGTTACCGAACGTCGTGCGCGT a G  G  G  G  G  G  I  E  G  P  T  L  R  Q  W  L  A  A  R  A − GGTGGAGGCGGTGGGGACAAAACTCTGGCTGCTCGTGCTGGTGGAGGCGGTGGGGACAAA 121 ---------+---------+---------+---------+---------+---------+ 180 CCCCCTCCGCCACCC a G  G  G  G  G  D  K  T  L  A  A  R  A  G  G  G  G  G  D  K − ACTCACACA 181 ---------  189 a T  H  T    −

[0292] This duplex was amplified in a PCR reaction using 1885-52 and 1885-58 as the sense and antisense primers.

[0293] The Fc portion of the molecule was generated in a PCR reaction with DNA from the EMP-Fc fusion strain #3688 (see Example 3) using the primers 1885-54 and 1200-54. The full length fusion gene was obtained from a third PCR reaction using the outside primers 1885-52 and 1200-54.

[0294] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for Fc-EMP herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3798.

[0295] The nucelotide and amino acid sequences (SEQ ID NOS: 9 and 10) of the fusion protein are shown in FIG. 9.

[0296] TMP-Fc. A DNA sequence coding for a monomer of the TPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was obtained fortuitously in the ligation in TMP-TMP-Fc, presumably due to the ability of primer 1885-54 to anneal to 1885-53 as well as to 1885-58. A single clone having the correct nucleotide sequence for the TMP-Fc construct was selected and designated Amgen strain #3788.

[0297] The nucleotide and amino acid sequences (SEQ ID NOS: 11 and 12) of the fusion protein are shown in FIG. 10.

[0298] Expression in E. coli. Cultures of each of the pAMG21-Fc-fusion constructs in E. coli GM221 were grown at 37° C. in Luria Broth medium containing 50 mg/ml kanamycin. Induction of gene product expression from the luxPR promoter was achieved following the addition of the synthetic autoinducer N-(3-oxohexanoyl)-DL-homoserine lactone to the culture media to a final concentration of 20 ng/ml. Cultures were incubated at 37° C. for a further 3 hours. After 3 hours, the bacterial cultures were examined by microscopy for the presence of inclusion bodies and were then collected by centrifugation. Refractile inclusion bodies were observed in induced cultures indicating that the Fc-fusions were most likely produced in the insoluble fraction in E. coli. Cell pellets were lysed directly by resuspension in Laemmli sample buffer containing 10% b-mercaptoethanol and were analyzed by SDS-PAGE. In each case, an intense coomassie-stained band of the appropriate molecular weight was observed on an SDS-PAGE gel.

[0299] pAMG21. The expression plasmid pAMG21 can be derived from the Amgen expression vector pCFM1656 (ATCC #69576) which in turn be derived from the Amgen expression vector system described in U.S. Pat. No. 4,710,473. The pCFM1656 plasmid can be derived from the described pCFM836 plasmid (Patent No. 4,710,473) by:

[0300] (a) destroying the two endogenous NdeI restriction sites by end filling with T4 polymerase enzyme followed by blunt end ligation;

[0301] (b) replacing the DNA sequence between the unique AatII and ClaI restriction sites containing the synthetic P_(L) promoter with a similar fragment obtained from pCFM636 (U.S. Pat. No. 4,710,473) containing the PL promoter (see SEQ ID NO: 386 below); and

[0302] (c) substituting the small DNA sequence between the unique ClaI and KpnI restriction sites with the oligonucleotide having the sequence of SEQ ID NO: 388. SEQ ID NO: 386: AatII 5′  CTAATTCCGCTCTCACCTACCAAACAATGCCCCCCTGCAAAAAATAAATTCATAT- 3′  TGCAGATTAAGGCGAGAGTGGATGGTTTGTTACGGGGGGACGTTTTTTATTTAAGTATA     -AAAAAACATACAGATAACCATCTGCGGTGATAAATTATCTCTGGCGGTGTTGACATAAA-     -TTTTTTGTATGTCTATTGGTAGACGCCACTATTTAATAGAGACCGCCACAACTGTATTT-     -TACCACTGGCGGTGATACTGAGCACAT    3′     -ATGGTGACCGCCACTATGACTCGTGTAGC  5′                                 ClaI SEQ ID NO: 387: 5′  CGATTTGATTCTAGAAGGAGGAATAACATATGGTTAACGCGTTGGAATTCGGTAC  3′ 3′    TAAACTAAGATCTTCCTCCTTATTGTATACCAATTGCGCAACCTTAAGC      5′     ClaI                                               KpnI

[0303] The expression plasmid pAMG21 can then be derived from pCFM1656 by making a series of site-directed base changes by PCR overlapping oligo mutagenesis and DNA sequence substitutions. Starting with the BglII site (plasmid bp #180) immediately 5′ to the plasmid replication promoter P_(copB) and proceeding toward the plasmid replication genes, the base pair changes are as shown in Table B below. TABLE B Base pair changes resulting in pAMG21 pAMG21 bp # bp in pCFM1656 bp changed to in pAMG21 # 204 T/A C/G # 428 A/T G/C # 509 G/C A/T # 617 — insert two G/C bp # 679 G/C T/A # 980 T/A C/G # 994 G/C A/T # 1004 A/T C/G # 1007 C/G T/A # 1028 A/T T/A # 1047 C/G T/A # 1178 G/C T/A # 1466 G/C T/A # 2028 G/C bp deletion # 2187 C/G T/A # 2480 A/T T/A # 2499-2502 AGTG GTCA TCAC CAGT # 2642 TCCGAGC 7 bp deletion AGGCTCG # 3435 G/C A/T # 3446 G/C A/T # 3643 A/T T/A

[0304] The DNA sequence between the unique AatII (position #4364 in pCFM1656) and SacII (position #4585 in pCFM1656) restriction sites is substituted with the DNA sequence (SEQ ID NO: 23) shown in FIGS. 17A and 17B. During the ligation of the sticky ends of this substitution DNA sequence, the outside AatII and SacII sites are destroyed. There are unique AatII and SacII sites in the substituted DNA.

[0305] GM221 (Amgen #2596). The Amgen host strain #2596 is an E. coli K-12 strain derived from Amgen strain #393. It has been modified to contain both the temperature sensitive lambda repressor cI857s7 in the early ebg region and the lacI^(Q) repressor in the late ebg region (68 minutes). The presence of these two repressor genes allows the use of this host with a variety of expression systems, however both of these repressors are irrelevant to the expression from luxP_(R). The untransformed host has no antibiotic resistances.

[0306] The ribosome binding site of the cI857s7 gene has been modified to include an enhanced RBS. It has been inserted into the ebg operon between nucleotide position 1170 and 1411 as numbered in Genbank accession number M64441Gb_Ba with deletion of the intervening ebg sequence. The sequence of the insert is shown below with lower case letters representing the ebg sequences flanking the insert shown below (SEQ ID NO: 388): ttattttcgtGCGGCCGCACCATTATCACCGCCAGAGGTAAACTAGTCAA CACGCACGGTGTTAGATATTTATCCCTTGCGGTGATAGATTGAGCACATC GATTTGATTCTAGAAGGAGGGATAATATATGAGCACAAAAAAGAAACCAT TAACACAAGAGCAGCTTGAGGACGCACGTCGCCTTAAAGCAATTTATGAA AAAAAGAAAAATGAACTTGGCTTATCCCAGGAATCTGTCGCAGACAAGAT GGGGATGGGGCAGTCAGGCGTTGGTGCTTTATTTAATGGCATCAATGCAT TAAATGCTTATAACGCCGCATTGCTTACAAAAATTCTCAAAGTTAGCGTT GAAGAATTTAGCCCTTCAATCGCCAGAGAATCTACGAGATGTATGAAGCG GTTAGTATGCAGCCGTCACTTAGAAGTGAGTATGAGTACCCTGTTTTTTC TCATGTTCAGGCAGGGATGTTCTCACCTAAGCTTAGAACCTTTACCAAAG GTGATGCGGAGAGATGGGTAAGCACAACCAAAAAAGCCAGTCATTCTGCA TTCTGGCTTGAGGTTGAAGGTAATTCCATGACCGCACCAACAGGCTCCAA GCCAAGCTTTCCTGACGGAATGTTAATTCTCGTTGACCCTGAGCAGGCTG TTGAGCCAGGTGATTTCTGCATAGCCAGACTTGGGGGTGATGAGTTTACC TTCAAGAAACTGATCAGGGATAGCGGTCAGGTGTTTTTACAACCACTAAA CCCACAGTACCCAATGATCCCATGCAATGAGAGTTGTTCCGTTGTGGGGA AAGTTATCGCTAGTCAGTGGCCTGAAGAGACGTTTGGCTGATAGACTAGT GGATCCACTAGTgtttctgccc

[0307] The construct was delivered to the chromosome using a recombinant phage called MMebg-cI857s7enhanced RBS #4 into F'tet/393. After recombination and resolution only the chromosomal insert described above remains in the cell. It was renamed F'tet/GM101. F'tet/GM101 was then modified by the delivery of a lacI^(Q) construct into the ebg operon between nucleotide position 2493 and 2937 as numbered in the Genbank accession number M64441Gb_Ba with the deletion of the intervening ebg sequence. The sequence of the insert is shown below with the lower case letters representing the ebg sequences flanking the insert (SEQ ID NO: 389) shown below: ggcggaaaccGACGTCCATCGAATGGTGCAAAACCTTTCGCGGTATGGCA TGATAGCGCCCGGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAACCAGT AACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTT CCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAA GTCGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACA ACAACTGGCGGGCAAACAGTCGCTCCTGATTGGCGTTGCCACCTCCAGTC TGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGCC GATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGT CGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTG GGCTGATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAA GCTGCCTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGAC ACCCATCAACAGTATTATTTTCTCCCATGAAGACGGTACGCGACTGGGCG TGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGC CCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATA TCTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGA GTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAATCAGGGCATC GTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAAT GCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATCTCGGTAG TGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACC ACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTT GCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCG TCTCACTGGTGAAAAGAAAACCACCCTGGCGCCCAATACGCAAACCGCCT CTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC CGACTGGAAAGCGGACAGTAAGGTACCATAGGATCCaggCaCagga

[0308] The construct was delivered to the chromosome using a recombinant phage called AGebg-LacIQ#5 into F'tet/GM101. After recombination and resolution only the chromosomal insert described above remains in the cell. It was renamed F'tet/GM221. The F'tet episome was cured from the strain using acridine orange at a concentration of 25 μg/ml in LB. The cured strain was identified as tetracyline sensitive and was stored as GM221.

[0309] Expression. Cultures of pAMG21-Fc-TMP-TMP in E. coli GM221 in Luria Broth medium containing 50 μg/ml kanamycin were incubated at 37° C. prior to induction. Induction of Fc-TMP-TMP gene product expression from the luxPR promoter was achieved following the addition of the synthetic autoinducer N-(3-oxohexanoyl)-DL-homoserine lactone to the culture media to a final concentration of 20 ng/ml and cultures were incubated at 37° C. for a further 3 hours. After 3 hours, the bacterial cultures were examined by microscopy for the presence of inclusion bodies and were then collected by centrifugation. Refractile inclusion bodies were observed in induced cultures indicating that the Fc-TMP-TMP was most likely produced in the insoluble fraction in E. coli. Cell pellets were lysed directly by resuspension in Laenmuli sample buffer containing 10% •-mercaptoethanol and were analyzed by SDS-PAGE. An intense Coomassie stained band of approximately 30 kDa was observed on an SDS-PAGE gel. The expected gene product would be 269 amino acids in length and have an expected molecular weight of about 29.5 kDa. Fermentation was also carried out under standard batch conditions at the 10 L scale, resulting in similar expression levels of the Fc-TMP-TMP to those obtained at bench scale.

[0310] Purification of Fc-TMP-TMP. Cells are broken in water (1/10) by high pressure homogenization (2 passes at 14,000 PSI) and inclusion bodies are harvested by centrifugation (4200 RPM in J-6B for 1 hour). Inclusion bodies are solubilized in 6M guanidine, 50 mM Tris, 8 mM DTT, pH 8.7 for 1 hour at a 1/10 ratio. The solubilized mixture is diluted 20 times into 2M urea, 50 mM tris, 160 mM arginine, 3 mM cysteine, pH 8.5. The mixture is stirred overnight in the cold and then concentrated about 10 fold by ultafiltration. It is then diluted 3 fold with 10 mM Tris, 1.5M urea, pH 9. The pH of this mixture is then adjusted to pH 5 with acetic acid. The precipitate is removed by centrifugation and the supernatant is loaded onto a SP-Sepharose Fast Flow column equilibrated in 20 mM NaAc, 100 mM NaCl, pH 5(10 mg/ml protein load, room temperature). The protein is eluted off using a 20 column volume gradient in the same buffer ranging from 100 mM NaCl to 500 mM NaCl. The pool from the column is diluted 3 fold and loaded onto a SP-Sepharose HP column in 20 mM NaAc, 150 mM NaCl, pH 5(10 mg/ml protein load, room temperature). The protein is eluted off using a 20 column volume gradient in the same buffer ranging from 150 mM NaCl to 400 mM NaCl. The peak is pooled and filtered.

[0311] Characterization of Fc-TMP activity. The following is a summary of in vivo data in mice with various compounds of this invention.

[0312] Mice: Normal female BDF1 approximately 10-12 weeks of age.

[0313] Bleed schedule: Ten mice per group treated on day 0, two groups started 4 days apart for a total of 20 mice per group. Five mice bled at each time point, mice were bled a minimum of three times a week. Mice were anesthetized with isoflurane and a total volume of 140-160 μl of blood was obtained by puncture of the orbital sinus. Blood was counted on a Technicon H1E blood analyzer running software for murine blood. Parameters measured were white blood cells, red blood cells, hematocrit, hemoglobin, platelets, neutrophils.

[0314] Treatments: Mice were either injected subcutaneously for a bolus treatment or implanted with 7-day micro-osmotic pumps for continuous delivery. Subcutaneous injections were delivered in a volume of 0.2 ml. Osmotic pumps were inserted into a subcutaneous incision made in the skin between the scapulae of anesthetized mice. Compounds were diluted in PBS with 0.1% BSA. All experiments included one control group, labeled “carrier” that were treated with this diluent only. The concentration of the test articles in the pumps was adjusted so that the calibrated flow rate from the pumps gave the treatment levels indicated in the graphs.

[0315] Compounds: A dose titration of the compound was delivered to mice in 7 day micro-osmotic pumps. Mice were treated with various compounds at a single dose of 100 μg/kg in 7 day osmotic pumps. Some of the same compounds were then given to mice as a single bolus injection.

[0316] Activity test results: The results of the activity experiments are shown in FIGS. 11 and 12. In dose response assays using 7-day micro-osmotic pumps, the maximum effect was seen with the compound of SEQ ID NO: 18 was at 100 μg/kg/day; the 10 μg/kg/day dose was about 50% maximally active and 1 μg/kg/day was the lowest dose at which activity could be seen in this assay system. The compound at 10 μg/kg/day dose was about equally active as 100 μg/kg/day unpegylated rHu-MGDF in the same experiment.

EXAMPLE 3 Fc-EMP Fusions

[0317] Fc-EMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the EPO-mimetic peptide was constructed using standard PCR technology. Templates for PCR reactions were a vector containing the Fc sequence (pFc-A3, described in International application WO 97/23614, published Jul. 3, 1997) and a synthetic gene encoding EPO monomer. The synthetic gene for the monomer was constructed from the 4 overlapping oligonucleotides (SEQ ID NOS: 390 to 393, respectively) shown below: 1798-2 TAT GAA AGG TGG AGG TGG TGG TGG AGG TAC TTA CTC TTG CCA CTT CGG CCC GCT GAC TTG G 1798-3 CGG TTT GCA AAC CCA AGT CAG CGG GCC GAA GTG GCA AGA GTA AGT ACC TCC ACC ACC ACC TCC ACC TTT CAT 1798-4 GTT TGC AAA CCG CAG GGT GGC GGC GGC GGC GGC GGT GGT ACC TAT TCC TGT CAT TTT 1798-5 CCA GGT CAG CGG GCC AAA ATG ACA GGA ATA GGT ACC ACC GCC GCC GCC GCC GCC ACC CTG

[0318] The 4 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 394 and 395, respectively) shown below: TATGAAAGGTGGAGGTGGTGGTGGAGGTACTTACTCTTGCCACTTCGGCCCGCTGACTTG 1 ---------+---------+---------+---------+---------+---------+ 60 TACTTTCCACCTCCACCACCACCTCCATGAATGAGAACGGTGAAGCCGGGCGACTGAAC b M  K  G  G  G  G  G  G  G  T  Y  S  C  H  F  G  P  L  T  W − GGTTTGCAAACCGCAGGGTGGCGGCGGCGGCGGCGGTGGTACCTATTCCTGTCATTTT 61 ---------+---------+---------+---------+---------+----------+----------+-- 133 CCAAACGTTTGGCGTCCCACCGCCGCCGCCGCCGCCACCATGGATAAGGACAGTAAAACCGGGCGACTGGACC b V  C  K  P  Q  G  G  G  G  G  G  G  G  T  Y  S  C  H  F    -

[0319] This duplex was amplified in a PCR reaction using 1798-18 GCA GAA GAG CCT CTC CCT GTC TCC GGG TAA AGG TGG AGG TGG TGG TGG AGG TAC TTA CTC T and 1798-19 CTA ATT GGA TCC ACG AGA TTA ACC ACC CTG CGG TTT GCA A

[0320] as the sense and antisense primers (SEQ ID NOS: 396 and 397, respectively).

[0321] The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers 1216-52 AAC ATA AGT ACC TGT AGG ATC G 1798-17 AGA GTA AGT ACC TCC ACC ACC ACC TCC ACC TTT ACC CGG AGA CAG GGA GAG GCT CTT CTG C

[0322] which are SEQ ID NOS: 398 and 399, respectively. The oligonucleotides 1798-17 and 1798-18 contain an overlap of 61 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1216-52 and 1798-19.

[0323] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 (described below), also digested with XbaI and BamHI. Ligated DNA was transformed into competent host cells of E. coli strain 2596 (GM221, described herein). Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3718.

[0324] The nucleotide and amino acid sequence of the resulting fusion protein (SEQ ID NOS: 15 and 16) are shown in FIG. 13.

[0325] EMP-Fc. A DNA sequence coding for a monomer of the EPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. Templates for PCR reactions were the pFC-A3a vector and a synthetic gene encoding EPO monomer. The synthetic gene for the monomer was constructed from the 4 overlapping oligonucleotides 1798-4 and 1798-5 (above) and 1798-6 and 1798-7 (SEQ ID NOS: 400 and 401, respectively) shown below: 1798-6 GGC CCG CTG ACC TGG GTA TGT AAG CCA CAA GGG GGT GGG GGA GGC GGG GGG TAA TCT CGA G 1798-7 GAT CCT CGA GAT TAC CCC CCG CCT CCC CCA CCC CCT TGT GGC TTA CAT AC

[0326] The 4 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 402 and 403, respectively) shown below:       GTTTGCAAACCGCAGGGTGGCGGCGGCGGCGGCGGTGGTACCTATTCCTGTCATTTTGGC     1 _________+_________+_________+_________+_________+_________+   60                   GTCCCACCGCCGCCGCCGCCGCCACCATGGATAAGGACAGTAAAACCG A     V  C  K  P  Q  G  G  G  G  G  G  G  G  T  Y  S  C  H  F  G     -       CCGCTGACCTGGGTATGTAAGCCACAAGGGGGTGGGGGAGGCGGGGGGTAATCTCGAG    61 _________+_________+_________+_________+_________+_________+   122       GGCGACTGGACCCATACATTCGGTGTTCCCCCACCCCCTCCGCCCCCCATTAGAGCTCCTAG A     P  L  T  W  V  C  K  P  Q  G  G  G  G  G  G  G  *

[0327] This duplex was amplified in a PCR reaction using 1798-21 TTA TTT CAT ATG AAA GGT GGT AAC TAT TCC TGT CAT TTT and 1798-22 TGG ACA TGT GTG AGT TTT GTC CCC CCC GCC TCC CCC ACC CCC T

[0328] as the sense and antisense primers (SEQ ID NOS: 404 and 405, respectively).

[0329] The Fc portion of the molecule was generated in a PCR reaction with pFc-A3 using the primers 1798-23 AGG GGG TGG GGG AGG CGG GGG GGA CAA AAC TCA CAC ATG TCC A and 1200-54 GTT ATT GCT CAG CGG TGG CA

[0330] which are SEQ ID NOS: 406 and 407, respectively. The oligonucleotides 1798-22 and 1798-23 contain an overlap of 43 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1787-21 and 1200-54.

[0331] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described above. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3688.

[0332] The nucleotide and amino acid sequences (SEQ ID NOS: 17 and 18) of the resulting fusion protein are shown in FIG. 14.

[0333] EMP-EMP-Fc. A DNA sequence coding for a dimer of the EPO-mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. Templates for PCR reactions were the EMP-Fc plasmid from strain #3688 above and a synthetic gene encoding the EPO dimer. The synthetic gene for the dimer was constructed from the 8 overlapping oligonucleotides (SEQ ID NOS:408 to 415, respectively) shown below: 1869-23 TTT TTT ATC GAT TTG ATT CTA GAT TTG AGT TTT AAC TTT TAG AAG GAG GAA TAA AAT ATG 1869-48 TAA AAG TTA AAA CTC AAA TCT AGA ATC AAA TCG ATA AAA AA 1871-72 GGA GGT ACT TAC TCT TGC CAC TTC GGC CCG CTG ACT TGG GTT TGC AAA CCG 1871-73 AGT CAG CGG GCC GAA GTG GCA AGA GTA AGT ACC TCC CAT ATT TTA TTC CTC CTT C 1871-74 CAG GGT GGC GGC GGC GGC GGC GGT GGT ACC TAT TCC TGT CAT TTT GGC CCG CTG ACC TGG 1871-75 AAA ATG ACA GGA ATA GGT ACC ACC GCC GCC GCC GCC GCC ACC CTG CGG TTT GCA AAC CCA 1871-78 GTA TGT AAG CCA CAA GGG GGT GGG GGA GGC GGG GGG GAC AAA ACT CAC ACA TGT CCA 1871-79 AGT TTT GTC CCC CCC GCC TCC CCC ACC CCC TTG TGG CTT ACA TAC CCA GGT CAG CGG GCC

[0334] The 8 oligonucleotides were annealed to form the duplex encoding an amino acid sequence (SEQ ID NOS: 416 and 417, respectively) shown below:        TTTTTTATCGATTTGATTCTAGATTTGAGTTTTAACTTTTAGAAGGAGGAATAAATATG      1 _________+_________+_________+_________+_________+_________+ 60        AAAAATAGCTAAACTAAGATCTAAACTCAAAATTGAAATCTTCCTCCTTATTTTATAC a                                                              M    -        GGAGGTACTTACTCTTGCCACTTCGGCCCGCTGACTTGGGTTTGCAAACCGCAGGGTGGC     61 _________+_________+_________+_________+_________+_________+ 120        CCTCCATGAATGAGACGGTGAAGCCGGGCGACTGAACCCAAACGTTTGGCGTCCCACCG a      G  G  T  Y  S  C  H  F  G  P  L  T  W  V  C  K  P  Q  G  G   -        GGCGGCGGCGGCGGTGGTACCTATTCCTGTCATTTTGGCCCGCTGACCTGGGTATGTAAG    121 _________+_________+_________+_________+_________+_________+ 180        CCGCCGCCGCCGCCACCATGGATAAGGACAGTAAAACCGGGCGACTGGACCCATACATTC a      G  G  G  G  G  G  T  Y  S  C  H  F  G  P  L  T  W  V  C  K   -        CCACAAGGGGGTGGGGGAGGCGGGGGGGACAAAACTCACACATGTCCA    181 _________+_________+_________+_________+       228        GGTGTTCCCCCACCCCCTCCGCCCCCCCTGTTTTGA a      P  Q  G  G  G  G  G  G  G  D  K  T  H  T  C  P -

[0335] This duplex was amplified in a PCR reaction using 1869-23 and 1871-79 (shown above) as the sense and antisense primers.

[0336] The Fc portion of the molecule was generated in a PCR reaction with strain 3688 DNA using the primers 1798-23 and 1200-54 (shown above).

[0337] The oligonucleotides 1871-79 and 1798-23 contain an overlap of 31 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1869-23 and 1200-54.

[0338] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for Fc-EMP. Clones were screened for ability to produce the recombinant protein product and possession of the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3813.

[0339] The nucleotide and amino acid sequences (SEQ ID NOS: 19 and 20, respectively) of the resulting fusion protein are shown in FIG. 15. There is a silent mutation at position 145 (A to G, shown in boldface) such that the final construct has a different nucleotide sequence than the oligonucleotide 1871-72 from which it was derived.

[0340] Fc-EMP-EMP. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a dimer of the EPO-mimetic peptide was constructed using standard PCR technology. Templates for PCR reactions were the plasmids from strains 3688 and 3813 above.

[0341] The Fc portion of the molecule was generated in a PCR reaction with strain 3688 DNA using the primers 1216-52 and 1798-17 (shown above). The EMP dimer portion of the molecule was the product of a second PCR reaction with strain 3813 DNA using the primers 1798-18 (also shown above) and SEQ ID NO: 418, shown below:

[0342] 1798-20 CTA ATT GGA TCC TCG AGA TTA ACC CCC TTG TGG CTT ACAT

[0343] The oligonucleotides 1798-17 and 1798-18 contain an overlap of 61 nucleotides, allowing the two genes to be fused together in the correct reading frame by combining the above PCR products in a third reaction using the outside primers, 1216-52 and 1798-20.

[0344] The final PCR gene product (the full length fusion gene) was digested with restriction endonucleases XbaI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for Fc-EMP. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #3822.

[0345] The nucleotide and amino acid sequences (SEQ ID NOS: ______ and ______, respectively) of the fusion protein are shown in FIG. 16.

[0346] Characterization of Fc-EMP activity. Characterization was carried out in vivo as follows.

[0347] Mice: Normal female BDF1 approximately 10-12 weeks of age.

[0348] Bleed schedule: Ten mice per group treated on day 0, two groups started 4 days apart for a total of 20 mice per group. Five mice bled at each time point, mice were bled a maximum of three times a week. Mice were anesthetized with isoflurane and a total volume of 140-160 ml of blood was obtained by puncture of the orbital sinus. Blood was counted on a Technicon H1E blood analyzer running software for murine blood. Parameters measured were WBC, RBC, HCT, HGB, PLT, NEUT, LYMPH.

[0349] Treatments: Mice were either injected subcutaneously for a bolus treatment or implanted with 7 day micro-osmotic pumps for continuous delivery. Subcutaneous injections were delivered in a volume of 0.2 ml. Osmotic pumps were inserted into a subcutaneous incision made in the skin between the scapulae of anesthetized mice. Compounds were diluted in PBS with 0.1% BSA. All experiments included one control group, labeled “carrier” that were treated with this diluent only. The concentration of the test articles in the pumps was adjusted so that the calibrated flow rate from the pumps gave the treatment levels indicated in the graphs.

[0350] Experiments: Various Fc-conjugated EPO mimetic peptides (EMPs) were delivered to mice as a single bolus injection at a dose of 100 μg/kg. Fc-EMPs were delivered to mice in 7-day micro-osmotic pumps. The pumps were not replaced at the end of 7 days. Mice were bled until day 51 when HGB and HCT returned to baseline levels.

EXAMPLE 4 TNF-α Inhibitors

[0351] Fc-TNF-α inhibitors. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the TNF- inhibitory peptide was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-EMP fusion strain #3718 (see Example 3) using the sense primer 1216-52 and the antisense primer 2295-89 (SEQ ID NOS: 1112 and 1113, respectively). The nucleotides encoding the TNF-α inhibitory peptide were provided by the PCR primer 2295-89 shown below: 1216-52 AAC ATA AGT ACC TGT AGG ATC G 2295-89 CCG CGG ATC CAT TAC GGA CGG TGA CCC AGA GAG GTG TTT TTG TAG TGC GGC AGG AAG TCA CCA CCA CCT CCA CCT TTA CCC

[0352] The oligonucleotide 2295-89 overlaps the glycine linker and Fc portion of the template by 22 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

[0353] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4544.

[0354] The nucleotide and amino acid sequences (SEQ ID NOS: 1055 and 1056) of the fusion protein are shown in FIGS. 19A and 19B.

[0355] TNF-α inhibitor-Fc. A DNA sequence coding for a TNF-α inhibitory peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The template for the PCR reaction was a plasmid containing an unrelated peptide fused via a five glycine linker to Fc. The nucleotides encoding the TNF-α inhibitory peptide were provided by the sense PCR primer 2295-88, with primer 1200-54 serving as the antisense primer (SEQ ID NOS: 1117 and 407, respectively). The primer sequences are shown below: 2295-88 GAA TAA CAT ATG GAC TTC CTG CCG CAC TAC AAA AAC ACC TCT CTG GGT CAC CGT CCG GGT GGA GGC GGT GGG GAC AAA ACT 1200-54 GTT ATT GCT CAG CGG TGG CA

[0356] The oligonucleotide 2295-88 overlaps the glycine linker and Fc portion of the template by 24 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

[0357] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4543.

[0358] The nucleotide and amino acid sequences (SEQ ID NOS: 1057 and 1058) of the fusion protein are shown in FIGS. 20A and 20B.

[0359] Expression in E. coli. Cultures of each of the pAMG21-Fc-fusion constructs in E. coli GM221 were grown at 37° C. in Luria Broth medium containing 50 mg/ml kanamycin. Induction of gene product expression from the luxPR promoter was achieved following the addition of the synthetic autoinducer N-(3-oxohexanoyl)-DL-homoserine lactone to the culture media to a final concentration of 20 ng/ml. Cultures were incubated at 37° C. for a further 3 hours. After 3 hours, the bacterial cultures were examined by microscopy for the presence of inclusion bodies and were then collected by centrifugation. Refractile inclusion bodies were observed in induced cultures indicating that the Fc-fusions were most likely produced in the insoluble fraction in E. coli. Cell pellets were lysed directly by resuspension in Laemmli sample buffer containing 10% β-mercaptoethanol and were analyzed by SDS-PAGE. In each case, an intense coomassie-stained band of the appropriate molecular weight was observed on an SDS-PAGE gel.

[0360] Purification of Fc-peptide fusion proteins. Cells are broken in water (1/10) by high pressure homogenization (2 passes at 14,000 PSI) and inclusion bodies are harvested by centrifugation (4200 RPM in J-6B for 1 hour). Inclusion bodies are solubilized in 6M guanidine, 50 mM Tris, 8 mM 5 DTT, pH 8.7 for 1 hour at a 1/10 ratio. The solubilized mixture is diluted 20 times into 2M urea, 50 mM tris, 160 mM arginine, 3 mM cysteine, pH 8.5. The mixture is stirred overnight in the cold and then concentrated about 10 fold by ultafiltration. It is then diluted 3 fold with 10 mM Tris, 1.5M urea, pH 9. The pH of this mixture is then adjusted to pH 5 with acetic acid. The precipitate is removed by centrifugation and the supernatant is loaded onto a SP-Sepharose Fast Flow column equilibrated in 20 mM NaAc, 100 mM NaCl, pH 5 (10 mg/ml protein load, room temperature). The protein is eluted from the column using a 20 column volume gradient in the same buffer ranging from 100 mM NaCl to 500 mM NaCl. The pool from the column is diluted 3 fold and loaded onto a SP-Sepharose HP column in 20 mM NaAc, 150 mM NaCl, pH 5(10 mg/ml protein load, room temperature). The protein is eluted using a 20 column volume gradient in the same buffer ranging from 150 mM NaCl to 400 mM NaCl. The peak is pooled and filtered.

[0361] Characterization of activity of Fc-TNF-α inhibitor and TNF-αinhibitor -Fc. Binding of these peptide fusion proteins to TNF-α can be characterized by BIAcore by methods available to one of ordinary skill in the art who is armed with the teachings of the present specification.

EXAMPLE 5 IL-1 Antagonists

[0362] Fc-IL-1 antagonist. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of an IL-1 antagonist peptide was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-EMP fusion strain #3718 (see Example 3) using the sense primer 1216-52 and the antisense primer 2269-70 (SEQ ID NOS: 1112 and 1118, respectively). The nucleotides encoding the IL-1 antagonist peptide were provided by the PCR primer 2269-70 shown below: 1216-52 AAC ATA AGT ACC TGT AGG ATC G 2269-70 CCG CGG ATC CAT TAC AGC GGC AGA GCG TAC GGC TGC CAG TAA CCC GGG GTC CAT TCG AAA CCA CCA CCT CCA CCT TTA CCC

[0363] The oligonucleotide 2269-70 overlaps the glycine linker and Fc portion of the template by 22 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

[0364] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4506.

[0365] The nucleotide and amino acid sequences (SEQ ID NOS: 1059 and 1060) of the fusion protein are shown in FIGS. 21A and 21B.

[0366] IL-1 antagonist-Fc. A DNA sequence coding for an IL-1 antagonist peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The template for the PCR reaction was a plasmid containing an unrelated peptide fused via a five glycine linker to Fc. The nucleotides encoding the IL-1 antagonist peptide were provided by the sense PCR primer 2269-69, with primer 1200-54 serving as the antisense primer (SEQ ID NOS: 1119 and 407, respectively). The primer sequences are shown below: 2269-69 GAA TAA CAT ATG TTC GAA TGG ACC CCG GGT TAC TGG CAG CCG TAC GCT CTG CCC CTG GGT GGA GCC GGT GGG GAC AAA ACT 1200-54 GTT ATT GCT CAG CGG TGG CA

[0367] The oligonucleotide 2269-69 overlaps the glycine linker and Fc portion of the template by 24 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

[0368] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4505.

[0369] The nucleotide and amino acid sequences (SEQ ID NOS: 1061 and 1062) of the fusion protein are shown in FIGS. 22A and 22B. Expression and purification were carried out as in previous examples.

[0370] Characterization of Fc-IL-1 antagonist peptide and IL-1 antagonist peptide-Fc activity. IL-1 Receptor Binding competition between IL-1β, IL-1RA and Fc-conjugated IL-1 peptide sequences was carried out using the IGEN system. Reactions contained 0.4 nM biotin-IL-1R+15 nM IL-1-TAG+3 uM competitor+20 ug/ml streptavidin-conjugate beads, where competitors were IL-1RA, Fc-IL-1 antagonist, IL-1 antagonist-Fc). Competition was assayed over a range of competitor concentrations from 3 uM to 1.5 pM. The results are shown in Table C below: TABLE C Results from IL-1 Receptor Binding Competition Assay IL-1pep-Fc Fc-IL-1pep IL-1ra KI 281.5 59.58 1.405 EC50 530.0 112.2 2.645 95% Confidence Intervals EC50 280.2 to 1002  54.75 to 229.8 1.149 to 6.086 KI 148.9 to 532.5 29.08 to 122.1 0.6106 to 3.233 Goodness of Fit R² 0.9790 0.9687 0.9602

EXAMPLE 6 VEGF-Antagonists

[0371] Fc-VEGF Antagonist. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the VEGF mimetic peptide was constructed using standard PCR technology. The templates for the PCR reaction were the pFc-A3 plasmid and a synthetic VEGF mimetic peptide gene. The synthetic gene was assembled by annealing the following two oligonucleotides primer (SEQ ID NOS: 1120 and 1121, respectively): 2293-11 GTT GAA CCG AAC TGT GAC ATC CAT GTT ATG TGG GAA TGG GAA TGT TTT GAA CGT CTG 2293-12 CAG ACG TTC AAA ACA TTC CCA TTC CCA CAT AAC ATG GAT GTC ACA GTT CGG TTC AAC

[0372] The two oligonucleotides anneal to form the following duplex encoding an amino acid sequence shown below (SEQ ID NOS 1122):      GTTGAACCGAACTGTGACATCCATGTTATGTGGGAATGGGAATGTTTTGAACGTCTG    1 _________+_________+_________+_________+_________+_______ 57      CAACTTGGCTTGACACTGTAGGTACAATACACCCTTACCCTTACAAAACTTGCAGAC a    V  E  P  N  C  D  I  H  V  M  W  E  W  E  C  F  E  R  L   -

[0373] This duplex was amplified in a PCR reaction using 2293-05 and 2293-06 as the sense and antisense primers (SEQ ID NOS. 1125 and 1126).

[0374] The Fc portion of the molecule was generated in a PCR reaction with the pFc-A3 plasmid using the primers 2293-03 and 2293-04 as the sense and antisense primers (SEQ ID NOS. 1123 and 1124, respectively). The full length fusion gene was obtained from a third PCR reaction using the outside primers 2293-03 and 2293-06. These primers are shown below: 2293-03 ATT TGA TTC TAG AAG GAG GAA TAA CAT ATG GAC AAA ACT CAC ACA TGT 2293-04 GTC ACA GTT CGG TTC AAC ACC ACC ACC ACC ACC TTT ACC CGG AGA CAG GGA 2293-05 TCC CTG TCT CCG GGT AAA GGT GGT GGT GGT GGT GTT GAA CCG AAC TGT GAC ATC 2293-06 CCG CGG ATC CTC GAG TTA CAG ACG TTC AAA ACA TTC CCA

[0375] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4523.

[0376] The nucleotide and amino acid sequences (SEQ ID NOS: 1063 and 1064) of the fusion protein are shown in FIGS. 23A and 23B.

[0377] VEGF antagonist-Fc. A DNA sequence coding for a VEGF mimetic peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The templates for the PCR reaction were the pFc-A3 plasmid and the synthetic VEGF mimetic peptide gene described above. The synthetic duplex was amplified in a PCR reaction using 2293-07 and 2293-08 as the sense and antisense primers (SEQ ID NOS. 1127 and 1128, respectively).

[0378] The Fc portion of the molecule was generated in a PCR reaction with the pFc-A3 plasmid using the primers 2293-09 and 2293-10 as the sense and antisense primers (SEQ ID NOS. 1129 and 1130, respectively). The full length fusion gene was obtained from a third PCR reaction using the outside primers 2293-07 and 2293-10. These primers are shown below: 2293-07 ATT TGA TTC TAG AAG GAG GAA TAA CAT ATG GTT GAA CGG AAC TGT GAC 2293-08 ACA TGT GTG AGT TTT GTG ACC ACC ACC ACC ACC CAG ACG TTC AAA ACA TTC 2293-09 GAA TGT TTT GAA CGT CTG GGT GGT GGT GGT GGT GAC AAA ACT CAC ACA TGT 2293-10 CCG CGG ATC CTC GAG TTA TTT ACC CGG AGA CAG GGA GAG

[0379] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4524.

[0380] The nucleotide and amino acid sequences (SEQ ID NOS: 1065 and 1066) of the fusion protein are shown in FIGS. 24A and 24B. Expression and purification were carried out as in previous examples.

EXAMPLE 7 MMP Inhibitors

[0381] Fc-MMP inhibitor. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of an MMP inhibitory peptide was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-TNF-α inhibitor fusion strain #4544 (see Example 4) using the sense primer 1216-52 and the antisense primer 2308-67 (SEQ ID NOS: 1112 and 1131, respectively). The nucleotides encoding the MMP inhibitor peptide were provided by the PCR primer 2308-67 shown below: 1216-52 AAC ATA AGT ACC TGT AGG ATC G 2308-67 CCG CGG ATC CAT TAG CAC AGG GTG AAA CCC CAG TGG GTG GTG CAA CCA CCA CCT CCA CCT TTA CCC

[0382] The oligonucleotide 2308-67 overlaps the glycine linker and Fc portion of the template by 22 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

[0383] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4597.

[0384] The nucleotide and amino acid sequences (SEQ ID NOS: 1067 and 1068) of the fusion protein are shown in FIGS. 25A and 25B. Expression and purification were carried out as in previous examples.

[0385] MMP Inhibitor-Fc. A DNA sequence coding for an MMP inhibitory peptide fused in-frame to the Fc region of human IgG1 was constructed using standard PCR technology. The Fc and 5 glycine linker portion of the molecule was generated in a PCR reaction with DNA from the Fc-TNF-α inhibitor fusion strain #4543 (see Example 4). The nucleotides encoding the MMP inhibitory peptide were provided by the sense PCR primer 2308-66, with primer 1200-54 serving as the antisense primer (SEQ ID NOS: 1132 and 407, respectively). The primer sequences are shown below: 2308-66 GAA TAA CAT ATG TGC ACC ACC CAC TGG GGT TTC ACC CTG TGC GGT GGA GGC GGT GGG GAC AAA 1200-54 GTT ATT GCT CAG CGG TGG CA

[0386] The oligonucleotide 2269-69 overlaps the glycine linker and Fc portion of the template by 24 nucleotides, with the PCR resulting in the two genes being fused together in the correct reading frame.

[0387] The PCR gene product (the full length fusion gene) was digested with restriction endonucleases NdeI and BamHI, and then ligated into the vector pAMG21 and transformed into competent E. coli strain 2596 cells as described for EMP-Fc herein. Clones were screened for the ability to produce the recombinant protein product and to possess the gene fusion having the correct nucleotide sequence. A single such clone was selected and designated Amgen strain #4598.

[0388] The nucleotide and amino acid sequences (SEQ ID NOS: 1069 and 1070) of the fusion protein are shown in FIGS. 26A and 26B.

[0389] The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto, without departing from the spirit and scope of the invention as set forth herein. Abbreviations Abbreviations used throughout this specification are as defined below, unless otherwise defined in specific circumstances. Ac acetyl (used to refer to acetylated residues) AcBpa acetylated p-benzoyl-L-phenylalanine ADCC antibody-dependent cellular cytotoxicity Aib aminoisobutyric acid bA beta-alanine Bpa p-benzoyl-L-phenylalanine BrAc bromoacetyl (BrCH₂C(O) BSA Bovine serum albumin Bzl Benzyl Cap Caproic acid CTL Cytotoxic T lymphocytes CTLA4 Cytotoxic T lymphocyte antigen 4 DARC Duffy blood group antigen receptor DCC Dicylcohexylcarbodiimide Dde 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl EMP Erythropoietin-mimetic peptide ESI-MS Electron spray ionization mass spectrometry EPO Erythropoietin Fmoc fluorenylmethoxycarbonyl G-CSF Granulocyte colony stimulating factor GH Growth hormone HCT hematocrit HGB hemoglobin hGH Human growth hormone HOBt 1-Hydroxybenzotriazole HPLC high performance liquid chromatography IL interleukin IL-R interleukin receptor IL-1R interleukin-1 receptor IL-1ra interleukin-1 receptor antagonist Lau Lauric acid LPS lipopolysaccharide LYMPH lymphocytes MALDI-MS Matrix-assisted laser desorption ionization mass spectrometry Me methyl MeO methoxy MHC major histocompatibility complex MMP matrix metalloproteinase MMPI matrix metalloproteinase inhibitor 1-Nap 1-napthylalanine NEUT neutrophils NGF nerve growth factor Nle norleucine NMP N-methyl-2-pyrrolidinone PAGE polyacrylamide gel electrophoresis PBS Phosphate-buffered saline Pbf 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl PCR polymerase chain reaction Pec pipecolic acid PEG Poly(ethylene glycol) pGlu pyroglutamic acid Pic picolinic acid PLT platelets pY phosphotyrosine RBC red blood cells RBS ribosome binding site RT room temperature (25° C.) Sar sarcosine SDS sodium dodecyl sulfate STK serine-threonine kinases t-Boc tert-Butoxycarbonyl tBu tert-Butyl TGF tissue growth factor THF thymic humoral factor TK tyrosine kinase TMP Thrombopoietin-mimetic peptide TNF Tissue necrosis factor TPO Thrombopoietin TRAIL TNF-related apoptosis-inducing ligand Trt trityl UK urokinase UKR urokinase receptor VEGF vascular endothelial cell growth factor VIP vasoactive intestinal peptide WBC white blood cells

[0390]

1 1157 1 684 DNA HUMAN CDS (1)..(684) 1 atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg 48 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc 96 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc 144 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag 192 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg 240 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat 288 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc 336 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag 384 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc 432 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg 480 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct 528 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc 576 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg 624 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg 672 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 tct ccg ggt aaa 684 Ser Pro Gly Lys 225 2 228 PRT HUMAN 2 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys 225 3 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 3 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 4 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 4 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 5 794 DNA Artificial Sequence Fc-TMP 5 tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56 Met Asp Lys Thr His Thr 1 5 tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 10 15 20 ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 25 30 35 gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 40 45 50 aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 55 60 65 70 aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 75 80 85 ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 90 95 100 aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 105 110 115 aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 120 125 130 tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 135 140 145 150 aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 536 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 155 160 165 cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 584 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 170 175 180 ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 632 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 185 190 195 cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 200 205 210 aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly 215 220 225 230 ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 776 Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg 235 240 245 gct taatctcgag gatcc 794 Ala 6 247 PRT Artificial Sequence Fc-TMP 6 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg 225 230 235 240 Gln Trp Leu Ala Ala Arg Ala 245 7 861 DNA Artificial Sequence Fc-TMP-TMP 7 tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56 Met Asp Lys Thr His Thr 1 5 tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 10 15 20 ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 25 30 35 gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 40 45 50 aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 55 60 65 70 aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 75 80 85 ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 90 95 100 aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 105 110 115 aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 120 125 130 tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 135 140 145 150 aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 536 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 155 160 165 cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 584 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 170 175 180 ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 632 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 185 190 195 cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 200 205 210 aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly 215 220 225 230 ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 776 Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg 235 240 245 gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca acc ctt cgc 824 Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg 250 255 260 caa tgg ctt gca gca cgc gcataatctc gaggatccg 861 Gln Trp Leu Ala Ala Arg 265 8 268 PRT Artificial Sequence Fc-TMP-TMP 8 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg 225 230 235 240 Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile 245 250 255 Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg 260 265 9 855 DNA Artificial Sequence TMP-TMP-Fc 9 tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56 Met Ile Glu Gly Pro Thr 1 5 ctg cgt cag tgg ctg gct gct cgt gct ggc ggt ggt ggc gga ggg ggt 104 Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly 10 15 20 ggc att gag ggc cca acc ctt cgc caa tgg ctt gca gca cgc gca ggg 152 Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly 25 30 35 gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 200 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 40 45 50 gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 248 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 55 60 65 70 gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 296 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 75 80 85 gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 344 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 90 95 100 ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 392 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 105 110 115 aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 440 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 120 125 130 tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 488 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 135 140 145 150 cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 536 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 155 160 165 gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 584 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 170 175 180 aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 632 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 185 190 195 atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 680 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 200 205 210 acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 728 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 215 220 225 230 aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 776 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 235 240 245 tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 824 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 250 255 260 ctc tcc ctg tct ccg ggt aaa taatggatcc 855 Leu Ser Leu Ser Pro Gly Lys 265 10 269 PRT Artificial Sequence TMP-TMP-Fc 10 Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp 20 25 30 Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys 35 40 45 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 50 55 60 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 65 70 75 80 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 85 90 95 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 100 105 110 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 115 120 125 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 130 135 140 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 145 150 155 160 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 165 170 175 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 180 185 190 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 195 200 205 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 210 215 220 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 225 230 235 240 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 245 250 255 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 260 265 11 789 DNA Artificial Sequence TMP-Fc 11 tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56 Met Ile Glu Gly Pro Thr 1 5 ctg cgt cag tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa 104 Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys 10 15 20 act cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg 152 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 25 30 35 tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc 200 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 40 45 50 cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac 248 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 55 60 65 70 cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat 296 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 75 80 85 gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg 344 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 90 95 100 gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag 392 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 105 110 115 tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa 440 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 120 125 130 acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc 488 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 135 140 145 150 ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc 536 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 155 160 165 tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag 584 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 170 175 180 agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg 632 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 185 190 195 gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag 680 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 200 205 210 agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag 728 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 215 220 225 230 gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt 776 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 235 240 245 aaa taatggatcc 789 Lys 12 247 PRT Artificial Sequence TMP-Fc 12 Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly 1 5 10 15 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 20 25 30 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 35 40 45 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 50 55 60 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 65 70 75 80 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 85 90 95 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 100 105 110 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 115 120 125 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 130 135 140 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 145 150 155 160 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 165 170 175 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 180 185 190 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 195 200 205 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 210 215 220 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 225 230 235 240 Leu Ser Leu Ser Pro Gly Lys 245 13 14 PRT Artificial Sequence TMP 13 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 1 5 10 14 36 PRT Artificial Sequence TMP-TMP 14 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 15 812 DNA Artificial Sequence EMP-Fc 15 tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56 Met Asp Lys Thr His Thr 1 5 tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 10 15 20 ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 25 30 35 gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 40 45 50 aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 55 60 65 70 aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 75 80 85 ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 90 95 100 aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 105 110 115 aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 120 125 130 tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 135 140 145 150 aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 536 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 155 160 165 cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 584 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 170 175 180 ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 632 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 185 190 195 cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 200 205 210 aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly 215 220 225 230 ggt ggt ggt gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg 776 Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp 235 240 245 gtt tgc aaa ccg cag ggt ggt taatctcgtg gatcc 812 Val Cys Lys Pro Gln Gly Gly 250 16 253 PRT Artificial Sequence EMP-Fc 16 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His 225 230 235 240 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly 245 250 17 807 DNA Artificial Sequence EMP-Fc 17 tctagatttg ttttaactaa ttaaaggagg aataacat atg gga ggt act tac tct 56 Met Gly Gly Thr Tyr Ser 1 5 tgc cac ttc ggc ccg ctg act tgg gta tgt aag cca caa ggg ggt ggg 104 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly 10 15 20 gga ggc ggg ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 152 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 25 30 35 gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 200 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 40 45 50 gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 248 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 55 60 65 70 gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 296 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 75 80 85 ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 344 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 90 95 100 aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 392 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 105 110 115 tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 440 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 120 125 130 cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 488 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 135 140 145 150 gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 536 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 155 160 165 aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 584 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 170 175 180 atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 632 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 185 190 195 acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 680 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 200 205 210 aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 728 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 215 220 225 230 tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 776 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 235 240 245 ctc tcc ctg tct ccg ggt aaa taatggatcc 807 Leu Ser Leu Ser Pro Gly Lys 250 18 253 PRT Artificial Sequence EMP-Fc 18 Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys 1 5 10 15 Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys 20 25 30 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 35 40 45 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 50 55 60 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 65 70 75 80 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 85 90 95 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 100 105 110 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 115 120 125 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 130 135 140 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 145 150 155 160 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 165 170 175 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 180 185 190 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 195 200 205 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 210 215 220 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 225 230 235 240 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 245 250 19 881 DNA Artificial Sequence EMP-EMP-Fc 19 tctagatttg agttttaact tttagaagga ggaataaaat atg gga ggt act tac 55 Met Gly Gly Thr Tyr 1 5 tct tgc cac ttc ggc cca ctg act tgg gtt tgc aaa ccg cag ggt ggc 103 Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly 10 15 20 ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat ttt ggc ccg ctg acc 151 Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr 25 30 35 tgg gta tgt aag cca caa ggg ggt ggg gga ggc ggg ggg gac aaa act 199 Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr 40 45 50 cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca 247 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 55 60 65 gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 295 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 70 75 80 85 acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct 343 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 90 95 100 gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc 391 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 105 110 115 aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc 439 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 120 125 130 agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac 487 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 135 140 145 aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc 535 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 150 155 160 165 atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg 583 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 170 175 180 ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc 631 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 185 190 195 ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc 679 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 200 205 210 aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac 727 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 215 220 225 tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc 775 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 230 235 240 245 agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct 823 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 250 255 260 ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa 871 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 265 270 275 taatggatcc 881 20 277 PRT Artificial Sequence EMP-EMP-Fc 20 Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys 1 5 10 15 Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His 20 25 30 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly 35 40 45 Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 50 55 60 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 65 70 75 80 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 85 90 95 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 100 105 110 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 115 120 125 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 130 135 140 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 145 150 155 160 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 165 170 175 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 180 185 190 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 195 200 205 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 210 215 220 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 225 230 235 240 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 245 250 255 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 260 265 270 Leu Ser Pro Gly Lys 275 21 885 DNA Artificial Sequence Fc-EMP-EMP 21 tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56 Met Asp Lys Thr His Thr 1 5 tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc 104 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 10 15 20 ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 25 30 35 gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 40 45 50 aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 55 60 65 70 aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 75 80 85 ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 90 95 100 aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 105 110 115 aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg cct cca 440 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 120 125 130 tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 135 140 145 150 aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 536 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 155 160 165 cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 584 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 170 175 180 ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 632 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 185 190 195 cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 200 205 210 aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly 215 220 225 230 ggt ggt ggc gga ggt act tac tct tgc cac ttc ggc cca ctg act tgg 776 Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp 235 240 245 gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc 824 Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser 250 255 260 tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt 869 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly 265 270 275 taatctcgag gatcca 885 22 277 PRT Artificial Sequence Fc-EMP-EMP 22 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His 225 230 235 240 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly 245 250 255 Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys 260 265 270 Lys Pro Gln Gly Gly 275 23 1546 DNA Artificial Sequence pAMG21 23 gcgtaacgta tgcatggtct ccccatgcga gagtagggaa ctgccaggca tcaaataaaa 60 cgaaaggctc agtcgaaaga ctgggccttt cgttttatct gttgtttgtc ggtgaacgct 120 ctcctgagta ggacaaatcc gccgggagcg gatttgaacg ttgcgaagca acggcccgga 180 gggtggcggg caggacgccc gccataaact gccaggcatc aaattaagca gaaggccatc 240 ctgacggatg gcctttttgc gtttctacaa actcttttgt ttatttttct aaatacattc 300 aaatatggac gtcgtactta acttttaaag tatgggcaat caattgctcc tgttaaaatt 360 gctttagaaa tactttggca gcggtttgtt gtattgagtt tcatttgcgc attggttaaa 420 tggaaagtga ccgtgcgctt actacagcct aatatttttg aaatatccca agagcttttt 480 ccttcgcatg cccacgctaa acattctttt tctcttttgg ttaaatcgtt gtttgattta 540 ttatttgcta tatttatttt tcgataatta tcaactagag aaggaacaat taatggtatg 600 ttcatacacg catgtaaaaa taaactatct atatagttgt ctttctctga atgtgcaaaa 660 ctaagcattc cgaagccatt attagcagta tgaataggga aactaaaccc agtgataaga 720 cctgatgatt tcgcttcttt aattacattt ggagattttt tatttacagc attgttttca 780 aatatattcc aattaatcgg tgaatgattg gagttagaat aatctactat aggatcatat 840 tttattaaat tagcgtcatc ataatattgc ctccattttt tagggtaatt atccagaatt 900 gaaatatcag atttaaccat agaatgagga taaatgatcg cgagtaaata atattcacaa 960 tgtaccattt tagtcatatc agataagcat tgattaatat cattattgct tctacaggct 1020 ttaattttat taattattct gtaagtgtcg tcggcattta tgtctttcat acccatctct 1080 ttatccttac ctattgtttg tcgcaagttt tgcgtgttat atatcattaa aacggtaata 1140 gattgacatt tgattctaat aaattggatt tttgtcacac tattatatcg cttgaaatac 1200 aattgtttaa cataagtacc tgtaggatcg tacaggttta cgcaagaaaa tggtttgtta 1260 tagtcgatta atcgatttga ttctagattt gttttaacta attaaaggag gaataacata 1320 tggttaacgc gttggaattc gagctcacta gtgtcgacct gcagggtacc atggaagctt 1380 actcgaggat ccgcggaaag aagaagaaga agaagaaagc ccgaaaggaa gctgagttgg 1440 ctgctgccac cgctgagcaa taactagcat aaccccttgg ggcctctaaa cgggtcttga 1500 ggggtttttt gctgaaagga ggaaccgctc ttcacgctct tcacgc 1546 24 14 PRT Artificial Sequence TPO mimetic peptide 24 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala 1 5 10 25 14 PRT Artificial Sequence TPO-mimetic peptide 25 Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Ala Ala Arg Ala 1 5 10 26 14 PRT Artificial Sequence TPO-mimetic peptide 26 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 1 5 10 27 14 PRT Artificial Sequence TPO-mimetic peptide 27 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala 1 5 10 28 14 PRT Artificial Sequence TPO-mimetic peptide 28 Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala 1 5 10 29 14 PRT Artificial Sequence TPO-mimetic peptide 29 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 1 5 10 30 15 PRT Artificial Sequence TPO-mimetic peptide 30 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ala 1 5 10 15 31 14 PRT Artificial Sequence TPO-mimetic peptide 31 Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala 1 5 10 32 14 PRT Artificial Sequence TPO-mimetic peptide 32 Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala 1 5 10 33 9 PRT Artificial Sequence TPO-mimetic peptide 33 Val Arg Asp Gln Ile Xaa Xaa Xaa Leu 1 5 34 6 PRT Artificial Sequence TPO-mimetic peptide 34 Thr Leu Arg Glu Trp Leu 1 5 35 10 PRT Artificial Sequence TPO-mimetic peptide 35 Gly Arg Val Arg Asp Gln Val Ala Gly Trp 1 5 10 36 10 PRT Artificial Sequence TPO-mimetic peptide 36 Gly Arg Val Lys Asp Gln Ile Ala Gln Leu 1 5 10 37 10 PRT Artificial Sequence TPO-mimetic peptide 37 Gly Val Arg Asp Gln Val Ser Trp Ala Leu 1 5 10 38 10 PRT Artificial Sequence TPO-mimetic peptide 38 Glu Ser Val Arg Glu Gln Val Met Lys Tyr 1 5 10 39 10 PRT Artificial Sequence TPO-mimetic peptide 39 Ser Val Arg Ser Gln Ile Ser Ala Ser Leu 1 5 10 40 10 PRT Artificial Sequence TPO-mimetic peptide 40 Gly Val Arg Glu Thr Val Tyr Arg His Met 1 5 10 41 11 PRT Artificial Sequence TPO-mimetic peptide 41 Gly Val Arg Glu Val Ile Val Met His Met Leu 1 5 10 42 11 PRT Artificial Sequence TPO-mimetic peptide 42 Gly Arg Val Arg Asp Gln Ile Trp Ala Ala Leu 1 5 10 43 11 PRT Artificial Sequence TPO-mimetic peptide 43 Ala Gly Val Arg Asp Gln Ile Leu Ile Trp Leu 1 5 10 44 11 PRT Artificial Sequence TPO-mimetic peptide 44 Gly Arg Val Arg Asp Gln Ile Met Leu Ser Leu 1 5 10 45 11 PRT Artificial Sequence TPO-mimetic peptide 45 Gly Arg Val Arg Asp Gln Ile Xaa Xaa Xaa Leu 1 5 10 46 10 PRT Artificial Sequence TPO-mimetic peptide 46 Cys Thr Leu Arg Gln Trp Leu Gln Gly Cys 1 5 10 47 10 PRT Artificial Sequence TPO-mimetic peptide 47 Cys Thr Leu Gln Glu Phe Leu Glu Gly Cys 1 5 10 48 10 PRT Artificial Sequence TPO-mimetic peptide 48 Cys Thr Arg Thr Glu Trp Leu His Gly Cys 1 5 10 49 12 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 49 Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys 1 5 10 50 12 PRT Artificial Sequence TPO-mimetic peptide 50 Cys Thr Leu Arg Glu Trp Val Phe Ala Gly Leu Cys 1 5 10 51 13 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 51 Cys Thr Leu Arg Gln Trp Leu Ile Leu Leu Gly Met Cys 1 5 10 52 14 PRT Artificial Sequence TPO-mimetic peptide 52 Cys Thr Leu Ala Glu Phe Leu Ala Ser Gly Val Glu Gln Cys 1 5 10 53 14 PRT Artificial Sequence TPO-mimetic peptide 53 Cys Ser Leu Gln Glu Phe Leu Ser His Gly Gly Tyr Val Cys 1 5 10 54 14 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 54 Cys Thr Leu Arg Glu Phe Leu Asp Pro Thr Thr Ala Val Cys 1 5 10 55 14 PRT Artificial Sequence TPO-mimetic peptide 55 Cys Thr Leu Lys Glu Trp Leu Val Ser His Glu Val Trp Cys 1 5 10 56 10 PRT Artificial Sequence TPO-mimetic peptide 56 Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Cys 1 5 10 57 11 PRT Artificial Sequence TPO-mimetic peptide 57 Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Cys 1 5 10 58 12 PRT Artificial Sequence TPO-mimetic peptide 58 Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Cys 1 5 10 59 13 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 59 Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Cys 1 5 10 60 14 PRT Artificial Sequence TPO-mimetic peptide 60 Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa Cys 1 5 10 61 10 PRT Artificial Sequence TPO-mimetic peptide 61 Arg Glu Gly Pro Thr Leu Arg Gln Trp Met 1 5 10 62 10 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 62 Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala 1 5 10 63 10 PRT Artificial Sequence TPO-mimetic peptide 63 Glu Arg Gly Pro Phe Trp Ala Lys Ala Cys 1 5 10 64 10 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 64 Arg Glu Gly Pro Arg Cys Val Met Trp Met 1 5 10 65 14 PRT Artificial Sequence TPO-mimetic peptide 65 Cys Gly Thr Glu Gly Pro Thr Leu Ser Thr Trp Leu Asp Cys 1 5 10 66 14 PRT Artificial Sequence TPO-mimetic peptide 66 Cys Glu Gln Asp Gly Pro Thr Leu Leu Glu Trp Leu Lys Cys 1 5 10 67 14 PRT Artificial Sequence TPO-mimetic peptide 67 Cys Glu Leu Val Gly Pro Ser Leu Met Ser Trp Leu Thr Cys 1 5 10 68 14 PRT Artificial Sequence TPO-mimetic peptide 68 Cys Leu Thr Gly Pro Phe Val Thr Gln Trp Leu Tyr Glu Cys 1 5 10 69 14 PRT Artificial Sequence TPO-mimetic peptide 69 Cys Arg Ala Gly Pro Thr Leu Leu Glu Trp Leu Thr Leu Cys 1 5 10 70 14 PRT Artificial Sequence TPO-mimetic peptide 70 Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys 1 5 10 71 13 PRT Artificial Sequence TPO-mimetic peptide 71 Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys 1 5 10 72 14 PRT Artificial Sequence TPO-mimetic peptide 72 Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys 1 5 10 73 14 PRT Artificial Sequence TPO-MIMETIC PEPTIDE 73 Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys 1 5 10 74 15 PRT Artificial Sequence TPO-mimetic peptide 74 Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys 1 5 10 15 75 16 PRT Artificial Sequence TPO-mimetic peptide 75 Gly Gly Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys Gly Gly 1 5 10 15 76 18 PRT Artificial Sequence TPO-mimetic peptide 76 Gly Gly Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys 1 5 10 15 Gly Gly 77 19 PRT Artificial Sequence TPO-mimetic peptide 77 Gly Asn Ala Asp Gly Pro Thr Leu Arg Gln Trp Leu Glu Gly Arg Arg 1 5 10 15 Pro Lys Asn 78 19 PRT Artificial Sequence TPO-mimetic peptide 78 Leu Ala Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu His Gly Asn Gly 1 5 10 15 Arg Asp Thr 79 19 PRT Artificial Sequence TPO-mimetic peptide 79 His Gly Arg Val Gly Pro Thr Leu Arg Glu Trp Lys Thr Gln Val Ala 1 5 10 15 Thr Lys Lys 80 18 PRT Artificial Sequence TPO-mimetic peptide 80 Thr Ile Lys Gly Pro Thr Leu Arg Gln Trp Leu Lys Ser Arg Glu His 1 5 10 15 Thr Ser 81 18 PRT Artificial Sequence TPO-mimetic peptide 81 Ile Ser Asp Gly Pro Thr Leu Lys Glu Trp Leu Ser Val Thr Arg Gly 1 5 10 15 Ala Ser 82 18 PRT Artificial Sequence TPO-mimetic peptide 82 Ser Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Thr Ser Arg Thr Pro 1 5 10 15 His Ser 83 14 PRT Artificial Sequence EPO-mimetic peptide 83 Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro 1 5 10 84 28 PRT Artificial Sequence EPO-mimetic peptide 84 Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro Tyr Xaa 1 5 10 15 Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro 20 25 85 14 PRT Artificial Sequence EPO-mimetic peptide 85 Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro 1 5 10 86 14 PRT Artificial Sequence EPO-mimetic peptide 86 Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro 1 5 10 87 20 PRT Artificial Sequence EPO-mimetic peptide 87 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly 20 88 20 PRT Artificial Sequence EPO-mimetic peptide 88 Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Leu Gly Gly 20 89 20 PRT Artificial Sequence EPO-mimetic peptide 89 Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser 1 5 10 15 Pro Leu Gly Gly 20 90 20 PRT Artificial Sequence EPO-mimetic peptide 90 Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg 1 5 10 15 Pro Gly Gly Gly 20 91 20 PRT Artificial Sequence EPO-mimetic peptide 91 Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly 1 5 10 15 Tyr Lys Gly Gly 20 92 40 PRT Artificial Sequence EPO-mimetic peptide 92 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr 20 25 30 Trp Val Cys Lys Pro Gln Gly Gly 35 40 93 20 PRT Artificial Sequence EPO-mimetic peptide 93 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly 20 94 23 PRT Artificial Sequence EPO-mimetic peptide 94 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Ser Ser Lys 20 95 46 PRT Artificial Sequence EPO-mimetic peptide 95 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Ser Ser Lys Gly Gly Thr Tyr Ser Cys His Phe Gly 20 25 30 Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Ser Ser Lys 35 40 45 96 23 PRT Artificial Sequence EPO-mimetic peptide 96 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Ser Ser Lys 20 97 22 PRT Artificial Sequence EPO-mimetic peptide 97 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Ser Ser 20 98 23 PRT Artificial Sequence EPO-mimetic peptide 98 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Ser Ser Lys 20 99 5 PRT Artificial Sequence G-CSF-mimetic peptide 99 Glu Glu Asp Cys Lys 1 5 100 5 PRT Artificial Sequence G-CSF-mimetic peptide 100 Glu Glu Asp Xaa Lys 1 5 101 6 PRT Artificial Sequence G-CSF-mimetic peptide 101 Xaa Gly Glu Asp Xaa Lys 1 5 102 5 PRT Artificial Sequence G-CSF-mimetic peptide 102 Xaa Ser Asp Xaa Lys 1 5 103 5 PRT Artificial Sequence G-CSF-mimetic peptide 103 Glu Glu Asp Cys Lys 1 5 104 5 PRT Artificial Sequence G-CSF-mimetic peptide 104 Glu Glu Asp Xaa Lys 1 5 105 6 PRT Artificial Sequence Antiviral (HBV) 105 Leu Leu Gly Arg Met Lys 1 5 106 11 PRT Artificial Sequence TNF-antagonist peptide 106 Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr 1 5 10 107 11 PRT Artificial Sequence TNF-antagonist peptide 107 Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr 1 5 10 108 11 PRT Artificial Sequence TNF-antagonist peptide 108 Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr 1 5 10 109 9 PRT Artificial Sequence TNF-antagonist peptide 109 Phe Cys Ala Ser Glu Asn His Cys Tyr 1 5 110 9 PRT Artificial Sequence TNF-antagonist peptide 110 Tyr Cys Ala Ser Glu Asn His Cys Tyr 1 5 111 9 PRT Artificial Sequence TNF-antagonist peptide 111 Phe Cys Asn Ser Glu Asn His Cys Tyr 1 5 112 9 PRT Artificial Sequence TNF-antagonist peptide 112 Phe Cys Asn Ser Glu Asn Arg Cys Tyr 1 5 113 10 PRT Artificial Sequence TNF-antagonist peptide 113 Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr 1 5 10 114 11 PRT Artificial Sequence TNF-antagonist peptide 114 Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe 1 5 10 115 9 PRT Artificial Sequence TNF-antagonist peptide 115 Phe Cys Val Ser Asn Asp Arg Cys Tyr 1 5 116 11 PRT Artificial Sequence TNF-antagonist peptide 116 Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr 1 5 10 117 9 PRT Artificial Sequence TNF-antagonist peptide 117 Tyr Cys Lys Glu Pro Gly Gln Cys Tyr 1 5 118 9 PRT Artificial Sequence TNF-antagonist peptide 118 Tyr Cys Arg Lys Glu Met Gly Cys Tyr 1 5 119 9 PRT Artificial Sequence TNF-antagonist peptide 119 Phe Cys Arg Lys Glu Met Gly Cys Tyr 1 5 120 9 PRT Artificial Sequence TNF-antagonist peptide 120 Tyr Cys Trp Ser Gln Asn Leu Cys Tyr 1 5 121 10 PRT Artificial Sequence TNF-antagonist peptide 121 Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr 1 5 10 122 9 PRT Artificial Sequence TNF-antagonist peptide 122 Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr 1 5 123 9 PRT Artificial Sequence TNF-antagonist peptide 123 Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr 1 5 124 10 PRT Artificial Sequence EPO-mimetic peptide 124 Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa 1 5 10 125 15 PRT Artificial Sequence CTLA4-mimetic 125 Gly Phe Val Cys Ser Gly Ile Phe Ala Val Gly Val Gly Arg Cys 1 5 10 15 126 15 PRT Artificial Sequence CTLA4-MIMETIC 126 Ala Pro Gly Val Arg Leu Gly Cys Ala Val Leu Gly Arg Tyr Cys 1 5 10 15 127 27 PRT Artificial Sequence C3b antagonist 127 Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr Ala Gly His 1 5 10 15 Met Ala Asn Leu Thr Ser His Ala Ser Ala Ile 20 25 128 13 PRT Artificial Sequence C3b antagonist 128 Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr 1 5 10 129 11 PRT Artificial Sequence C3b antagonist 129 Cys Val Val Gln Asp Trp Gly His His Ala Cys 1 5 10 130 6 PRT Artificial Sequence Mdm/hdm antagonist peptide 130 Thr Phe Ser Asp Leu Trp 1 5 131 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 131 Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro 1 5 10 132 12 PRT Artificial Sequence MDM/HDM ANTAGONIST PEPTIDE 132 Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro 1 5 10 133 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 133 Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro 1 5 10 134 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 134 Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro 1 5 10 135 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 135 Met Pro Arg Phe Met Asp Tyr Trp Glu Gly Leu Asn 1 5 10 136 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 136 Val Gln Asn Phe Ile Asp Tyr Trp Thr Gln Gln Phe 1 5 10 137 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 137 Thr Gly Pro Ala Phe Thr His Tyr Trp Ala Thr Phe 1 5 10 138 15 PRT Artificial Sequence Mdm/hdm antagonist peptide 138 Ile Asp Arg Ala Pro Thr Phe Arg Asp His Trp Phe Ala Leu Val 1 5 10 15 139 15 PRT Artificial Sequence Mdm/hdm antagonist peptide 139 Pro Arg Pro Ala Leu Val Phe Ala Asp Tyr Trp Glu Thr Leu Tyr 1 5 10 15 140 15 PRT Artificial Sequence Mdm/hdm antagonist peptide 140 Pro Ala Phe Ser Arg Phe Trp Ser Asp Leu Ser Ala Gly Ala His 1 5 10 15 141 15 PRT Artificial Sequence MDM/HDM ANTAGONIST PEPTIDE 141 Pro Ala Phe Ser Arg Phe Trp Ser Lys Leu Ser Ala Gly Ala His 1 5 10 15 142 10 PRT Artificial Sequence Mdm/hdm antagonist peptide 142 Pro Xaa Phe Xaa Asp Tyr Trp Xaa Xaa Leu 1 5 10 143 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 143 Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro 1 5 10 144 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 144 Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro 1 5 10 145 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 145 Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro 1 5 10 146 12 PRT Artificial Sequence Mdm/hdm antagonist peptide 146 Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro 1 5 10 147 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 147 Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys 1 5 10 148 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 148 Asp Ile Thr Trp Asp Glu Leu Trp Lys Ile Met Asn 1 5 10 149 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 149 Asp Tyr Thr Trp Phe Glu Leu Trp Asp Met Met Gln 1 5 10 150 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 150 Gln Ile Thr Trp Ala Gln Leu Trp Asn Met Met Lys 1 5 10 151 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 151 Asp Met Thr Trp His Asp Leu Trp Thr Leu Met Ser 1 5 10 152 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 152 Asp Tyr Ser Trp His Asp Leu Trp Glu Met Met Ser 1 5 10 153 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 153 Glu Ile Thr Trp Asp Gln Leu Trp Glu Val Met Asn 1 5 10 154 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 154 His Val Ser Trp Glu Gln Leu Trp Asp Ile Met Asn 1 5 10 155 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 155 His Ile Thr Trp Asp Gln Leu Trp Arg Ile Met Thr 1 5 10 156 13 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 156 Arg Asn Met Ser Trp Leu Glu Leu Trp Glu His Met Lys 1 5 10 157 18 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 157 Ala Glu Trp Thr Trp Asp Gln Leu Trp His Val Met Asn Pro Ala Glu 1 5 10 15 Ser Gln 158 14 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 158 His Arg Ala Glu Trp Leu Ala Leu Trp Glu Gln Met Ser Pro 1 5 10 159 14 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 159 Lys Lys Glu Asp Trp Leu Ala Leu Trp Arg Ile Met Ser Val 1 5 10 160 11 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 160 Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys 1 5 10 161 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 161 Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys 1 5 10 162 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 162 Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys 1 5 10 163 12 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 163 Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys 1 5 10 164 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 164 Ser Cys Val Lys Trp Gly Lys Lys Glu Phe Cys Gly Ser 1 5 10 165 12 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 165 Ser Cys Trp Lys Tyr Trp Gly Lys Glu Cys Gly Ser 1 5 10 166 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 166 Ser Cys Tyr Glu Trp Gly Lys Leu Arg Trp Cys Gly Ser 1 5 10 167 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 167 Ser Cys Leu Arg Trp Gly Lys Trp Ser Asn Cys Gly Ser 1 5 10 168 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 168 Ser Cys Trp Arg Trp Gly Lys Tyr Gln Ile Cys Gly Ser 1 5 10 169 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 169 Ser Cys Val Ser Trp Gly Ala Leu Lys Leu Cys Gly Ser 1 5 10 170 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 170 Ser Cys Ile Arg Trp Gly Gln Asn Thr Phe Cys Gly Ser 1 5 10 171 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 171 Ser Cys Trp Gln Trp Gly Asn Leu Lys Ile Cys Gly Ser 1 5 10 172 13 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 172 Ser Cys Val Arg Trp Gly Gln Leu Ser Ile Cys Gly Ser 1 5 10 173 21 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 173 Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala Ile Leu Thr 1 5 10 15 Thr Met Leu Ala Lys 20 174 18 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 174 Arg Arg Trp Lys Lys Asn Phe Ile Ala Val Ser Ala Ala Asn Arg Phe 1 5 10 15 Lys Lys 175 18 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 175 Arg Lys Trp Gln Lys Thr Gly His Ala Val Arg Ala Ile Gly Arg Leu 1 5 10 15 Ser Ser 176 14 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 176 Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 1 5 10 177 18 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 177 Lys Ile Trp Ser Ile Leu Ala Pro Leu Gly Thr Thr Leu Val Lys Leu 1 5 10 15 Val Ala 178 14 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 178 Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu 1 5 10 179 18 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 179 Leu Lys Trp Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys 1 5 10 15 Leu Leu 180 17 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 180 Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys Thr Leu Ser His Phe Ser 1 5 10 15 Val 181 17 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 181 Ala Glu Trp Pro Ser Pro Thr Arg Val Ile Ser Thr Thr Tyr Phe Gly 1 5 10 15 Ser 182 17 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 182 Ala Glu Leu Ala His Trp Pro Pro Val Lys Thr Val Leu Arg Ser Phe 1 5 10 15 Thr 183 17 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 183 Ala Glu Gly Ser Trp Leu Gln Leu Leu Asn Leu Met Lys Gln Met Asn 1 5 10 15 Asn 184 10 PRT Artificial Sequence CALMODULIN ANTAGONIST PEPTIDE 184 Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys 1 5 10 185 27 PRT Artificial Sequence VINCULIN-BINDING 185 Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Gly Val Ser 1 5 10 15 Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg 20 25 186 27 PRT Artificial Sequence VINCULIN-BINDING 186 Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Arg Val Ser 1 5 10 15 Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg 20 25 187 30 PRT Artificial Sequence VINCULIN-BINDING 187 Ser Arg Gly Val Asn Phe Ser Glu Trp Leu Tyr Asp Met Ser Ala Ala 1 5 10 15 Met Lys Glu Ala Ser Asn Val Phe Pro Ser Arg Arg Ser Arg 20 25 30 188 30 PRT Artificial Sequence VINCULIN-BINDING 188 Ser Ser Gln Asn Trp Asp Met Glu Ala Gly Val Glu Asp Leu Thr Ala 1 5 10 15 Ala Met Leu Gly Leu Leu Ser Thr Ile His Ser Ser Ser Arg 20 25 30 189 31 PRT Artificial Sequence VINCULIN-BINDING 189 Ser Ser Pro Ser Leu Tyr Thr Gln Phe Leu Val Asn Tyr Glu Ser Ala 1 5 10 15 Ala Thr Arg Ile Gln Asp Leu Leu Ile Ala Ser Arg Pro Ser Arg 20 25 30 190 31 PRT Artificial Sequence VINCULIN-BINDING 190 Ser Ser Thr Gly Trp Val Asp Leu Leu Gly Ala Leu Gln Arg Ala Ala 1 5 10 15 Asp Ala Thr Arg Thr Ser Ile Pro Pro Ser Leu Gln Asn Ser Arg 20 25 30 191 18 PRT Artificial Sequence VINCULIN-BINDING 191 Asp Val Tyr Thr Lys Lys Glu Leu Ile Glu Cys Ala Arg Arg Val Ser 1 5 10 15 Glu Lys 192 22 PRT Artificial Sequence C4BP-BINDING 192 Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala Gln Phe His Ile 1 5 10 15 Asp Tyr Asn Asn Val Ser 20 193 22 PRT Artificial Sequence C4BP-BINDING 193 Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala 1 5 10 15 Glu Gly Trp His Val Asn 20 194 34 PRT Artificial Sequence C4BP-BINDING 194 Leu Val Thr Val Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala 1 5 10 15 Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala Glu Gly Trp His 20 25 30 Val Asn 195 14 PRT Artificial Sequence C4BP-BINDING 195 Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser 1 5 10 196 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 196 Ala Glu Pro Met Pro His Ser Leu Asn Phe Ser Gln Tyr Leu Trp Tyr 1 5 10 15 Thr 197 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 197 Ala Glu His Thr Tyr Ser Ser Leu Trp Asp Thr Tyr Ser Pro Leu Ala 1 5 10 15 Phe 198 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 198 Ala Glu Leu Asp Leu Trp Met Arg His Tyr Pro Leu Ser Phe Ser Asn 1 5 10 15 Arg 199 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 199 Ala Glu Ser Ser Leu Trp Thr Arg Tyr Ala Trp Pro Ser Met Pro Ser 1 5 10 15 Tyr 200 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 200 Ala Glu Trp His Pro Gly Leu Ser Phe Gly Ser Tyr Leu Trp Ser Lys 1 5 10 15 Thr 201 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 201 Ala Glu Pro Ala Leu Leu Asn Trp Ser Phe Phe Phe Asn Pro Gly Leu 1 5 10 15 His 202 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 202 Ala Glu Trp Ser Phe Tyr Asn Leu His Leu Pro Glu Pro Gln Thr Ile 1 5 10 15 Phe 203 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 203 Ala Glu Pro Leu Asp Leu Trp Ser Leu Tyr Ser Leu Pro Pro Leu Ala 1 5 10 15 Met 204 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 204 Ala Glu Pro Thr Leu Trp Gln Leu Tyr Gln Phe Pro Leu Arg Leu Ser 1 5 10 15 Gly 205 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 205 Ala Glu Ile Ser Phe Ser Glu Leu Met Trp Leu Arg Ser Thr Pro Ala 1 5 10 15 Phe 206 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 206 Ala Glu Leu Ser Glu Ala Asp Leu Trp Thr Thr Trp Phe Gly Met Gly 1 5 10 15 Ser 207 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 207 Ala Glu Ser Ser Leu Trp Arg Ile Phe Ser Pro Ser Ala Leu Met Met 1 5 10 15 Ser 208 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 208 Ala Glu Ser Leu Pro Thr Leu Thr Ser Ile Leu Trp Gly Lys Glu Ser 1 5 10 15 Val 209 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 209 Ala Glu Thr Leu Phe Met Asp Leu Trp His Asp Lys His Ile Leu Leu 1 5 10 15 Thr 210 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 210 Ala Glu Ile Leu Asn Phe Pro Leu Trp His Glu Pro Leu Trp Ser Thr 1 5 10 15 Glu 211 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 211 Ala Glu Ser Gln Thr Gly Thr Leu Asn Thr Leu Phe Trp Asn Thr Leu 1 5 10 15 Arg 212 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 212 Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa 1 5 213 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 213 Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 214 18 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 214 Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser 1 5 10 15 Gly Leu 215 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 215 Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 216 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 216 Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 217 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 217 Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 218 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 218 Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 219 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 219 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr 1 5 10 220 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 220 Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr 1 5 10 221 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 221 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 222 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 222 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 223 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 223 Phe Glu Trp Thr Pro Gly Trp Pro Tyr Gln Xaa Tyr 1 5 10 224 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 224 Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 225 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 225 Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 226 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 226 Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 227 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 227 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 228 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 228 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 229 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 229 Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr 1 5 10 230 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 230 Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr 1 5 10 231 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 231 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr 1 5 10 232 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 232 Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr 1 5 10 233 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 233 Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr 1 5 10 234 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 234 Phe Glu Trp Thr Xaa Val Tyr Trp Gln Xaa Tyr 1 5 10 235 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 235 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 236 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 236 Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr 1 5 10 237 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 237 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 238 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 238 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr 1 5 10 239 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 239 Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr 1 5 10 240 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 240 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 241 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 241 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 242 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 242 Phe Glu Trp Thr Pro Gly Trp Xaa Gln Xaa Tyr 1 5 10 243 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 243 Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 244 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 244 Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 245 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 245 Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 246 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 246 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 247 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 247 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 248 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 248 Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr 1 5 10 249 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 249 Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr 1 5 10 250 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 250 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr 1 5 10 251 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 251 Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr 1 5 10 252 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 252 Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr 1 5 10 253 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 253 Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr 1 5 10 254 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 254 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 255 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 255 Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr 1 5 10 256 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 256 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 257 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 257 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 258 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 258 Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 259 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 259 Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 260 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 260 Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 261 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 261 Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr 1 5 10 262 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 262 Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr 1 5 10 263 4 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 263 Thr Lys Pro Arg 1 264 5 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 264 Arg Lys Ser Ser Lys 1 5 265 5 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 265 Arg Lys Gln Asp Lys 1 5 266 6 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 266 Asn Arg Lys Gln Asp Lys 1 5 267 6 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 267 Arg Lys Gln Asp Lys Arg 1 5 268 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 268 Glu Asn Arg Lys Gln Asp Lys Arg Phe 1 5 269 6 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 269 Val Thr Lys Phe Tyr Phe 1 5 270 5 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 270 Val Thr Lys Phe Tyr 1 5 271 5 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 271 Val Thr Asp Phe Tyr 1 5 272 17 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 272 Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr 1 5 10 15 Arg 273 17 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 273 Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg 1 5 10 15 Thr 274 20 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 274 Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His 1 5 10 15 Pro Met Ser Ser 20 275 20 PRT Artificial Sequence MAST CELL ANTAGONISTS/MAST CELL PROTEASE INHIBITOR PEPTIDE 275 Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His 1 5 10 15 Pro Met Ser Ser 20 276 20 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 276 Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His 1 5 10 15 Trp Ser Met Ala 20 277 20 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 277 Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His 1 5 10 15 Trp Ser Met Ala 20 278 20 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 278 Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser 1 5 10 15 Ala Lys His Gly 20 279 6 PRT Artificial Sequence ANTI-HBV 279 Leu Leu Gly Arg Met Lys 1 5 280 8 PRT Artificial Sequence ANTI-HBV 280 Ala Leu Leu Gly Arg Met Lys Gly 1 5 281 6 PRT Artificial Sequence ANTI-HBV 281 Leu Asp Pro Ala Phe Arg 1 5 282 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 282 Arg Pro Leu Pro Pro Leu Pro 1 5 283 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 283 Arg Glu Leu Pro Pro Leu Pro 1 5 284 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 284 Ser Pro Leu Pro Pro Leu Pro 1 5 285 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 285 Gly Pro Leu Pro Pro Leu Pro 1 5 286 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 286 Arg Pro Leu Pro Ile Pro Pro 1 5 287 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 287 Arg Pro Leu Pro Ile Pro Pro 1 5 288 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 288 Arg Arg Leu Pro Pro Thr Pro 1 5 289 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 289 Arg Gln Leu Pro Pro Thr Pro 1 5 290 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 290 Arg Pro Leu Pro Ser Arg Pro 1 5 291 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 291 Arg Pro Leu Pro Thr Arg Pro 1 5 292 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 292 Ser Arg Leu Pro Pro Leu Pro 1 5 293 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 293 Arg Ala Leu Pro Ser Pro Pro 1 5 294 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 294 Arg Arg Leu Pro Arg Thr Pro 1 5 295 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 295 Arg Pro Val Pro Pro Ile Thr 1 5 296 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 296 Ile Leu Ala Pro Pro Val Pro 1 5 297 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 297 Arg Pro Leu Pro Met Leu Pro 1 5 298 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 298 Arg Pro Leu Pro Ile Leu Pro 1 5 299 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 299 Arg Pro Leu Pro Ser Leu Pro 1 5 300 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 300 Arg Pro Leu Pro Ser Leu Pro 1 5 301 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 301 Arg Pro Leu Pro Met Ile Pro 1 5 302 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 302 Arg Pro Leu Pro Leu Ile Pro 1 5 303 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 303 Arg Pro Leu Pro Pro Thr Pro 1 5 304 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 304 Arg Ser Leu Pro Pro Leu Pro 1 5 305 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 305 Arg Pro Gln Pro Pro Pro Pro 1 5 306 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 306 Arg Gln Leu Pro Ile Pro Pro 1 5 307 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 307 Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro 1 5 10 308 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 308 Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa 1 5 10 309 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 309 Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa 1 5 10 310 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 310 Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro 1 5 10 311 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 311 Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Pro Pro 1 5 10 312 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 312 Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa 1 5 10 313 12 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 313 Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa 1 5 10 314 10 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 314 Leu Xaa Xaa Arg Pro Leu Pro Xaa Xaa Pro 1 5 10 315 10 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 315 Xaa Xaa Xaa Arg Pro Leu Pro Xaa Leu Pro 1 5 10 316 10 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 316 Pro Pro Xaa Xaa Tyr Pro Pro Pro Xaa Pro 1 5 10 317 11 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 317 Xaa Pro Pro Xaa Pro Xaa Lys Pro Xaa Trp Leu 1 5 10 318 11 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 318 Arg Pro Xaa Xaa Pro Xaa Arg Xaa Ser Xaa Pro 1 5 10 319 11 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 319 Pro Pro Val Pro Pro Arg Pro Xaa Xaa Thr Leu 1 5 10 320 7 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 320 Xaa Pro Xaa Leu Pro Xaa Lys 1 5 321 10 PRT Artificial Sequence SH3 ANTAGONIST PEPTIDE 321 Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro 1 5 10 322 7 PRT Artificial Sequence INHIBITION OF PLATELET AGGREGATION 322 Cys Xaa Xaa Arg Gly Asp Cys 1 5 323 7 PRT Artificial Sequence SRC ANTAGONIT 323 Arg Pro Leu Pro Pro Leu Pro 1 5 324 6 PRT Artificial Sequence SRC ANTAGONIT 324 Pro Pro Val Pro Pro Arg 1 5 325 11 PRT Artificial Sequence ANTI-CANCER 325 Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa 1 5 10 326 20 PRT Artificial Sequence P16-MIMETIC 326 Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser 1 5 10 15 Arg Asp Cys Asp 20 327 20 PRT Artificial Sequence P16-MIMETIC 327 Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly 1 5 10 15 Asp Phe Ala Trp 20 328 20 PRT Artificial Sequence P16-MIMETIC 328 Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg 1 5 10 15 Leu Ile Phe Ser 20 329 20 PRT Artificial Sequence P16-MIMETIC 329 Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser 1 5 10 15 Lys Arg Lys Pro 20 330 5 PRT Artificial Sequence P16-MIMETIC 330 Arg Arg Leu Ile Phe 1 5 331 36 PRT Artificial Sequence P16-MIMETIC 331 Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg 1 5 10 15 Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met 20 25 30 Lys Trp Lys Lys 35 332 24 PRT Artificial Sequence P16-MIMETIC 332 Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln 1 5 10 15 Asn Arg Arg Met Lys Trp Lys Lys 20 333 8 PRT Artificial Sequence PREFERRED LINKER 333 Gly Gly Gly Lys Gly Gly Gly Gly 1 5 334 8 PRT Artificial Sequence PREFERRED LINKER 334 Gly Gly Gly Asn Gly Ser Gly Gly 1 5 335 8 PRT Artificial Sequence PREFERRED LINKER 335 Gly Gly Gly Cys Gly Gly Gly Gly 1 5 336 5 PRT Artificial Sequence PREFERRED LINKER 336 Gly Pro Asn Gly Gly 1 5 337 41 PRT Artificial Sequence TPO-MIMETIC 337 Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala 1 5 10 15 Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr 20 25 30 Leu Arg Gln Trp Leu Ala Ala Arg Ala 35 40 338 41 PRT Artificial Sequence TPO-MIMETIC 338 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala Gly Gly Gly Gly Gly 35 40 339 49 PRT Artificial Sequence EPO-MIMETIC 339 Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu 1 5 10 15 Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr 20 25 30 Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly 35 40 45 Gly 340 49 PRT Artificial Sequence EPO-MIMETIC 340 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe 20 25 30 Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly 35 40 45 Gly 341 28 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 341 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu 1 5 10 15 Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 20 25 342 29 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 342 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile 1 5 10 15 Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 20 25 343 30 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 343 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 20 25 30 344 31 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 344 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 20 25 30 345 32 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 345 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 20 25 30 346 33 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 346 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg 20 25 30 Ala 347 34 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 347 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala 20 25 30 Arg Ala 348 35 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 348 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala 20 25 30 Ala Arg Ala 35 349 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 349 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 350 37 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 350 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp 20 25 30 Leu Ala Ala Arg Ala 35 351 38 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 351 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln 20 25 30 Trp Leu Ala Ala Arg Ala 35 352 42 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 352 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro 20 25 30 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 35 40 353 32 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 353 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro 1 5 10 15 Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 20 25 30 354 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 354 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 355 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 355 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 356 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 356 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 357 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 357 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 358 37 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 358 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp 20 25 30 Leu Ala Ala Arg Ala 35 359 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 359 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 360 37 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 360 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp 20 25 30 Leu Ala Ala Arg Ala 35 361 37 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 361 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Cys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp 20 25 30 Leu Ala Ala Arg Ala 35 362 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 362 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Asn Gly Ser Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 363 36 PRT Artificial Sequence TPO-MIMETIC PEPTIDES 363 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 364 57 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP 364 aaaaaaggat cctcgagatt aagcacgagc agccagccac tgacgcagag tcggacc 57 365 39 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP 365 aaaggtggag gtggtggtat cgaaggtccg actctgcgt 39 366 42 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP 366 cagtggctgg ctgctcgtgc ttaatctcga ggatcctttt tt 42 367 81 DNA Artificial Sequence TMP CONSTRUCT 367 aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 1 5 10 15 gct gct cgt gct taatctcgag gatccttttt t 81 Ala Ala Arg Ala 20 368 20 PRT Artificial Sequence TMP CONSTRUCT 368 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 1 5 10 15 Ala Ala Arg Ala 20 369 22 DNA Artificial Sequence PCR PRIMER FOR Fc CONSTRUCT 369 aacataagta cctgtaggat cg 22 370 52 DNA Artificial Sequence PCR PRIMER FOR Fc CONSTRUCT 370 ttcgatacca ccacctccac ctttacccgg agacagggag aggctcttct gc 52 371 60 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP-TMP SEQUENCE 371 aaaggtggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct 60 372 48 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP-TMP SEQUENCE 372 acctccacca ccagcacgag cagccagcca ctgacgcaga gtcggacc 48 373 66 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP-TMP SEQUENCE 373 ggtggtggag gtggcggcgg aggtattgag ggcccaaccc ttcgccaatg gcttgcagca 60 cgcgca 66 374 76 PRT Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT TMP-TMP SEQUENCE 374 Ala Ala Ala Ala Ala Ala Ala Gly Gly Ala Thr Cys Cys Thr Cys Gly 1 5 10 15 Ala Gly Ala Thr Thr Ala Thr Gly Cys Gly Cys Gly Thr Gly Cys Thr 20 25 30 Gly Cys Ala Ala Gly Cys Cys Ala Thr Thr Gly Gly Cys Gly Ala Ala 35 40 45 Gly Gly Gly Thr Thr Gly Gly Gly Cys Cys Cys Thr Cys Ala Ala Thr 50 55 60 Ala Cys Cys Thr Cys Cys Gly Cys Cys Gly Cys Cys 65 70 75 375 126 DNA Artificial Sequence TMP-TMP CONSTRUCT 375 aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 1 5 10 15 gct gct cgt gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca 96 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro 20 25 30 acc ctt cgc caa tgg ctt gca gca cgc gca 126 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 35 40 376 42 PRT Artificial Sequence TMP-TMP CONSTRUCT 376 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 1 5 10 15 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro 20 25 30 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 35 40 377 39 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 377 ttttttcata tgatcgaagg tccgactctg cgtcagtgg 39 378 48 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 378 agcacgagca gccagccact gacgcagagt cggaccttcg atcatatg 48 379 45 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 379 ctggctgctc gtgctggtgg aggcggtggg gacaaaactc acaca 45 380 51 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 380 ctggctgctc gtgctggcgg tggtggcgga gggggtggca ttgagggccc a 51 381 54 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 381 aagccattgg cgaagggttg ggccctcaat gccaccccct ccgccaccac cgcc 54 382 54 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 382 acccttcgcc aatggcttgc agcacgcgca gggggaggcg gtggggacaa aact 54 383 27 DNA Artificial Sequence OLIGONUCLEOTIDE USED IN CONSTRUCTION OF TMP-TMP CONSTRUCT 383 cccaccgcct ccccctgcgc gtgctgc 27 384 189 DNA Artificial Sequence TMP-TMP CONSTRUCT 384 ttttttcat atg atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 51 Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg 1 5 10 gct ggc ggt ggt ggc gga ggg ggt ggc att gag ggc cca acc ctt cgc 99 Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg 15 20 25 30 caa tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa act ctg 147 Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu 35 40 45 gct gct cgt gct ggt gga ggc ggt ggg gac aaa actcacaca 189 Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys 50 55 385 57 PRT Artificial Sequence TMP-TMP CONSTRUCT 385 Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp 20 25 30 Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu Ala Ala 35 40 45 Arg Ala Gly Gly Gly Gly Gly Asp Lys 50 55 386 141 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT pAMG21 386 ctaattccgc tctcacctac caaacaatgc ccccctgcaa aaaataaatt catataaaaa 60 acatacagat aaccatctgc ggtgataaat tatctctggc ggtgttgaca taaataccac 120 tggcggtgat actgagcaca t 141 387 55 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT pAMG21 387 cgatttgatt ctagaaggag gaataacata tggttaacgc gttggaattc ggtac 55 388 872 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT GM221 388 ttattttcgt gcggccgcac cattatcacc gccagaggta aactagtcaa cacgcacggt 60 gttagatatt tatcccttgc ggtgatagat tgagcacatc gatttgattc tagaaggagg 120 gataatatat gagcacaaaa aagaaaccat taacacaaga gcagcttgag gacgcacgtc 180 gccttaaagc aatttatgaa aaaaagaaaa atgaacttgg cttatcccag gaatctgtcg 240 cagacaagat ggggatgggg cagtcaggcg ttggtgcttt atttaatggc atcaatgcat 300 taaatgctta taacgccgca ttgcttacaa aaattctcaa agttagcgtt gaagaattta 360 gcccttcaat cgccagagaa tctacgagat gtatgaagcg gttagtatgc agccgtcact 420 tagaagtgag tatgagtacc ctgttttttc tcatgttcag gcagggatgt tctcacctaa 480 gcttagaacc tttaccaaag gtgatgcgga gagatgggta agcacaacca aaaaagccag 540 tgattctgca ttctggcttg aggttgaagg taattccatg accgcaccaa caggctccaa 600 gccaagcttt cctgacggaa tgttaattct cgttgaccct gagcaggctg ttgagccagg 660 tgatttctgc atagccagac ttgggggtga tgagtttacc ttcaagaaac tgatcaggga 720 tagcggtcag gtgtttttac aaccactaaa cccacagtac ccaatgatcc catgcaatga 780 gagttgttcc gttgtgggga aagttatcgc tagtcagtgg cctgaagaga cgtttggctg 840 atagactagt ggatccacta gtgtttctgc cc 872 389 1197 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT GM221 389 ggcggaaacc gacgtccatc gaatggtgca aaacctttcg cggtatggca tgatagcgcc 60 cggaagagag tcaattcagg gtggtgaatg tgaaaccagt aacgttatac gatgtcgcag 120 agtatgccgg tgtctcttat cagaccgttt cccgcgtggt gaaccaggcc agccacgttt 180 ctgcgaaaac gcgggaaaaa gtcgaagcgg cgatggcgga gctgaattac attcccaacc 240 gcgtggcaca acaactggcg ggcaaacagt cgctcctgat tggcgttgcc acctccagtc 300 tggccctgca cgcgccgtcg caaattgtcg cggcgattaa atctcgcgcc gatcaactgg 360 gtgccagcgt ggtggtgtcg atggtagaac gaagcggcgt cgaagcctgt aaagcggcgg 420 tgcacaatct tctcgcgcaa cgcgtcagtg ggctgatcat taactatccg ctggatgacc 480 aggatgccat tgctgtggaa gctgcctgca ctaatgttcc ggcgttattt cttgatgtct 540 ctgaccagac acccatcaac agtattattt tctcccatga agacggtacg cgactgggcg 600 tggagcatct ggtcgcattg ggtcaccagc aaatcgcgct gttagcgggc ccattaagtt 660 ctgtctcggc gcgtctgcgt ctggctggct ggcataaata tctcactcgc aatcaaattc 720 agccgatagc ggaacgggaa ggcgactgga gtgccatgtc cggttttcaa caaaccatgc 780 aaatgctgaa tgagggcatc gttcccactg cgatgctggt tgccaacgat cagatggcgc 840 tgggcgcaat gcgcgccatt accgagtccg ggctgcgcgt tggtgcggat atctcggtag 900 tgggatacga cgataccgaa gacagctcat gttatatccc gccgttaacc accatcaaac 960 aggattttcg cctgctgggg caaaccagcg tggaccgctt gctgcaactc tctcagggcc 1020 aggcggtgaa gggcaatcag ctgttgcccg tctcactggt gaaaagaaaa accaccctgg 1080 cgcccaatac gcaaaccgcc tctccccgcg cgttggccga ttcattaatg cagctggcac 1140 gacaggtttc ccgactggaa agcggacagt aaggtaccat aggatccagg cacagga 1197 390 61 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT EMP 390 tatgaaaggt ggaggtggtg gtggaggtac ttactcttgc cacttcggcc cgctgacttg 60 g 61 391 72 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT EMP 391 cggtttgcaa acccaagtca gcgggccgaa gtggcaagag taagtacctc caccaccacc 60 tccacctttc at 72 392 57 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT EMP 392 gtttgcaaac cgcagggtgg cggcggcggc ggcggtggta cctattcctg tcatttt 57 393 60 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT EMP 393 ccaggtcagc gggccaaaat gacaggaata ggtaccaccg ccgccgccgc cgccaccctg 60 394 118 DNA Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT EMP 394 t atg aaa ggt gga ggt ggt ggt gga ggt act tac tct tgc cac ttc ggc 49 Met Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly 1 5 10 15 ccg ctg act tgg gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt 97 Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly 20 25 30 ggt acc tat tcc tgt cat ttt 118 Gly Thr Tyr Ser Cys His Phe 35 395 39 PRT Artificial Sequence SEQUENCE COMPRISING PL PROMOTER USED TO CONSTRUCT EMP 395 Met Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly 1 5 10 15 Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly 20 25 30 Gly Thr Tyr Ser Cys His Phe 35 396 61 DNA Artificial Sequence SENSE PCR PRIMER TO AMPLIFY EMP CONSTRUCT 396 gcagaagagc ctctccctgt ctccgggtaa aggtggaggt ggtggtggag gtacttactc 60 t 61 397 40 DNA Artificial Sequence ANTISENSE PCR PRIMER TO AMPLIFY EMP CONSTRUCT 397 ctaattggat ccacgagatt aaccaccctg cggtttgcaa 40 398 81 DNA Artificial Sequence ANTISENSE PRIMER FOR TNF-alpha INHIBITOR PEPTIDE CONSTRUCT 398 ccgcggatcc attacggacg gtgacccaga gaggtgtttt tgtagtgcgg caggaagtca 60 ccaccacctc cacctttacc c 81 399 61 DNA Artificial Sequence PCR PRIMER FOR Fc-LINKER SEQUENCE 399 agagtaagta cctccaccac cacctccacc tttacccgga gacagggaga ggctcttctg 60 c 61 400 61 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP 400 ggcccgctga cctgggtatg taagccacaa gggggtgggg gaggcggggg gtaatctcga 60 g 61 401 50 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP 401 gatcctcgag attacccccc gcctccccca cccccttgtg gcttacatac 50 402 118 DNA Artificial Sequence EMP CONSTRUCT 402 gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc 48 Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser 1 5 10 15 tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg 96 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly 20 25 30 gga ggc ggg ggg taatctcgag 118 Gly Gly Gly Gly 35 403 36 PRT Artificial Sequence EMP CONSTRUCT 403 Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser 1 5 10 15 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly 20 25 30 Gly Gly Gly Gly 35 404 39 DNA Artificial Sequence SENSE PCR PRIMER FOR EMP CONSTRUCT 404 ttatttcata tgaaaggtgg taactattcc tgtcatttt 39 405 43 DNA Artificial Sequence ANTISENSE PCR PRIMER FOR EMP CONSTRUCT 405 tggacatgtg tgagttttgt cccccccgcc tcccccaccc cct 43 406 43 DNA Artificial Sequence PCR PRIMER FOR Fc CONSTRUCT 406 agggggtggg ggaggcgggg gggacaaaac tcacacatgt cca 43 407 20 DNA Artificial Sequence PCR PRIMER FOR Fc CONSTRUCT 407 gttattgctc agcggtggca 20 408 60 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 408 ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaatatg 60 409 41 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 409 taaaagttaa aactcaaatc tagaatcaaa tcgataaaaa a 41 410 51 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 410 ggaggtactt actcttgcca cttcggcccg ctgacttggg tttgcaaacc g 51 411 55 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 411 agtcagcggg ccgaagtggc aagagtaagt acctcccata ttttattcct ccttc 55 412 60 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 412 cagggtggcg gcggcggcgg cggtggtacc tattcctgtc attttggccc gctgacctgg 60 413 60 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 413 aaaatgacag gaataggtac caccgccgcc gccgccgcca ccctgcggtt tgcaaaccca 60 414 57 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 414 gtatgtaagc cacaaggggg tgggggaggc gggggggaca aaactcacac atgtcca 57 415 60 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT EMP-EMP-Fc 415 agttttgtcc cccccgcctc ccccaccccc ttgtggctta catacccagg tcagcgggcc 60 416 228 DNA Artificial Sequence EMP-EMP CONSTRUCT 416 ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaat 57 atg gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg gtt tgc 105 Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys 1 5 10 15 aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat 153 Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His 20 25 30 ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg gga ggc 201 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly 35 40 45 ggg ggg gac aaa act cac aca tgt cca 228 Gly Gly Asp Lys Thr His Thr Cys Pro 50 55 417 57 PRT Artificial Sequence EMP-EMP CONSTRUCT 417 Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys 1 5 10 15 Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His 20 25 30 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly 35 40 45 Gly Gly Asp Lys Thr His Thr Cys Pro 50 55 418 40 DNA Artificial Sequence PCR PRIMER FOR EMP-EMP CONSTRUCT 418 ctaattggat cctcgagatt aacccccttg tggcttacat 40 419 16 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 419 Xaa Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa 1 5 10 15 420 16 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 420 Xaa Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Xaa Xaa 1 5 10 15 421 10 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 421 Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys 1 5 10 422 19 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 422 Gly Gly Thr Tyr Ser Cys His Gly Pro Leu Thr Trp Val Cys Lys Pro 1 5 10 15 Gln Gly Gly 423 19 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 423 Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg 1 5 10 15 Pro Gly Gly 424 18 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 424 Gly Gly Pro His His Val Tyr Ala Cys Arg Met Gly Pro Leu Thr Trp 1 5 10 15 Ile Cys 425 18 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 425 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln 426 20 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 426 Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln 1 5 10 15 Pro Leu Arg Gly 20 427 22 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 427 Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys 1 5 10 15 Arg Pro Ser Pro Lys Ala 20 428 13 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 428 Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 429 11 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 429 Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys 1 5 10 430 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 430 Ala Glu Pro Val Tyr Gln Tyr Glu Leu Asp Ser Tyr Leu Arg Ser Tyr 1 5 10 15 Tyr 431 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 431 Ala Glu Leu Asp Leu Ser Thr Phe Tyr Asp Ile Gln Tyr Leu Leu Arg 1 5 10 15 Thr 432 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 432 Ala Glu Phe Phe Lys Leu Gly Pro Asn Gly Tyr Val Tyr Leu His Ser 1 5 10 15 Ala 433 11 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 433 Phe Lys Leu Xaa Xaa Xaa Gly Tyr Val Tyr Leu 1 5 10 434 17 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 434 Ala Glu Ser Thr Tyr His His Leu Ser Leu Gly Tyr Met Tyr Thr Leu 1 5 10 15 Asn 435 11 PRT Artificial Sequence UKR ANTAGONIST PEPTIDE 435 Tyr His Xaa Leu Xaa Xaa Gly Tyr Met Tyr Thr 1 5 10 436 6 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 436 Arg Asn Arg Gln Lys Thr 1 5 437 4 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 437 Arg Asn Arg Gln 1 438 5 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 438 Arg Asn Arg Gln Lys 1 5 439 5 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 439 Asn Arg Gln Lys Thr 1 5 440 4 PRT Artificial Sequence MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE 440 Arg Gln Lys Thr 1 441 7 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 441 Arg Xaa Glu Thr Xaa Trp Xaa 1 5 442 7 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 442 Arg Xaa Glu Thr Xaa Trp Xaa 1 5 443 5 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 443 Arg Gly Asp Gly Xaa 1 5 444 7 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 444 Cys Arg Gly Asp Gly Xaa Cys 1 5 445 15 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 445 Cys Xaa Xaa Xaa Arg Leu Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 1 5 10 15 446 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 446 Cys Ala Arg Arg Leu Asp Ala Pro Cys 1 5 447 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 447 Cys Pro Ser Arg Leu Asp Ser Pro Cys 1 5 448 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 448 Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa 1 5 449 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 449 Cys Xaa Cys Arg Gly Asp Cys Xaa Cys 1 5 450 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 450 Cys Asp Cys Arg Gly Asp Cys Phe Cys 1 5 451 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 451 Cys Asp Cys Arg Gly Asp Cys Leu Cys 1 5 452 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 452 Cys Leu Cys Arg Gly Asp Cys Ile Cys 1 5 453 8 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 453 Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa 1 5 454 10 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 454 Xaa Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa Xaa 1 5 10 455 8 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 455 Cys Trp Asp Asp Gly Trp Leu Cys 1 5 456 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 456 Cys Trp Asp Asp Leu Trp Trp Leu Cys 1 5 457 8 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 457 Cys Trp Asp Asp Gly Leu Met Cys 1 5 458 8 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 458 Cys Trp Asp Asp Gly Trp Met Cys 1 5 459 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 459 Cys Ser Trp Asp Asp Gly Trp Leu Cys 1 5 460 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 460 Cys Pro Asp Asp Leu Trp Trp Leu Cys 1 5 461 12 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 461 Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa 1 5 10 462 16 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 462 Cys Gln Asn Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu 1 5 10 15 463 17 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 463 Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn Glu 1 5 10 15 Asp 464 19 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 464 Arg Lys Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu 1 5 10 15 Thr Asn Glu 465 13 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 465 Lys Lys Ala Leu Thr Asn Glu Ala Glu Asn Trp Ala Asp 1 5 10 466 16 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 466 Cys Gln Xaa Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Xaa Glu 1 5 10 15 467 19 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 467 Arg Lys Xaa Asn Xaa Xaa Trp Thr Trp Val Gly Thr Xaa Lys Xaa Leu 1 5 10 15 Thr Glu Glu 468 17 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 468 Ala Glu Asn Trp Ala Asp Gly Glu Pro Asn Asn Lys Xaa Asn Xaa Glu 1 5 10 15 Asp 469 16 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 469 Cys Xaa Xaa Xaa Tyr Thr Xaa Leu Val Ala Ile Gln Asn Lys Xaa Glu 1 5 10 15 470 19 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 470 Arg Lys Xaa Xaa Xaa Xaa Trp Xaa Trp Val Gly Thr Xaa Lys Xaa Leu 1 5 10 15 Thr Xaa Glu 471 16 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 471 Ala Xaa Asn Trp Xaa Xaa Xaa Glu Pro Asn Asn Xaa Xaa Xaa Glu Asp 1 5 10 15 472 13 PRT Artificial Sequence SELECTIN ANTAGONIST PEPTIDE 472 Xaa Lys Xaa Lys Thr Xaa Glu Ala Xaa Asn Trp Xaa Xaa 1 5 10 473 12 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 473 Xaa Xaa Asn Phe Phe Trp Lys Thr Phe Xaa Ser Xaa 1 5 10 474 17 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 474 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 15 Lys 475 15 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 475 Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 1 5 10 15 476 13 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 476 Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 1 5 10 477 16 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 477 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 15 478 14 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 478 Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 479 12 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 479 Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 480 16 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 480 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 15 481 15 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 481 Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 1 5 10 15 482 13 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 482 Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 1 5 10 483 16 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 483 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 15 484 14 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 484 Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 485 12 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 485 Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 486 17 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 486 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 15 Lys 487 15 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 487 Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 1 5 10 15 488 13 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 488 Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 1 5 10 489 16 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 489 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 15 490 14 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 490 Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 491 12 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 491 Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 492 17 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 492 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 15 Lys 493 15 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 493 Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 1 5 10 15 494 13 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 494 Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys 1 5 10 495 16 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 495 Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 15 496 14 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 496 Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 497 12 PRT Artificial Sequence SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE 497 Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 498 25 PRT Artificial Sequence CAP37 MIMETIC/LPS BINDING PEPTIDE 498 Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe 1 5 10 15 Val Met Thr Ala Ala Ser Cys Phe Gln 20 25 499 20 PRT Artificial Sequence CAP37 MIMETIC/LPS BINDING PEPTIDE 499 Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr 1 5 10 15 Ala Ala Ser Cys 20 500 27 PRT Artificial Sequence CAP37 MIMETIC/LPS BINDING PEPTIDE 500 Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly 1 5 10 15 Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val 20 25 501 18 PRT Artificial Sequence VEGF- ANTAGONIST PEPTIDE 501 Gly Glu Arg Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Trp 1 5 10 15 Glu Ile 502 18 PRT Artificial Sequence VEGF- ANTAGONIST PEPTIDE 502 Glu Glu Leu Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Tyr 1 5 10 15 Val Lys 503 33 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 503 Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys 1 5 10 15 Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln 20 25 30 Gln 504 33 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 504 Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys 1 5 10 15 Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln 20 25 30 Glu 505 22 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 505 Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys 1 5 10 15 Thr Leu Leu Ser Ala Val 20 506 22 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 506 Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys 1 5 10 15 Thr Leu Leu Ser Ala Val 20 507 23 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 507 Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe 1 5 10 15 Lys Thr Leu Leu Ser Ala Val 20 508 24 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 508 Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu 1 5 10 15 Phe Lys Thr Leu Leu Ser Ala Val 20 509 24 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 509 Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu 1 5 10 15 Phe Lys Thr Leu Leu Ser Ala Val 20 510 11 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 510 Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser 1 5 10 511 26 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 511 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln 20 25 512 26 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 512 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln 20 25 513 26 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 513 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln 20 25 514 22 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 514 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 Ile Ser Trp Ile Lys Arg 20 515 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 515 Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu Ile Ser Trp 1 5 10 15 Ile Lys Arg 516 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 516 Lys Leu Leu Leu Leu Leu Lys Leu Leu Leu Leu Lys 1 5 10 517 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 517 Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys 1 5 10 518 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 518 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys 1 5 10 519 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 519 Lys Lys Leu Leu Lys Leu Lys Leu Lys Leu Lys Lys 1 5 10 520 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 520 Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys 1 5 10 521 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 521 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys 1 5 10 522 6 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 522 Lys Leu Leu Leu Leu Lys 1 5 523 8 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 523 Lys Leu Leu Leu Lys Leu Leu Lys 1 5 524 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 524 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys 1 5 10 525 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 525 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys 1 5 10 526 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 526 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys 1 5 10 527 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 527 Lys Ala Ala Ala Lys Ala Ala Ala Lys Ala Ala Lys 1 5 10 528 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 528 Lys Val Val Val Lys Val Val Val Lys Val Val Lys 1 5 10 529 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 529 Lys Val Val Val Lys Val Lys Val Lys Val Val Lys 1 5 10 530 11 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 530 Lys Val Val Val Lys Val Lys Val Lys Val Lys 1 5 10 531 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 531 Lys Val Val Val Lys Val Lys Val Lys Val Val Lys 1 5 10 532 6 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 532 Lys Leu Ile Leu Lys Leu 1 5 533 6 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 533 Lys Val Leu His Leu Leu 1 5 534 6 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 534 Leu Lys Leu Arg Leu Leu 1 5 535 6 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 535 Lys Pro Leu His Leu Leu 1 5 536 8 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 536 Lys Leu Ile Leu Lys Leu Val Arg 1 5 537 8 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 537 Lys Val Phe His Leu Leu His Leu 1 5 538 8 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 538 His Lys Phe Arg Ile Leu Lys Leu 1 5 539 8 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 539 Lys Pro Phe His Ile Leu His Leu 1 5 540 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 540 Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys 1 5 10 541 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 541 Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys 1 5 10 542 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 542 Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys 1 5 10 543 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 543 Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Pro Lys 1 5 10 544 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 544 Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Val Lys 1 5 10 545 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 545 Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg 1 5 10 546 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 546 Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg 1 5 10 547 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 547 Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg 1 5 10 548 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 548 Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg 1 5 10 549 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 549 Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg 1 5 10 550 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 550 Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg 1 5 10 551 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 551 Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg 1 5 10 552 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 552 Arg Ile Ala Val Lys Trp Arg Leu Arg Phe Ile Lys 1 5 10 553 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 553 Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg 1 5 10 554 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 554 Lys Lys Ile Gly Trp Leu Ile Ile Arg Val Arg Arg 1 5 10 555 14 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 555 Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg 1 5 10 556 14 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 556 Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg Val Arg 1 5 10 557 14 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 557 Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg Arg Val 1 5 10 558 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 558 Lys Ile Val Ile Arg Ile Arg Ala Arg Leu Ile Arg Ile Arg Ile Arg 1 5 10 15 559 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 559 Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu 1 5 10 15 560 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 560 Lys Ile Gly Ile Lys Ala Arg Val Arg Ile Ile Arg Val Lys Ile Ile 1 5 10 15 561 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 561 Arg Ile Ile Val His Ile Arg Leu Arg Ile Ile His His Ile Arg Leu 1 5 10 15 562 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 562 His Ile Gly Ile Lys Ala His Val Arg Ile Ile Arg Val His Ile Ile 1 5 10 15 563 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 563 Arg Ile Tyr Val Lys Ile His Leu Arg Tyr Ile Lys Lys Ile Arg Leu 1 5 10 15 564 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 564 Lys Ile Gly His Lys Ala Arg Val His Ile Ile Arg Tyr Lys Ile Ile 1 5 10 15 565 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 565 Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu 1 5 10 15 566 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 566 Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile 1 5 10 15 567 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 567 Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg 1 5 10 15 Lys Ile Val 568 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 568 Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu 1 5 10 15 Ile Lys Lys 569 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 569 Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly 1 5 10 15 Arg Leu Arg 570 25 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 570 Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg 1 5 10 15 Lys Ile Val Lys Val Lys Arg Ile Arg 20 25 571 26 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 571 Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu 1 5 10 15 Ile Lys Lys Ile Arg Lys Arg Val Ile Lys 20 25 572 30 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 572 Lys Ala Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly 1 5 10 15 Arg Leu Arg Lys Ile Gly Trp Lys Lys Arg Val Arg Ile Lys 20 25 30 573 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 573 Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu 1 5 10 15 574 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 574 Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile 1 5 10 15 575 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 575 Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg 1 5 10 15 Lys Ile Val 576 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 576 Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu 1 5 10 15 Ile Lys Lys 577 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 577 Arg Ile Tyr Val Ser Lys Ile Ser Ile Tyr Ile Lys Lys Ile Arg Leu 1 5 10 15 578 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 578 Lys Ile Val Ile Phe Thr Arg Ile Arg Leu Thr Ser Ile Arg Ile Arg 1 5 10 15 Ser Ile Val 579 16 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 579 Lys Pro Ile His Lys Ala Arg Pro Thr Ile Ile Arg Tyr Lys Met Ile 1 5 10 15 580 26 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 580 Xaa Cys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro 1 5 10 15 Leu Phe Lys Thr Leu Leu Ser Ala Val Cys 20 25 581 26 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 581 Cys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro 1 5 10 15 Leu Phe Lys Thr Leu Leu Ser Ala Val Cys 20 25 582 27 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 582 Cys Lys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser 1 5 10 15 Pro Leu Phe Lys Thr Leu Leu Ser Ala Val Cys 20 25 583 17 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 583 Xaa Cys Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg 1 5 10 15 Cys 584 19 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 584 Xaa Cys Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys 1 5 10 15 Ile Ile Cys 585 29 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 585 Xaa Cys Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile 1 5 10 15 Arg Leu Ile Lys Lys Ile Arg Lys Arg Val Ile Lys Cys 20 25 586 13 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 586 Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys Cys 1 5 10 587 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 587 Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys 1 5 10 588 13 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 588 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys Cys 1 5 10 589 12 PRT Artificial Sequence ANTIPATHOGENIC PEPTIDE 589 Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys 1 5 10 590 28 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 590 His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln 1 5 10 15 Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn 20 25 591 28 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 591 His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln 1 5 10 15 Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn 20 25 592 3 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 592 Xaa Xaa Xaa 1 593 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 593 Xaa Ser Xaa Leu Asn 1 5 594 7 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 594 Xaa Lys Lys Tyr Xaa Xaa Xaa 1 5 595 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 595 Lys Lys Tyr Leu 1 596 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 596 Asn Ser Ile Leu Asn 1 5 597 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 597 Lys Lys Tyr Leu 1 598 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 598 Lys Lys Tyr Ala 1 599 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 599 Ala Val Lys Lys Tyr Leu 1 5 600 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 600 Ser Ile Leu Asn 1 601 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 601 Lys Lys Tyr Val 1 602 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 602 Ser Ile Xaa Asn 1 603 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 603 Lys Lys Tyr Leu Xaa 1 5 604 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 604 Asn Ser Tyr Leu Asn 1 5 605 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 605 Asn Ser Ile Tyr Asn 1 5 606 11 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 606 Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn 1 5 10 607 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 607 Xaa Lys Lys Tyr Leu 1 5 608 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 608 Xaa Lys Lys Tyr Leu 1 5 609 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 609 Lys Lys Tyr Xaa 1 610 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 610 Val Lys Lys Tyr Leu 1 5 611 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 611 Leu Asn Ser Ile Leu Asn 1 5 612 7 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 612 Tyr Leu Asn Ser Ile Leu Asn 1 5 613 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 613 Lys Lys Tyr Leu Asn 1 5 614 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 614 Lys Lys Tyr Leu Asn Ser 1 5 615 7 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 615 Lys Lys Tyr Leu Asn Ser Ile 1 5 616 8 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 616 Lys Lys Tyr Leu Asn Ser Ile Leu 1 5 617 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 617 Lys Lys Tyr Leu 1 618 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 618 Lys Lys Tyr Asp Ala 1 5 619 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 619 Ala Val Lys Lys Tyr Leu 1 5 620 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 620 Asn Ser Ile Leu Asn 1 5 621 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 621 Lys Lys Tyr Val 1 622 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 622 Xaa Ile Xaa Asn 1 623 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 623 Asn Ser Tyr Leu Asn 1 5 624 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 624 Asn Ser Ile Tyr Asn 1 5 625 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 625 Lys Lys Tyr Leu Xaa 1 5 626 11 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 626 Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn 1 5 10 627 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 627 Lys Lys Tyr Leu 1 628 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 628 Lys Lys Tyr Asp Ala 1 5 629 6 PRT Artificial Sequence VIP-MIMETIC 629 Ala Val Lys Lys Tyr Leu 1 5 630 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 630 Asn Ser Ile Leu Asn 1 5 631 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 631 Lys Lys Tyr Val 1 632 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 632 Xaa Ile Xaa Asn 1 633 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 633 Xaa Lys Lys Tyr Leu 1 5 634 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 634 Xaa Lys Lys Tyr Leu 1 5 635 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 635 Lys Lys Tyr Xaa 1 636 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 636 Val Lys Lys Tyr Leu 1 5 637 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 637 Leu Asn Ser Ile Leu Asn 1 5 638 7 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 638 Tyr Leu Asn Ser Ile Leu Asn 1 5 639 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 639 Lys Lys Tyr Leu Xaa 1 5 640 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 640 Lys Lys Tyr Leu Asn 1 5 641 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 641 Lys Lys Tyr Leu Asn Ser 1 5 642 7 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 642 Lys Lys Tyr Leu Asn Ser Ile 1 5 643 8 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 643 Lys Lys Tyr Leu Asn Ser Ile Leu 1 5 644 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 644 Lys Lys Lys Tyr Leu Asp 1 5 645 7 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 645 Xaa Cys Lys Lys Tyr Leu Cys 1 5 646 6 PRT Artificial Sequence VIP-MIMETIC 646 Cys Lys Lys Tyr Leu Lys 1 5 647 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 647 Lys Lys Tyr Ala 1 648 8 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 648 Trp Trp Thr Asp Thr Gly Leu Trp 1 5 649 8 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 649 Trp Trp Thr Asp Asp Gly Leu Trp 1 5 650 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 650 Trp Trp Asp Thr Arg Gly Leu Trp Val Trp Thr Ile 1 5 10 651 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 651 Phe Trp Gly Asn Asp Gly Ile Trp Leu Glu Ser Gly 1 5 10 652 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 652 Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala 1 5 10 653 12 PRT Artificial Sequence VIP-MIMETIC 653 Arg Trp Asp Asp Asn Gly Leu Trp Val Val Val Leu 1 5 10 654 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 654 Ser Gly Met Trp Ser His Tyr Gly Ile Trp Met Gly 1 5 10 655 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 655 Gly Gly Arg Trp Asp Gln Ala Gly Leu Trp Val Ala 1 5 10 656 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 656 Lys Leu Trp Ser Glu Gln Gly Ile Trp Met Gly Glu 1 5 10 657 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 657 Cys Trp Ser Met His Gly Leu Trp Leu Cys 1 5 10 658 12 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 658 Gly Cys Trp Asp Asn Thr Gly Ile Trp Val Pro Cys 1 5 10 659 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 659 Asp Trp Asp Thr Arg Gly Leu Trp Val Tyr 1 5 10 660 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 660 Ser Leu Trp Asp Glu Asn Gly Ala Trp Ile 1 5 10 661 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 661 Lys Trp Asp Asp Arg Gly Leu Trp Met His 1 5 10 662 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 662 Gln Ala Trp Asn Glu Arg Gly Leu Trp Thr 1 5 10 663 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 663 Gln Trp Asp Thr Arg Gly Leu Trp Val Ala 1 5 10 664 9 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 664 Trp Asn Val His Gly Ile Trp Gln Glu 1 5 665 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 665 Ser Trp Asp Thr Arg Gly Leu Trp Val Glu 1 5 10 666 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 666 Asp Trp Asp Thr Arg Gly Leu Trp Val Ala 1 5 10 667 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 667 Ser Trp Gly Arg Asp Gly Leu Trp Ile Glu 1 5 10 668 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 668 Glu Trp Thr Asp Asn Gly Leu Trp Ala Leu 1 5 10 669 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 669 Ser Trp Asp Glu Lys Gly Leu Trp Ser Ala 1 5 10 670 10 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 670 Ser Trp Asp Ser Ser Gly Leu Trp Met Asp 1 5 10 671 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 671 Ser His Leu Tyr Trp Gln Pro Tyr Ser Val Gln 1 5 10 672 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 672 Thr Leu Val Tyr Trp Gln Pro Tyr Ser Leu Gln Thr 1 5 10 673 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 673 Arg Gly Asp Tyr Trp Gln Pro Tyr Ser Val Gln Ser 1 5 10 674 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 674 Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr 1 5 10 675 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 675 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr 1 5 10 676 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 676 Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser 1 5 10 677 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 677 Asn Met Val Tyr Trp Gln Pro Tyr Ser Ile Gln Thr 1 5 10 678 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 678 Ser Val Val Phe Trp Gln Pro Tyr Ser Val Gln Thr 1 5 10 679 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 679 Thr Phe Val Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 680 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 680 Thr Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg 1 5 10 681 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 681 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 682 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 682 Ser Pro Val Phe Trp Gln Pro Tyr Ser Ile Gln Ile 1 5 10 683 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 683 Trp Ile Glu Trp Trp Gln Pro Tyr Ser Val Gln Ser 1 5 10 684 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 684 Ser Leu Ile Tyr Trp Gln Pro Tyr Ser Leu Gln Met 1 5 10 685 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 685 Thr Arg Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 686 12 PRT Artificial Sequence IL-1 ANTAGONIST 686 Arg Cys Asp Tyr Trp Gln Pro Tyr Ser Val Gln Thr 1 5 10 687 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 687 Met Arg Val Phe Trp Gln Pro Tyr Ser Val Gln Asn 1 5 10 688 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 688 Lys Ile Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr 1 5 10 689 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 689 Arg His Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 690 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 690 Ala Leu Val Trp Trp Gln Pro Tyr Ser Glu Gln Ile 1 5 10 691 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 691 Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser 1 5 10 692 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 692 Trp Glu Gln Pro Tyr Ala Leu Pro Leu Glu 1 5 10 693 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 693 Gln Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 694 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 694 Asp Leu Arg Tyr Trp Gln Pro Tyr Ser Val Gln Val 1 5 10 695 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 695 Glu Leu Val Trp Trp Gln Pro Tyr Ser Leu Gln Leu 1 5 10 696 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 696 Asp Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Trp 1 5 10 697 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 697 Asn Gly Asn Tyr Trp Gln Pro Tyr Ser Phe Gln Val 1 5 10 698 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 698 Glu Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg 1 5 10 699 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 699 Glu Leu Met Tyr Trp Gln Pro Tyr Ser Val Gln Glu 1 5 10 700 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 700 Asn Leu Leu Tyr Trp Gln Pro Tyr Ser Met Gln Asp 1 5 10 701 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 701 Gly Tyr Glu Trp Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 702 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 702 Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 703 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 703 Leu Ser Glu Gln Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 704 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 704 Gly Gly Gly Trp Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 705 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 705 Val Gly Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 706 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 706 Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 707 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 707 Gln Ala Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 708 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 708 Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr 1 5 10 709 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 709 Arg Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 710 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 710 Thr Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg 1 5 10 711 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 711 Gly Arg Ile Trp Phe Gln Pro Tyr Ser Val Gln Arg 1 5 10 712 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 712 Gly Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg 1 5 10 713 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 713 Ala Arg Thr Trp Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 714 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 714 Ala Arg Val Trp Trp Gln Pro Tyr Ser Val Gln Met 1 5 10 715 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 715 Arg Leu Met Phe Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 716 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 716 Glu Ser Met Trp Tyr Gln Pro Tyr Ser Val Gln Arg 1 5 10 717 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 717 His Phe Gly Trp Trp Gln Pro Tyr Ser Val His Met 1 5 10 718 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 718 Ala Arg Phe Trp Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 719 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 719 Arg Leu Val Tyr Trp Gln Pro Tyr Ala Pro Ile Tyr 1 5 10 720 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 720 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Tyr Gln Thr 1 5 10 721 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 721 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Leu Pro Ile 1 5 10 722 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 722 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Ala 1 5 10 723 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 723 Ser Arg Val Trp Tyr Gln Pro Tyr Ala Lys Gly Leu 1 5 10 724 12 PRT Artificial Sequence IL-1 ANTAGONIST 724 Ser Arg Val Trp Tyr Gln Pro Tyr Ala Gln Gly Leu 1 5 10 725 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 725 Ser Arg Val Trp Tyr Gln Pro Tyr Ala Met Pro Leu 1 5 10 726 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 726 Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Ala 1 5 10 727 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 727 Ser Arg Val Trp Tyr Gln Pro Tyr Ser Leu Gly Leu 1 5 10 728 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 728 Ser Arg Val Trp Tyr Gln Pro Tyr Ala Arg Glu Leu 1 5 10 729 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 729 Ser Arg Val Trp Tyr Gln Pro Tyr Ser Arg Gln Pro 1 5 10 730 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 730 Ser Arg Val Trp Tyr Gln Pro Tyr Phe Val Gln Pro 1 5 10 731 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 731 Glu Tyr Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 732 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 732 Ile Pro Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 733 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 733 Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 734 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 734 Asp Pro Leu Phe Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 735 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 735 Ser Arg Gln Trp Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 736 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 736 Ile Arg Ser Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 737 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 737 Arg Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 738 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 738 Arg Leu Leu Trp Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 739 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 739 Glu Tyr Arg Trp Phe Gln Pro Tyr Ala Leu Pro Leu 1 5 10 740 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 740 Asp Ala Tyr Trp Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 741 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 741 Trp Ser Gly Tyr Phe Gln Pro Tyr Ala Leu Pro Leu 1 5 10 742 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 742 Asn Ile Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 743 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 743 Thr Arg Asp Trp Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 744 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 744 Asp Ser Ser Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 745 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 745 Ile Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 746 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 746 Asn Leu Arg Trp Asp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 747 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 747 Leu Pro Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 748 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 748 Asp Ser Tyr Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 749 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 749 Arg Ser Gln Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 750 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 750 Ala Arg Phe Trp Leu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 751 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 751 Asn Ser Tyr Phe Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 752 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 752 Arg Phe Met Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 753 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 753 Ala His Leu Phe Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 754 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 754 Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 755 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 755 Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 756 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 756 Tyr Phe Gln Pro Tyr Ala Leu Gly Leu 1 5 757 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 757 Tyr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 758 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 758 Arg Trp Trp Gln Pro Tyr Ala Thr Pro Leu 1 5 10 759 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 759 Gly Trp Tyr Gln Pro Tyr Ala Leu Gly Phe 1 5 10 760 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 760 Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu 1 5 10 761 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 761 Ile Trp Tyr Gln Pro Tyr Ala Met Pro Leu 1 5 10 762 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 762 Ser Asn Met Gln Pro Tyr Gln Arg Leu Ser 1 5 10 763 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 763 Thr Phe Val Tyr Trp Gln Pro Tyr Ala Val Gly Leu Pro Ala Ala Glu 1 5 10 15 Thr Ala Cys Asn 20 764 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 764 Thr Phe Val Tyr Trp Gln Pro Tyr Ser Val Gln Met Thr Ile Thr Gly 1 5 10 15 Lys Val Thr Met 20 765 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 765 Thr Phe Val Tyr Trp Gln Pro Tyr Ser Ser His Xaa Xaa Val Pro Xaa 1 5 10 15 Gly Phe Pro Leu 20 766 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 766 Thr Phe Val Tyr Trp Gln Pro Tyr Tyr Gly Asn Pro Gln Trp Ala Ile 1 5 10 15 His Val Arg His 20 767 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 767 Thr Phe Val Tyr Trp Gln Pro Tyr Val Leu Leu Glu Leu Pro Glu Gly 1 5 10 15 Ala Val Arg Ala 20 768 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 768 Thr Phe Val Tyr Trp Gln Pro Tyr Val Asp Tyr Val Trp Pro Ile Pro 1 5 10 15 Ile Ala Gln Val 20 769 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 769 Gly Trp Tyr Gln Pro Tyr Val Asp Gly Trp Arg 1 5 10 770 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 770 Arg Trp Glu Gln Pro Tyr Val Lys Asp Gly Trp Ser 1 5 10 771 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 771 Glu Trp Tyr Gln Pro Tyr Ala Leu Gly Trp Ala Arg 1 5 10 772 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 772 Gly Trp Trp Gln Pro Tyr Ala Arg Gly Leu 1 5 10 773 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 773 Leu Phe Glu Gln Pro Tyr Ala Lys Ala Leu Gly Leu 1 5 10 774 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 774 Gly Trp Glu Gln Pro Tyr Ala Arg Gly Leu Ala Gly 1 5 10 775 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 775 Ala Trp Val Gln Pro Tyr Ala Thr Pro Leu Asp Glu 1 5 10 776 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 776 Met Trp Tyr Gln Pro Tyr Ser Ser Gln Pro Ala Glu 1 5 10 777 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 777 Gly Trp Thr Gln Pro Tyr Ser Gln Gln Gly Glu Val 1 5 10 778 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 778 Asp Trp Phe Gln Pro Tyr Ser Ile Gln Ser Asp Glu 1 5 10 779 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 779 Pro Trp Ile Gln Pro Tyr Ala Arg Gly Phe Gly 1 5 10 780 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 780 Arg Pro Leu Tyr Trp Gln Pro Tyr Ser Val Gln Val 1 5 10 781 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 781 Thr Leu Ile Tyr Trp Gln Pro Tyr Ser Val Gln Ile 1 5 10 782 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 782 Arg Phe Asp Tyr Trp Gln Pro Tyr Ser Asp Gln Thr 1 5 10 783 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 783 Trp His Gln Phe Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 784 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 784 Glu Trp Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr Leu Leu 1 5 10 15 Arg 785 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 785 Trp Glu Gln Asn Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Phe Ala 1 5 10 15 Asp 786 16 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 786 Ser Asp Val Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Glu Met 1 5 10 15 787 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 787 Tyr Tyr Asp Gly Val Tyr Trp Gln Pro Tyr Ser Val Gln Val Met Pro 1 5 10 15 Ala 788 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 788 Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 789 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 789 Gln Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 790 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 790 Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 791 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 791 Arg Ser Leu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 792 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 792 Thr Ile Ile Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 793 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 793 Trp Glu Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 794 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 794 Ser Tyr Asp Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 795 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 795 Ser Arg Ile Trp Cys Gln Pro Tyr Ala Leu Pro Leu 1 5 10 796 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 796 Glu Ile Met Phe Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 797 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 797 Asp Tyr Val Trp Gln Gln Pro Tyr Ala Leu Pro Leu 1 5 10 798 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 798 Met Asp Leu Leu Val Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 799 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 799 Gly Ser Lys Val Ile Leu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 800 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 800 Arg Gln Gly Ala Asn Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 801 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 801 Gly Gly Gly Asp Glu Pro Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 802 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 802 Ser Gln Leu Glu Arg Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 803 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 803 Glu Thr Trp Val Arg Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 804 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 804 Lys Lys Gly Ser Thr Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 805 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 805 Leu Gln Ala Arg Met Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 806 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 806 Glu Pro Arg Ser Gln Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 807 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 807 Val Lys Gln Lys Trp Arg Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 808 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 808 Leu Arg Arg His Asp Val Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 809 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 809 Arg Ser Thr Ala Ser Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 810 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 810 Glu Ser Lys Glu Asp Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 811 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 811 Glu Gly Leu Thr Met Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 812 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 812 Glu Gly Ser Arg Glu Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 813 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 813 Val Ile Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 814 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 814 Val Trp Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 815 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 815 Ala Ser Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 816 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 816 Phe Tyr Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 817 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 817 Glu Gly Trp Trp Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 818 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 818 Trp Gly Glu Trp Leu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 819 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 819 Asp Tyr Val Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 820 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 820 Ala His Thr Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 821 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 821 Phe Ile Glu Trp Phe Gln Pro Tyr Ala Leu Pro Leu 1 5 10 822 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 822 Trp Leu Ala Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 823 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 823 Val Met Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 824 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 824 Glu Arg Met Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 825 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 825 Asn Xaa Xaa Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu 1 5 10 826 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 826 Trp Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 827 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 827 Thr Leu Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 828 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 828 Val Trp Arg Trp Glu Gln Pro Tyr Ala Leu Pro Leu 1 5 10 829 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 829 Leu Leu Trp Thr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 830 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 830 Ser Arg Ile Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu 1 5 10 831 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 831 Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 832 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 832 Trp Gly Tyr Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu 1 5 10 833 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 833 Thr Ser Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 834 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 834 Val His Pro Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu 1 5 10 835 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 835 Glu His Ser Tyr Phe Gln Pro Tyr Ala Leu Pro Leu 1 5 10 836 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 836 Xaa Xaa Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 837 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 837 Ala Gln Leu His Ser Gln Pro Tyr Ala Leu Pro Leu 1 5 10 838 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 838 Trp Ala Asn Trp Phe Gln Pro Tyr Ala Leu Pro Leu 1 5 10 839 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 839 Ser Arg Leu Tyr Ser Gln Pro Tyr Ala Leu Pro Leu 1 5 10 840 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 840 Gly Val Thr Phe Ser Gln Pro Tyr Ala Leu Pro Leu 1 5 10 841 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 841 Ser Ile Val Trp Ser Gln Pro Tyr Ala Leu Pro Leu 1 5 10 842 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 842 Ser Arg Asp Leu Val Gln Pro Tyr Ala Leu Pro Leu 1 5 10 843 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 843 His Trp Gly His Val Tyr Trp Gln Pro Tyr Ser Val Gln Asp Asp Leu 1 5 10 15 Gly 844 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 844 Ser Trp His Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val Pro 1 5 10 15 Glu 845 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 845 Trp Arg Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Pro Glu Ser 1 5 10 15 Ala 846 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 846 Thr Trp Asp Ala Val Tyr Trp Gln Pro Tyr Ser Val Gln Lys Trp Leu 1 5 10 15 Asp 847 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 847 Thr Pro Pro Trp Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Asp 1 5 10 15 Pro 848 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 848 Tyr Trp Ser Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val His 1 5 10 15 Ser 849 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 849 Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu 1 5 10 850 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 850 Tyr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 851 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 851 Glu Trp Ile Gln Pro Tyr Ala Thr Gly Leu 1 5 10 852 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 852 Asn Trp Glu Gln Pro Tyr Ala Lys Pro Leu 1 5 10 853 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 853 Ala Phe Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 854 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 854 Phe Leu Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 855 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 855 Val Cys Lys Gln Pro Tyr Leu Glu Trp Cys 1 5 10 856 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 856 Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 857 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 857 Gln Gly Trp Leu Thr Trp Gln Asp Ser Val Asp Met Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 858 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 858 Phe Ser Glu Ala Gly Tyr Thr Trp Pro Glu Asn Thr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 859 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 859 Thr Glu Ser Pro Gly Gly Leu Asp Trp Ala Lys Ile Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 860 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 860 Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 861 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 861 Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 862 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 862 Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 863 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 863 Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 864 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 864 Ser Trp Ser Glu Ala Phe Glu Gln Pro Arg Asn Leu Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 865 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 865 Gln Tyr Ala Glu Pro Ser Ala Leu Asn Asp Trp Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 866 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 866 Asn Gly Asp Trp Ala Thr Ala Asp Trp Ser Asn Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 867 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 867 Thr His Asp Glu His Ile Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 868 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 868 Met Leu Glu Lys Thr Tyr Thr Thr Trp Thr Pro Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 869 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 869 Trp Ser Asp Pro Leu Thr Arg Asp Ala Asp Leu Tyr Trp Gln Pro Tyr 1 5 10 15 Ala Leu Pro Leu 20 870 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 870 Ser Asp Ala Phe Thr Thr Gln Asp Ser Gln Ala Met Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 871 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 871 Gly Asp Asp Ala Ala Trp Arg Thr Asp Ser Leu Thr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 872 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 872 Ala Ile Ile Arg Gln Leu Tyr Arg Trp Ser Glu Met Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 873 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 873 Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 874 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 874 Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 875 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 875 Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 876 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 876 Gln Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 877 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 877 Glu Asn Pro Phe Thr Trp Gln Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 878 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 878 Val Thr Pro Phe Thr Trp Glu Asp Ser Asn Val Phe Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 879 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 879 Gln Ile Pro Phe Thr Trp Glu Gln Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 880 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 880 Gln Ala Pro Leu Thr Trp Gln Glu Ser Ala Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 881 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 881 Glu Pro Thr Phe Thr Trp Glu Glu Ser Lys Ala Thr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 882 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 882 Thr Thr Thr Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 883 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 883 Glu Ser Pro Leu Thr Trp Glu Glu Ser Ser Ala Leu Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 884 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 884 Glu Thr Pro Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 885 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 885 Glu Ala Thr Phe Thr Trp Ala Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 886 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 886 Glu Ala Leu Phe Thr Trp Lys Glu Ser Thr Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 887 20 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 887 Ser Thr Pro Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro Tyr 1 5 10 15 Ala Leu Pro Leu 20 888 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 888 Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 889 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 889 Lys Ala Pro Phe Thr Trp Glu Glu Ser Gln Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 890 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 890 Ser Thr Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 891 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 891 Asp Ser Thr Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 892 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 892 Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 893 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 893 Gln Thr Ala Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 894 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 894 Glu Thr Leu Phe Thr Trp Glu Glu Ser Asn Ala Thr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 895 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 895 Val Ser Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 896 7 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 896 Gln Pro Tyr Ala Leu Pro Leu 1 5 897 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 897 Xaa Xaa Pro Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 898 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 898 Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 899 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 899 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 900 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 900 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 901 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 901 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 902 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 902 Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 903 18 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 903 Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Xaa Tyr Ala Leu 1 5 10 15 Pro Leu 904 16 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 904 Ala Asp Val Leu Tyr Trp Gln Pro Tyr Ala Pro Val Thr Leu Trp Val 1 5 10 15 905 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 905 Gly Asp Val Ala Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Thr Ser 1 5 10 15 Leu 906 18 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 906 Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser 1 5 10 15 Gly Leu 907 8 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 907 Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa 1 5 908 8 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 908 Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa 1 5 909 8 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 909 Xaa Xaa Gly Xaa Tyr Xaa Xaa Xaa 1 5 910 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 910 Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa 1 5 911 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 911 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 912 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 912 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 913 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 913 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 914 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 914 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 915 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 915 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 916 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 916 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 917 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 917 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa 1 5 10 15 Tyr Xaa Xaa Xaa Leu 20 918 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 918 Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 919 18 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 919 Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser 1 5 10 15 Gly Leu 920 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 920 Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 921 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 921 Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 922 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 922 Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 923 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 923 Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 924 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 924 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 925 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 925 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr 1 5 10 926 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 926 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 927 10 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 927 Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr 1 5 10 928 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 928 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 929 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 929 Ala Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 930 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 930 Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 931 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 931 Phe Glu Ala Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 932 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 932 Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 933 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 933 Phe Glu Trp Thr Ala Gly Tyr Trp Gln Xaa Tyr 1 5 10 934 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 934 Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr 1 5 10 935 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 935 Phe Glu Trp Thr Pro Gly Ala Trp Gln Xaa Tyr 1 5 10 936 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 936 Phe Glu Trp Thr Pro Gly Tyr Ala Gln Xaa Tyr 1 5 10 937 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 937 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Ala 1 5 10 938 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 938 Phe Glu Trp Thr Gly Gly Tyr Trp Gln Xaa Tyr 1 5 10 939 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 939 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 940 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 940 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 941 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 941 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 942 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 942 Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr 1 5 10 943 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 943 Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr 1 5 10 944 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 944 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr 1 5 10 945 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 945 Phe Glu Trp Thr Pro Asn Tyr Trp Gln Xaa Tyr 1 5 10 946 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 946 Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr 1 5 10 947 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 947 Phe Glu Trp Thr Val Pro Tyr Trp Gln Xaa Tyr 1 5 10 948 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 948 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 949 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 949 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 950 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 950 Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 951 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 951 Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 952 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 952 Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 953 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 953 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 954 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 954 Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr 1 5 10 955 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 955 Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr 1 5 10 956 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 956 Ser His Leu Tyr Xaa Gln Pro Tyr Ser Val Gln Met 1 5 10 957 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 957 Thr Leu Val Tyr Xaa Gln Pro Tyr Ser Leu Gln Thr 1 5 10 958 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 958 Arg Gly Asp Tyr Xaa Gln Pro Tyr Ser Val Gln Ser 1 5 10 959 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 959 Asn Met Val Tyr Xaa Gln Pro Tyr Ser Ile Gln Thr 1 5 10 960 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 960 Val Tyr Trp Gln Pro Tyr Ser Val Gln 1 5 961 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 961 Val Tyr Xaa Gln Pro Tyr Ser Val Gln 1 5 962 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 962 Thr Phe Val Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 963 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 963 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa 1 5 10 964 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 964 Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa 1 5 10 965 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 965 Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr 1 5 10 966 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 966 Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr 1 5 10 967 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 967 Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr 1 5 10 968 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 968 Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr 1 5 10 969 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 969 Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 970 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 970 Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 971 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 971 Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 972 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 972 Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 973 9 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 973 Val Tyr Trp Gln Pro Tyr Ser Val Gln 1 5 974 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 974 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 975 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 975 Arg Leu Val Tyr Xaa Gln Pro Tyr Ser Val Gln Arg 1 5 10 976 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 976 Arg Leu Asp Tyr Trp Gln Pro Tyr Ser Val Gln Arg 1 5 10 977 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 977 Arg Leu Val Trp Phe Gln Pro Tyr Ser Val Gln Arg 1 5 10 978 12 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 978 Arg Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg 1 5 10 979 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 979 Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 980 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 980 Asp Asn Ser Ser Trp Tyr Asp Ser Phe Leu Leu 1 5 10 981 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 981 Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Ala 1 5 10 982 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 982 Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu 1 5 10 983 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 983 Pro Ala Arg Glu Asp Asn Thr Ala Trp Tyr Asp Ser Phe Leu Ile Trp 1 5 10 15 Cys 984 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 984 Thr Ser Glu Tyr Asp Asn Thr Thr Trp Tyr Glu Lys Phe Leu Ala Ser 1 5 10 15 Gln 985 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 985 Ser Gln Ile Pro Asp Asn Thr Ala Trp Tyr Gln Ser Phe Leu Leu His 1 5 10 15 Gly 986 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 986 Ser Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr 1 5 10 15 Tyr 987 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 987 Glu Gln Ile Tyr Asp Asn Thr Ala Trp Tyr Asp His Phe Leu Leu Ser 1 5 10 15 Tyr 988 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 988 Thr Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr 1 5 10 15 Tyr 989 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 989 Thr Tyr Thr Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Met Ser 1 5 10 15 Tyr 990 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 990 Thr Met Thr Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser 1 5 10 15 Tyr 991 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 991 Thr Ile Asp Asn Thr Ala Trp Tyr Ala Asn Leu Val Gln Thr Tyr Pro 1 5 10 15 Gln 992 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 992 Thr Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Ala Gln Tyr Pro 1 5 10 15 Asp 993 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 993 His Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr Tyr Thr 1 5 10 15 Pro 994 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 994 Ser Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser Tyr Lys 1 5 10 15 Ala 995 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 995 Gln Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Leu Gln Tyr Asn 1 5 10 15 Ala 996 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 996 Asn Gln Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Leu Gln Tyr Asn 1 5 10 15 Thr 997 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 997 Thr Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Asn His Asn 1 5 10 15 Leu 998 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 998 His Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Gln Gln Gly Trp 1 5 10 15 His 999 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 999 Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 1000 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1000 Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 1001 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1001 Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 1002 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1002 Xaa Xaa Xaa Gln Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 1003 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1003 Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 1004 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1004 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 1005 17 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1005 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Ser 1 5 10 15 Asp 1006 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1006 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 1007 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1007 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 1008 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1008 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 1009 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1009 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 1010 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1010 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 1011 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1011 Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr 1 5 10 1012 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1012 Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr 1 5 10 1013 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1013 Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr 1 5 10 1014 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1014 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 1015 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1015 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 1016 15 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1016 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu 1 5 10 15 1017 21 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1017 Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro 1 5 10 15 Tyr Ala Leu Pro Leu 20 1018 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1018 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr 1 5 10 1019 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1019 Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr 1 5 10 1020 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1020 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr 1 5 10 1021 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1021 Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr 1 5 10 1022 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1022 Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr 1 5 10 1023 11 PRT Artificial Sequence IL-1 ANTAGONIST PEPTIDE 1023 Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr 1 5 10 1024 20 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1024 Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly 1 5 10 15 Tyr Lys Gly Gly 20 1025 20 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1025 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly 20 1026 20 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1026 Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Leu Gly Gly 20 1027 19 PRT Artificial Sequence VEGF-ANTAGONIST 1027 Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe 1 5 10 15 Glu Arg Leu 1028 10 PRT Artificial Sequence MMP INHIBITOR 1028 Cys Thr Thr His Trp Gly Phe Thr Leu Cys 1 5 10 1029 20 PRT Artificial Sequence MMP INHIBITOR 1029 Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg 1 5 10 15 Pro Gly Gly Gly 20 1030 20 PRT Artificial Sequence EPO MIMETIC PEPTIDE 1030 Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser 1 5 10 15 Pro Leu Gly Gly 20 1031 20 PRT Artificial Sequence VEGF- ANTAGONIST 1031 Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu 1 5 10 15 Thr Glu Ala Gln 20 1032 19 PRT Artificial Sequence TPO-MIMETIC 1032 Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala 1 5 10 15 Ala Arg Ala 1033 19 PRT Artificial Sequence TPO-MIMETIC 1033 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Gly Gly 1034 25 PRT Artificial Sequence TPO-MIMETIC 1034 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln Gly Gly Gly Gly Gly Gly Gly 20 25 1035 19 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1035 Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg 1 5 10 15 Pro Gly Gly 1036 18 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1036 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 15 Pro Gln 1037 20 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1037 Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln 1 5 10 15 Pro Leu Arg Gly 20 1038 22 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1038 Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys 1 5 10 15 Arg Pro Ser Pro Lys Ala 20 1039 13 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1039 Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 1040 11 PRT Artificial Sequence EPO MIMETIC PEPTIDE 1040 Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys 1 5 10 1041 12 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1041 Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys 1 5 10 1042 11 PRT Artificial Sequence EPO-MIMETIC PEPTIDE 1042 Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa 1 5 10 1043 5 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1043 Asp Leu Xaa Xaa Leu 1 5 1044 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1044 Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr Thr Leu 1 5 10 1045 20 PRT Artificial Sequence TNF-ALPHA INHIBITOR 1045 Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu 1 5 10 15 Gly His Arg Pro 20 1046 20 PRT Artificial Sequence TNF-ALPHA INHIBITOR 1046 Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro Gly 1 5 10 15 Gly Gly Gly Gly 20 1047 20 PRT Artificial Sequence IL-1 R ANTAGONIST 1047 Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr 1 5 10 15 Ala Leu Pro Leu 20 1048 20 PRT Artificial Sequence IL-1 R ANTAGONIST 1048 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Gly 1 5 10 15 Gly Gly Gly Gly 20 1049 24 PRT Artificial Sequence VEGF-ANTAGONIST 1049 Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile His Val Met Trp 1 5 10 15 Glu Trp Glu Cys Phe Glu Arg Leu 20 1050 24 PRT Artificial Sequence VEGF-ANTAGONIST 1050 Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe 1 5 10 15 Glu Arg Leu Gly Gly Gly Gly Gly 20 1051 15 PRT Artificial Sequence MMP INHIBITOR 1051 Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe Thr Leu Cys 1 5 10 15 1052 15 PRT Artificial Sequence MMP INHIBITOR 1052 Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly 1 5 10 15 1053 10 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1053 Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr 1 5 10 1054 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1054 Arg Thr Asp Leu Asp Ser Leu Arg Thr 1 5 1055 757 DNA Artificial Sequence Fc-TNF-ALPHA INHIBITORS 1055 cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 1 5 10 15 ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 65 70 75 acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 80 85 90 95 aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 100 105 110 ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 160 165 170 175 cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 ctg tct ccg ggt aaa ggt gga ggt ggt ggt gac ttc ctg ccg cac tac 720 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr 225 230 235 aaa aac acc tct ctg ggt cac cgt ccg taatggatcc 757 Lys Asn Thr Ser Leu Gly His Arg Pro 240 245 1056 248 PRT Artificial Sequence Fc-TNF-ALPHA INHIBITORS 1056 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys 225 230 235 240 Asn Thr Ser Leu Gly His Arg Pro 245 1057 761 DNA Artificial Sequence TNF-ALPHA INHIBITOR-Fc 1057 cat atg gac ttc ctg ccg cac tac aaa aac acc tct ctg ggt cac cgt 48 Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg 1 5 10 15 ccg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96 Pro Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro 20 25 30 gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 35 40 45 ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 50 55 60 gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 240 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 65 70 75 gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 288 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 80 85 90 95 cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac 336 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 100 105 110 cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 384 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 115 120 125 gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 432 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 130 135 140 ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 480 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 145 150 155 acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 528 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 160 165 170 175 agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 576 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 180 185 190 tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 624 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 195 200 205 tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 672 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 210 215 220 ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 720 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 225 230 235 aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc gcgg 761 Lys Ser Leu Ser Leu Ser Pro Gly Lys 240 245 1058 248 PRT Artificial Sequence TNF-ALPHA INHIBITOR-Fc 1058 Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro 1 5 10 15 Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 20 25 30 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 35 40 45 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 50 55 60 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 65 70 75 80 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 85 90 95 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 100 105 110 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 115 120 125 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 130 135 140 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 145 150 155 160 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 165 170 175 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 180 185 190 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 195 200 205 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 210 215 220 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 225 230 235 240 Ser Leu Ser Leu Ser Pro Gly Lys 245 1059 763 DNA Artificial Sequence Fc-IL-1 ANTAGONIST 1059 cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 1 5 10 15 ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 65 70 75 acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 80 85 90 95 aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 100 105 110 ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 160 165 170 175 cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 ctg tct ccg ggt aaa ggt gga ggt ggt ggt ttc gaa tgg acc ccg ggt 720 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly 225 230 235 tac tgg cag ccg tac gct ctg ccg ctg taatggatcc ctcgag 763 Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 240 245 1060 248 PRT Artificial Sequence Fc-IL-1 ANTAGONIST 1060 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr 225 230 235 240 Trp Gln Pro Tyr Ala Leu Pro Leu 245 1061 757 DNA Artificial Sequence IL-1 ANTAGONIST-Fc 1061 cat atg ttc gaa tgg acc ccg ggt tac tgg cag ccg tac gct ctg ccg 48 Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro 1 5 10 15 ctg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96 Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro 20 25 30 gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 35 40 45 ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 50 55 60 gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 240 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 65 70 75 gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 288 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 80 85 90 95 cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac 336 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 100 105 110 cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 384 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 115 120 125 gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 432 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 130 135 140 ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 480 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 145 150 155 acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 528 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 160 165 170 175 agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 576 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 180 185 190 tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 624 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 195 200 205 tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 672 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 210 215 220 ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 720 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 225 230 235 aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc 757 Lys Ser Leu Ser Leu Ser Pro Gly Lys 240 245 1062 248 PRT Artificial Sequence IL-1 ANTAGONIST-Fc 1062 Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu 1 5 10 15 Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 20 25 30 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 35 40 45 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 50 55 60 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 65 70 75 80 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 85 90 95 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 100 105 110 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 115 120 125 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 130 135 140 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 145 150 155 160 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 165 170 175 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 180 185 190 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 195 200 205 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 210 215 220 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 225 230 235 240 Ser Leu Ser Leu Ser Pro Gly Lys 245 1063 773 DNA Artificial Sequence Fc-VEGF ANTAGONIST 1063 cat atg gac aaa act cac aca tgt cca ccg tgc cca gca cct gaa ctc 48 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 1 5 10 15 ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc 96 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 65 70 75 acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 80 85 90 95 aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 100 105 110 ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 160 165 170 175 cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 ctg tct ccg ggt aaa ggt ggt ggt ggt ggt gtt gaa ccg aac tgt gac 720 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp 225 230 235 atc cat gtt atg tgg gaa tgg gaa tgt ttt gaa cgt ctg taactcgagg 769 Ile His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu 240 245 250 atcc 773 1064 252 PRT Artificial Sequence Fc-VEGF ANTAGONIST 1064 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile 225 230 235 240 His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu 245 250 1065 773 DNA Artificial Sequence VEGF ANTAGONIST-Fc 1065 cat atg gtt gaa ccg aac tgt gac atc cat gtt atg tgg gaa tgg gaa 48 Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu 1 5 10 15 tgt ttt gaa cgt ctg ggt ggt ggt ggt ggt gac aaa act cac aca tgt 96 Cys Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys 20 25 30 cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc 144 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 35 40 45 ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag 192 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 50 55 60 gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag 240 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 65 70 75 ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag 288 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 80 85 90 95 ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc 336 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 100 105 110 acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag 384 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 115 120 125 gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa 432 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 130 135 140 gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc 480 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 145 150 155 cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa 528 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 160 165 170 175 ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag 576 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 180 185 190 ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc 624 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 195 200 205 tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag 672 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 210 215 220 cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac 720 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 225 230 235 cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa taactcgagg 769 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 240 245 250 atcc 773 1066 252 PRT Artificial Sequence VEGF ANTAGONIST-Fc 1066 Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys 1 5 10 15 Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro 20 25 30 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 35 40 45 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 50 55 60 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 65 70 75 80 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 85 90 95 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 100 105 110 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 115 120 125 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 130 135 140 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 145 150 155 160 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 165 170 175 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 180 185 190 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 195 200 205 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 210 215 220 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 225 230 235 240 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 245 250 1067 748 DNA Artificial Sequence Fc-MMP INHIBITOR 1067 cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 1 5 10 15 ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 65 70 75 acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 80 85 90 95 aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 100 105 110 ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 160 165 170 175 cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 ctg tct ccg ggt aaa ggt gga ggt ggt ggt tgc acc acc cac tgg ggt 720 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly 225 230 235 ttc acc ctg tgc taatggatcc ctcgag 748 Phe Thr Leu Cys 240 1068 243 PRT Artificial Sequence Fc-MMP INHIBITOR 1068 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe 225 230 235 240 Thr Leu Cys 1069 763 DNA Artificial Sequence MMP INHIBITOR-Fc 1069 cat atg tgc acc acc cac tgg ggt ttc acc ctg tgc ggt gga ggc ggt 48 Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly 1 5 10 15 ggg gac aaa ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct 96 Gly Asp Lys Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro 20 25 30 tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc 144 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 35 40 45 cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca 192 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 50 55 60 tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac 240 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 65 70 75 tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg 288 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 80 85 90 95 gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc 336 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 100 105 110 ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc 384 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 115 120 125 aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa 432 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 130 135 140 ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat 480 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 145 150 155 gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc 528 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 160 165 170 175 tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag 576 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 180 185 190 aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc 624 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 195 200 205 ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg 672 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 210 215 220 aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac 720 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 225 230 235 acg cag aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc 763 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 240 245 250 1070 250 PRT Artificial Sequence MMP INHIBITOR-Fc 1070 Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly 1 5 10 15 Asp Lys Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys 20 25 30 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 35 40 45 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 50 55 60 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 65 70 75 80 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 85 90 95 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 100 105 110 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 115 120 125 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 130 135 140 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 145 150 155 160 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 165 170 175 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 180 185 190 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 195 200 205 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 210 215 220 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 225 230 235 240 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 245 250 1071 13 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1071 Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys 1 5 10 1072 13 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1072 Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys 1 5 10 1073 8 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1073 Cys Leu Ser Gly Ser Leu Ser Cys 1 5 1074 6 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1074 Asn Gly Arg Ala His Ala 1 5 1075 5 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1075 Cys Asn Gly Arg Cys 1 5 1076 9 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1076 Cys Asp Cys Arg Gly Asp Cys Phe Cys 1 5 1077 7 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1077 Cys Gly Ser Leu Val Arg Cys 1 5 1078 8 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1078 Arg Thr Asp Leu Asp Ser Leu Arg 1 5 1079 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1079 Gly Asp Leu Asp Leu Leu Lys Leu Arg Leu Thr Leu 1 5 10 1080 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1080 Gly Asp Leu His Ser Leu Arg Gln Leu Leu Ser Arg 1 5 10 1081 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1081 Arg Asp Asp Leu His Met Leu Arg Leu Gln Leu Trp 1 5 10 1082 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1082 Ser Ser Asp Leu His Ala Leu Lys Lys Arg Tyr Gly 1 5 10 1083 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1083 Arg Gly Asp Leu Lys Gln Leu Ser Glu Leu Thr Trp 1 5 10 1084 12 PRT Artificial Sequence INTEGRIN-BINDING PEPTIDE 1084 Arg Gly Asp Leu Ala Ala Leu Ser Ala Pro Pro Val 1 5 10 1085 20 PRT Artificial Sequence VEGF-ANTAGONIST 1085 Arg Gly Trp Val Glu Ile Cys Val Ala Asp Asp Asn Gly Met Cys Val 1 5 10 15 Thr Glu Ala Gln 20 1086 19 PRT Artificial Sequence VEGF-ANTAGONIST 1086 Gly Trp Asp Glu Cys Asp Val Ala Arg Met Trp Glu Trp Glu Cys Phe 1 5 10 15 Ala Gly Val 1087 16 PRT Artificial Sequence VEGF-ANTAGONIST 1087 Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu 1 5 10 15 1088 16 PRT Artificial Sequence VEGF-ANTAGONIST 1088 Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu 1 5 10 15 1089 19 PRT Artificial Sequence VEGF-ANTAGONIST 1089 Gly Gly Asn Glu Cys Asp Ile Ala Arg Met Trp Glu Trp Glu Cys Phe 1 5 10 15 Glu Arg Leu 1090 16 PRT Artificial Sequence VEGF-ANTAGONIST 1090 Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu 1 5 10 15 1091 8 PRT Artificial Sequence MMP INHIBITOR 1091 Cys Leu Arg Ser Gly Xaa Gly Cys 1 5 1092 10 PRT Artificial Sequence MMP INHIBITOR 1092 Cys Xaa Xaa His Trp Gly Phe Xaa Xaa Cys 1 5 10 1093 5 PRT Artificial Sequence MMP INHIBITOR 1093 Cys Xaa Pro Xaa Cys 1 5 1094 10 PRT Artificial Sequence MMP INHIBITOR 1094 Cys Arg Arg His Trp Gly Phe Glu Phe Cys 1 5 10 1095 10 PRT Artificial Sequence MMP INHIBITOR 1095 Ser Thr Thr His Trp Gly Phe Thr Leu Ser 1 5 10 1096 10 PRT Artificial Sequence CTLA4-MIMETIC PEPTIDE 1096 Cys Ser Leu His Trp Gly Phe Trp Trp Cys 1 5 10 1097 15 PRT Artificial Sequence CARBOHYDRATE (GD1 ALPHA) MIMETIC PEPTIDE 1097 Trp His Trp Arg His Arg Ile Pro Leu Gln Leu Ala Ala Gly Arg 1 5 10 15 1098 6 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1098 Leu Lys Thr Pro Arg Val 1 5 1099 8 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1099 Asn Thr Leu Lys Thr Pro Arg Val 1 5 1100 11 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1100 Asn Thr Leu Lys Thr Pro Arg Val Gly Gly Cys 1 5 10 1101 6 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1101 Lys Asp Lys Ala Thr Phe 1 5 1102 10 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1102 Lys Asp Lys Ala Thr Phe Gly Cys His Asp 1 5 10 1103 12 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1103 Lys Asp Lys Ala Thr Phe Gly Cys His Asp Gly Cys 1 5 10 1104 6 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1104 Thr Leu Arg Val Tyr Lys 1 5 1105 9 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1105 Ala Thr Leu Arg Val Tyr Lys Gly Gly 1 5 1106 10 PRT Artificial Sequence BETA-2GPI AB BINDING PEPTIDE 1106 Cys Ala Thr Leu Arg Val Tyr Lys Gly Gly 1 5 10 1107 14 PRT Artificial Sequence MEMBRANE-TRANSPORTING PEPTIDE 1107 Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 1 5 10 1108 12 PRT Artificial Sequence MEMBRANE-TRANSPORTING PEPTIDE 1108 Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly 1 5 10 1109 27 PRT Artificial Sequence MEMBRANE-TRANSPORTING PEPTIDE 1109 Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 1 5 10 15 Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 20 25 1110 14 PRT Artificial Sequence EPO MIMETIC PEPTIDE 1110 Xaa Cys Xaa Xaa Gly Trp Val Gly Xaa Cys Xaa Xaa Trp Xaa 1 5 10 1111 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL 1111 Cys Val His Ala Tyr Arg Ser 1 5 1112 7 PRT Artificial Sequence ANTIPROLIFERATIVE ANTIVIRAL PEPTIDE 1112 Cys Val His Ala Tyr Arg Ala 1 5 1113 7 PRT Artificial Sequence ANTIPROLIFERATIVE ANTIVIRAL PEPTIDE 1113 Cys Val His Ala Pro Arg Ser 1 5 1114 7 PRT Artificial Sequence ANTIPROLIFERATIVE ANTIVIRAL PEPTIDE 1114 Cys Val His Ala Pro Arg Ala 1 5 1115 81 DNA Artificial Sequence SENSE PCR PRIMER FOR TNF-alpha INHIBITOR PEPTIDE 1115 gaataacata tggacttcct gccgcactac aaaaacacct ctctgggtca ccgtccgggt 60 ggaggcggtg gggacaaaac t 81 1116 81 DNA Artificial Sequence ANTISENSE PCR PRIMER FOR Fc-LINKER CONSTRUCT 1116 ccgcggatcc attacagcgg cagagcgtac ggctgccagt aacccggggt ccattcgaaa 60 ccaccacctc cacctttacc c 81 1117 81 DNA Artificial Sequence SENSE PCR PRIMER FOR TNF-alpha INHIBITOR PEPTIDE 1117 gaataacata tgttcgaatg gaccccgggt tactggcagc cgtacgctct gccgctgggt 60 ggaggcggtg gggacaaaac t 81 1118 57 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT VEGF MIMETIC PEPTIDE 1118 gttgaaccga actgtgacat ccatgttatg tgggaatggg aatgttttga acgtctg 57 1119 57 DNA Artificial Sequence OLIGONUCLEOTIDE USED TO CONSTRUCT VEGF MIMETIC PEPTIDE 1119 cagacgttca aaacattccc attcccacat aacatggatg tcacagttcg gttcaac 57 1120 57 DNA Artificial Sequence VEGF ANTAGONIST CONSTRUCT 1120 gtt gaa ccg aac tgt gac atc cat gtt atg tgg gaa tgg gaa tgt ttt 48 Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe 1 5 10 15 gaa cgt ctg 57 Glu Arg Leu 1121 19 PRT Artificial Sequence VEGF ANTAGONIST CONSTRUCT 1121 Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe 1 5 10 15 Glu Arg Leu 1122 48 DNA Artificial Sequence SENSE PCR PRIMER FOR Fc CONSTRUCT 1122 atttgattct agaaggagga ataacatatg gacaaaactc acacatgt 48 1123 51 DNA Artificial Sequence ANTI-SENSE PCR PRIMER FOR Fc CONSTRUCT 1123 gtcacagttc ggttcaacac caccaccacc acctttaccc ggagacaggg a 51 1124 54 DNA Artificial Sequence SENSE PCR PRIMER FOR VEGF ANTAGONIST CONSTRUCT 1124 tccctgtctc cgggtaaagg tggtggtggt ggtgttgaac cgaactgtga catc 54 1125 39 DNA Artificial Sequence ANTI-SENSE PCR PRIMER FOR VEGF ANTAGONIST CONSTRUCT 1125 ccgcggatcc tcgagttaca gacgttcaaa acattccca 39 1126 48 DNA Artificial Sequence SENSE PCR PRIMER FOR VEGF ANTAGONIST CONSTRUCT 1126 atttgattct agaaggagga ataacatatg gttgaaccga actgtgac 48 1127 51 DNA Artificial Sequence ANTI-SENSE PCR PRIMER FOR VEGF ANTAGONIST CONSTRUCT 1127 acatgtgtga gttttgtcac caccaccacc acccagacgt tcaaaacatt c 51 1128 51 DNA Artificial Sequence SENSE PCR PRIMER FOR Fc CONSTRUCT 1128 gaatgttttg aacgtctggg tggtggtggt ggtgacaaaa ctcacacatg t 51 1129 39 DNA Artificial Sequence ANTI-SENSE PCR PRIMER FOR Fc CONSTRUCT 1129 ccgcggatcc tcgagttatt tacccggaga cagggagag 39 1130 66 DNA Artificial Sequence ANTI-SENSE PCR PRIMER FOR Fc-LINKER CONSTRUCT 1130 ccgcggatcc attagcacag ggtgaaaccc cagtgggtgg tgcaaccacc acctccacct 60 ttaccc 66 1131 63 DNA Artificial Sequence SENSE PCR PRIMER FOR MMP INHIBITORY PEPTIDE 1131 gaataacata tgtgcaccac ccactggggt ttcaccctgt gcggtggagg cggtggggac 60 aaa 63 1132 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1132 Cys Val His Ser Tyr Arg Ser 1 5 1133 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1133 Cys Val His Ser Tyr Arg Ala 1 5 1134 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1134 Cys Val His Ser Pro Arg Ser 1 5 1135 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1135 Cys Val His Ser Pro Arg Ala 1 5 1136 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1136 Cys Val His Thr Tyr Arg Ser 1 5 1137 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1137 Cys Val His Thr Tyr Arg Ala 1 5 1138 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1138 Cys Val His Thr Pro Arg Ser 1 5 1139 7 PRT Artificial Sequence ANTIPROLIFERATIVE, ANTIVIRAL PEPTIDE 1139 Cys Val His Thr Pro Arg Ala 1 5 1140 6 PRT Artificial Sequence ANTI-ISCHEMIC, GROWTH HORMONE-LIBERATING PEPTIDE 1140 His Trp Ala Trp Phe Lys 1 5 1141 18 PRT Artificial Sequence VEGF ANTAGONIST PEPTIDE 1141 Gly Glu Arg Trp Cys Phe Asp Gly Pro Leu Thr Trp Val Cys Gly Glu 1 5 10 15 Glu Ser 1142 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1142 Ala Xaa Xaa Xaa 1 1143 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1143 Val Xaa Xaa Xaa 1 1144 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1144 Ala Val Xaa Xaa Xaa 1 5 1145 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1145 Val Ala Xaa Xaa Xaa 1 5 1146 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1146 Lys Xaa Xaa Xaa 1 1147 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1147 Ala Lys Xaa Xaa Xaa 1 5 1148 5 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1148 Val Lys Xaa Xaa Xaa 1 5 1149 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1149 Ala Val Lys Xaa Xaa Xaa 1 5 1150 6 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1150 Val Ala Lys Xaa Xaa Xaa 1 5 1151 4 PRT Artificial Sequence VIP-MIMETIC PEPTIDE 1151 Xaa Xaa Xaa Xaa 1 1152 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 1152 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 1153 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 1153 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 1154 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 1154 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 1155 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 1155 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 1156 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 1156 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 1157 36 PRT Artificial Sequence PEPTIDE SEQUENCE MODIFIED FOR PEGYLATION 1157 Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly 1 5 10 15 Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30 Ala Ala Arg Ala 35 

What is claimed is:
 1. A composition of matter of the formula (X¹)_(a)—F¹—(X²)_(b) and multimers thereof, wherein: F¹ is an Fc domain; X¹ and X² are each independently selected from -(L¹)_(c)-P¹, -(L¹)_(c)-P¹-(L²)_(d)-P², -(L¹)_(c)-P¹-(L²)_(d)-P²-(L³)_(e)-P³, and -(L¹)_(c)-P¹-(L²)_(d)-P²-(L³)_(e)-P³-(L⁴)_(f)-P⁴ P¹, P², P³, and P⁴ are each independently sequences of pharmacologically active peptides; L¹, L², L³, and L⁴ are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is
 1. 2. The composition of matter of claim 1 of the formulae X¹'F¹ or F¹—X².
 3. The composition of matter of claim 1 of the formula F¹-(L¹)_(c)-P¹.
 4. The composition of matter of claim 1 of the formula F¹-(L¹)_(c)-P¹-(L²)_(d)-P².
 5. The composition of matter of claim 1 wherein F¹ is an IgG Fc domain.
 6. The composition of matter of claim 1 wherein F¹ is an IgG1 Fc domain.
 7. The composition of matter of claim 1 wherein F¹ comprises the sequence of SEQ ID NO:
 2. 8. The composition of matter of claim 1 wherein X¹ and X² comprise an IL-1 antagonist peptide sequence.
 9. The composition of matter of claim 8 wherein the IL-1 antagonist peptide sequence is selected from SEQ ID NOS: 212, 907, 908, 909, 910, 917, and
 979. 10. The composition of matter of claim 8 wherein the IL-1 antagonist peptide sequence is selected from SEQ ID NOS: 213 to 271, 671 to 906, 911 to 916, and 918 to
 1023. 11. The composition of matter of claim 8 wherein F¹ comprises the sequence of SEQ ID NO:
 2. 12. The composition of matter of claim 1 wherein X¹ and X² comprise an EPO-mimetic peptide sequence.
 13. The composition of matter of claim 12 wherein the EPO-mimetic peptide sequence is selected from Table
 5. 14. The composition of matter of claim 12 wherein F¹ comprises the sequence of SEQ ID NO:
 2. 15. The composition of matter of claim 12 comprising a sequence selected from SEQ ID NOS: 83, 84, 85, 124, 419, 420, 421, and
 461. 16. The composition of matter of claim 12 comprising a sequence selected from SEQ ID NOS: 339 and
 340. 17. The composition of matter of claim 12 comprising a sequence selected from SEQ ID NOS: 20 and
 22. 18. The composition of matter of claim 3 wherein P¹ is a TPO-mimetic peptide sequence.
 19. The composition of matter of claim 18 wherein P¹ is a TPO-mimetic peptide sequence selected from Table
 6. 20. The composition of matter of claim 18 wherein F¹ comprises the sequence of SEQ ID NO:
 2. 21. The composition of matter of claim 18 having a sequence selected from SEQ ID NOS: 6 and
 12. 22. A DNA encoding a composition of matter of any of claims 1 to
 21. 23. An expression vector comprising the DNA of claim
 22. 24. A host cell comprising the expression vector of claim
 23. 25. The cell of claim 24, wherein the cell is an E. coli cell.
 26. A process for preparing a pharmacologically active compound, which comprises a. selecting at least one randomized peptide that modulates the activity of a protein of interest; and b. preparing a pharmacologic agent comprising at least one Fc domain covalently linked to at least one amino acid sequence of the selected peptide or peptides.
 27. The process of claim 26, wherein the peptide is selected in a process comprising one or more techniques selected from yeast-based screening, rational design, protein structural analysis, or screening of a phage display library, an E. coli display library, a ribosomal library, or a chemical peptide library.
 28. The process of claim 26, wherein the preparation of the pharmacologic agent is carried out by: a. preparing a gene construct comprising a nucleic acid sequence encoding the selected peptide and a nucleic acid sequence encoding an Fc domain; and b. expressing the gene construct.
 29. The process of claim 26, wherein the gene construct is expressed in an E. coli cell.
 30. The process of claim 26, wherein the protein of interest is a cell surface receptor.
 31. The process of claim 26, wherein the protein of interest has a linear epitope.
 32. The process of claim 26, wherein the protein of interest is a cytokine receptor.
 33. The process of claim 26, wherein the peptide is an EPO-mimetic peptide.
 34. The process of claim 26, wherein the peptide is a TPO-mimetic peptide.
 35. The process of claim 26, wherein the peptide is an IL-1 antagonist peptide.
 36. The process of claim 26, wherein the protein of interest is selected from the TNF family.
 37. The process of claim 26, wherein the peptide is a TNF-antagonist peptide.
 38. The process of claim 26, wherein the peptide is a CTLA4-mimetic peptide.
 39. The process of claim 26, wherein the peptide is selected from Tables 4 to
 20. 40. The process of claim 26, wherein the selection of the peptide is carried out by a process comprising: a. preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain; b. conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein i) a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5′ end of a coding strand of the gene construct, and ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3′ end of the noncoding strand of the gene construct.
 41. The process of claim 26, wherein the compound is derivatized.
 42. The process of claim 26, wherein the derivatized compound comprises a cyclic portion, a cross-linking site, a non-peptidyl linkage, an N-terminal replacement, a C-terminal replacement, or a modified amino acid moiety.
 43. The process of claim 26 wherein the Fc domain is an IgG Fc domain.
 44. The process of claim 26, wherein the vehicle is an IgG1 Fc domain.
 45. The process of claim 26, wherein the vehicle comprises the sequence of SEQ ID NO:
 2. 46. The process of claim 26, wherein the compound prepared is of the formula (X¹)_(a)—F¹—(X²)_(b) and multimers thereof, wherein: F¹ is an Fc domain; X¹ and X² are each independently selected from -(L¹)_(c)-P¹, -(L¹)_(c)-P¹-(L²)_(d)-P², -(L¹)_(c)-P¹-(L²)_(d)-P²-(L³)_(e)-P³, and -(L¹)_(c)-P¹-(L²)_(d)-P²-(L³)_(e)-P³-(L⁴)_(f)-P⁴ P¹, P², P³, and P⁴ are each independently sequences of pharmacologically active peptides; L¹, L², L³, and L⁴ are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is
 1. 47. The process of claim 46, wherein the compound prepared is of the formulae X¹—F¹ or F¹—X².
 48. The process of claim 46, wherein the compound prepared is of the formulae F¹-(L¹)_(c)-P¹ or F¹-(L¹)_(c)-P¹-(L²)_(d)-².
 49. The process of claim 46, wherein F'is an IgG Fc domain.
 50. The process of claim 46, wherein F'is an IgG1 Fc domain.
 51. The process of claim 46, wherein F'comprises the sequence of SEQ ID NO:
 2. 52. The composition of matter of claim 1, further comprising an effector molecule or domain selected from a group consisting of: a. radioisotopes; b. ricin A toxin; c. microbially derived toxins; d. biotin; e. streptavidin; and f. cytotoxic agents.
 53. The composition of matter of claim 52, wherein the vehicle is an Fc domain.
 54. The composition of matter of claim 52, wherein at least one pharmacologically active peptide is capable of binding a tumor-specific epitope.
 55. The composition of matter of claim 52, wherein the effector molecule is a radioisotope.
 56. The composition of matter of claim 55, wherein the radioisotope is selected from ⁹⁰Yttrium, ¹³¹Iodine, ²²⁵Actinium, and ²¹³Bismuth.
 57. A process for preparing a composition of matter, which comprises: a. selecting at least one randomized peptide that specifically binds to a target epitope; and b. preparing a pharmacologic agent comprising (i) at least one vehicle, (ii) at least one amino acid sequence of the selected peptide or peptides, and (iii) an effector molecule.
 58. The process of claim 57, wherein the vehicle is an Fc domain.
 59. The process of claim 57, wherein the target epitope is a tumor-specific epitope.
 60. The process of claim 57, wherein the effector molecule is selected from: a. radioisotopes; b. ricin A toxin; c. microbially derived toxins; d. biotin; e. streptavidin; and f. cytotoxic agents.
 61. The process of claim 60, wherein the effector molecule is a radioisotope.
 62. The process of claim 61, wherein the radioisotope is selected from ⁹⁰Yttrium, ¹³¹Iodine, ²²⁵Actinium, and ²¹³Bismuth. 